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Summary 
Résumé en Français 
Identification des modulateurs et des voies moléculaires impliqués dans l'interaction 
BIN1-Tau 
Les principales caractéristiques neuropathologiques de la maladie d’Alzheimer (MA) sont les 
plaques séniles extracellulaires composées de peptide amyloïde β (Aβ) et les 
enchevêtrements neurofibrillaires intracellulaires composés de Tau hyperphosphorylé. Les 
mécanismes conduisant à la formation de ces lésions sont encore peu connus et le 
laboratoire a récemment caractériser le gène “bridging integrator 1” (BIN1), deuxième 
facteur de risque génétique le plus associé au risque de MA, comme facteur de risque 
potentiellement associé à la pathologie Tau. Une interaction entre les deux protéines a été 
décrite in vitro et in vivo suggérant que BIN1 pourrait être impliqué dans le développement 
de la pathologie associée à Tau dans le cadre de la MA.  Cependant, ce rôle de l'interaction 
BIN1-Tau dans le processus pathophysiologique de la MA n'est pas connu et il reste ainsi à 
déterminer si cette interaction constitue une cible thérapeutique potentielle. Ce projet a 
visé alors à mieux comprendre les acteurs de cette interaction en identifiant les 
modulateurs et les voies moléculaires impliquées dans le contrôle de l'interaction BIN1-Tau, 
puis de déterminer comment cette interaction est modulée dans le contexte de la MA. Nous 
avons utilisé pour cela des approches complémentaires de biochimie, de résonance 
magnétique nucléaire et de microscopie confocale. Comme modèle cellulaire, des cultures 
primaires de neurones de rat ont été utilisées, et la méthode “proximity ligation assay” 
(PLA) a été développée comme approche principale pour observer l'interaction BIN1-Tau 
dans ces cellules. Nous avons déterminé que l'interaction se produit entre les domaines SH3 
de BIN1 et le PRD de Tau et nous avons démontré que l’interaction est modulée par la 
phosphorylation de Tau et BIN1: la phosphorylation de la Thréonine 231 de Tau diminue son 
interaction avec BIN1, tandis que la phosphorylation de BIN1 à la Thréonine 348 (T348) 
augmente son interaction avec Tau. Nous avons mis au point une approche de criblage 
d’haut contenu semi-automatisée et basé sur une bibliothèque de composés commerciaux. 
Ce criblage s’est basé sur des cultures primaires de neurones comme modèle cellulaire et le 
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PLA pour détecter l'interaction BIN1-Tau. Nous avons identifié plusieurs composés capables 
de moduler l'interaction BIN1-Tau, notamment U0126, un inhibiteur de MEK-1/2, qui 
diminue cette interaction, et la cyclosporine A, un inhibiteur de la calcineurine, qui au 
contraire augmente celle-ci en augmentant la phosphorylation de T348 de BIN1. Par ailleurs 
les “Cyclin-dependent kinases” (CDK) ont été montré comme contrôlant aussi ce site de 
phosphorylation. Nous avons donc mis en évidence le couple Calcineurine/CDK comme 
contrôlant la phosphorylation T348 de Bin1 et donc l’interaction BIN1-Tau. Nous avons 
également développé un modèle murin de tauopathie dans lequel nous avons surexprimé 
BIN1 humain. Nous avons observé que la surexpression de BIN1 résorbait les déficits de 
mémoire à long terme et réduisait la présence d'inclusions intracellulaires de Tau 
phosphorylée, provoquées par la surexpression de Tau, ce qui était associé à une 
augmentation de l'interaction BIN1-Tau. En utilisant des échantillons de cerveau humain 
post-mortem, nous avons observé que les niveaux de l’isoforme BIN1 neuronal étaient 
diminués dans les cerveaux d’AD, alors que les niveaux relatifs de BIN1 phosphorylé à T348 
étaient augmentés, suggérant un mécanisme compensatoire. Cette étude a démontré la 
complexité et la dynamique de l’interaction BIN1-Tau dans les neurones, a révélé des 
modulateurs et des voies moléculaires potentiellement impliquées dans cette interaction, et 
a montré que les variations de l’expression ou de l’activité de BIN1 ont des effets directs sur 
l’apprentissage et la mémoire, possiblement liés à la régulation de son interaction avec Tau. 
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Abstract in English 
Identification of the modulators of and the molecular pathways involved in the BIN1-Tau 
interaction  
The main neuropathological hallmarks of Alzheimer’s disease (AD) are the 
extracellular senile plaques composed of amyloid-β peptide (Aβ) and the intracellular 
neurofibrillary tangles composed of hyperphosphorylated Tau. The mechanisms leading to 
the formation of these lesions is not well understood and our lab has recently characterized 
the bridging integrator 1 (BIN1) gene, the second most associated genetic risk factor of AD 
and the first genetic risk factor to have a potential link to Tau pathology. The interaction 
between BIN1 and Tau proteins has been described in vitro and in vivo, which suggests that 
BIN1 might help us to understand Tau pathology in the context of AD. However, the role of 
BIN1-Tau interaction in the pathophysiological process of AD is not known, and whether this 
interaction is a potential therapeutic target remains to be determined. The aim of this 
project is to better understand the actors of BIN1-Tau interaction through the identification 
of the modulators and the molecular pathways involved therein, as well as to understand 
how BIN1-Tau interaction is modulated in the context of AD. We employed biochemistry, 
nuclear magnetic resonance, and confocal microscopy. We used rat primary neuronal 
cultures (PNC) as the cellular model and developed the proximity ligation assay (PLA) as the 
main readout of the BIN1-Tau interaction in cultured neurons. We determined that the 
interaction occurs between BIN1’s SH3 domain and Tau’s PRD domain, and demonstrated 
that it is modulated by Tau and BIN1 phosphorylation: phosphorylation of Tau at Threonine 
231 decreases its interaction with BIN1, while phosphorylation of BIN1 at Threonine 348 
(T348) increases its interaction with Tau. We developed a novel, semi-automated high 
content screening (HCS) assay based on a commercial compound library, also using PNC as 
the cellular model and PLA as the readout of BIN1-Tau interaction. We identified several 
compounds that are able to modulate the BIN1-Tau interaction, most notably U0126, an 
inhibitor of MEK-1/2, which reduced the interaction, and Cyclosporin A, an inhibitor of 
Calcineurin, which increased the interaction through increasing the BIN1 phosphorylation at 
T348. Furthermore, Cyclin-dependent kinases (CDK) were also shown as regulator of this 
phosphorylation site. These results suggest that the couple Calcineurin/CDK regulates BIN1 
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phosphorylation at T348 and consequently the BIN1-Tau interaction. We also developed a 
mouse model of tauopathy in which we overexpressed human BIN1. We observed that the 
overexpression of BIN1 rescued the long-term memory deficits and reduced the presence of 
intracellular inclusions of phosphorylated Tau, caused by Tau overexpression, and this was 
associated with an increase of BIN1-Tau interaction. Also, using post-mortem human brain 
samples, we observed that the levels of the neuronal BIN1 isoform were decreased in AD 
brains, whereas the relative levels of BIN1 phosphorylated at T348 were increased, 
suggesting a compensatory mechanism. Altogether, this study demonstrated the complexity 
and the dynamics of BIN1-Tau interaction in neurons, revealed modulators of and molecular 
pathways potentially involved in this interaction, and showed that variations in BIN1 
expression or activity have direct effects on learning and memory, possibly linked to the 
regulation of its interaction with Tau. 
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Introduction 
La Maladie d’Alzheimer 
En 1906, Alois Alzheimer décrit plusieurs caractéristiques anatamo-cliniques d’une 
forme de démence qui finira par porter son nom. La maladie d’Alzheimer est la principale 
forme de maladie neurodégénérative, représentant de l’ordre de 50 à 70% de ces maladies 
regroupées sous un continuum de syndromes apparentés tels que les démences vasculaires, 
la maladie à corps de Lewy, les dégénérescences fronto-temporales ou bien encore la 
paralysie supra-nucléaire progressive. Les frontières entre ces différentes formes de 
démence ne sont pas toujours clairement définies et les formes mixtes ne sont pas rares, ce 
qui peut poser un problème de diagnostic. 
D’ailleurs, dans le cadre de la maladie d’Alzheimer (qui est encore à ce jour un 
diagnostic différentiel donc basé sur l’exclusion d’autres causes susceptibles d’expliquer les 
symptômes cliniques observés,), on parlera de formes possibles, probables (du vivant du 
patient) et certaines. Ce diagnostic de certitude est basé sur un examen anatomo-
pathologique du cerveau et la mise en évidence de lésions cérébrales de types plaques 
amyloïdes et dégénérescence neurofibrillaires en quantité et localisation significatives. 
Le diagnostic du vivant du patient s’est appuyé durant longtemps principalement sur 
des examens neuropsychologiques permettant d’objectiver les symptômes hétérogènes 
cliniques résultant de la détérioration des fonctions cognitives et mnésiques associée à la 
maladie. Cependant, un certain nombre de marqueurs biologiques se sont développés au 
cours de ces vingt dernières années. L’imagerie médicale par résonance magnétique a 
permis de mettre en évidence une atrophie plus marquées de l’hippocampe chez les 
patients puis le développement de marqueurs utilisant la tomographie par émission de 
positron a récemment permis de pouvoir observer et quantifier les lésions amyloïdes et la 
dégénérescence neurofibrillaire du vivant du patient. En parallèle, des marqueurs 
protéiques quantifiables dans le liquide céphalo-rachidien ont montré leurs intérêts pour 
l’aide au diagnostic. Il s’agit dans ce cas de mesurer les quantités de peptides amyloïdes, de 
protéines Tau total et phosphorylés. Récemment se sont ajoutées les quantifications des 
neurofilaments et potentiellement des formes solubles de Trem2. L’utilisation de ces 
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marqueurs pour le diagnostic est pour l’instant encore restreinte aux centres de référence 
en France mais il se généralise d’ores et déjà dans les pays d’Europe du nord. Finalement, il 
est par ailleurs probable que dans les années à venir des marqueurs plasmatiques soient 
disponibles, là encore les peptides amyloïdes étant une piste prometteuse. 
La conséquence du développement de ces marqueurs biologiques conduit à une 
redéfinition du diagnostic de MA et à la possibilité de détecter de plus en plus tôt une 
problématique pathologique avant même les premiers signes cliniques (avec la définition de 
l’entité «mild cognitive impairment»). Si cette redéfinition du diagnostic clinique de MA 
n’aura probablement que peu d’impact sur les projections des cas de démences dans les 
années à venir, cette redéfinition risque cependant de modifier la catégorisation des types 
de démences au sein de ces projections (avec la possibilité de redéfinir de nouvelles 
catégories pathologiques comme nous commençons à le voir avec la «primary age-related 
tauopathy» même si la réalité de cette nouvelle entité pathologique est fortement discuté). 
Au niveau épidémiologique, il a été estimé en 2015 par l’organisation mondiale de la 
santé que la démence touchait 47 millions de personnes dans le monde (avec une incidence 
de, 9 millions de personnes chaque année). Selon les prédictions, le nombre de malades 
devrait atteindre 75 millions en 2030 et 132 millions d’ici à 2050. Cette augmentation 
s’explique par le fait que le premier facteur de risque de la démence (et principalement de 
la MA) est l’âge avec 5 % des plus de 65 ans touchés, et plus de 20% des plus de 80 ans et 
que l’espérance de vie progresse le plus vite dans les pays en voie de développement. En 
effet, près de 60 % des personnes atteintes de démence vivent dans un pays à revenu faible 
ou intermédiaire et on estime que la majeure partie des nouveaux cas (71 %) survient dans 
ces pays. 
Ces chiffres alarmants ne sont cependant qu’une estimation basée sur des 
observations réalisée essentiellement à partir de cohortes en population générale. Ainsi ce 
type d’information n’est pas forcement disponible dans de nombreux pays en voie de 
développement et particulièrement africains. Par ailleurs, un certain nombre de facteurs 
pourraient amener à une modification notable de ces projections dans un sens ou l’autre. En 
effet, concernant la MA, il s’agit d’une maladie multifactorielle résultant de l’interaction de 
facteurs génétiques et environnementaux. Même si la part des facteurs non modifiables 
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apparaît très élevée dans le cadre de cette pathologie (de l’ordre de 60 à 80%), la part des 
facteurs modifiables n’est évidemment pas négligeable. Ceci est d’autant plus important 
qu’il a été estimé que retarder de 5 ans l’apparition des premiers signes cliniques de la 
maladie pourrait réduire par deux le nombre de cas prévalent de la MA ceci par mortalité 
compétitive. En l’absence de traitements pharmaceutiques, connaître ces facteurs 
modifiables pourraient donc être un premier levier pour mieux endiguer le problème 
majeur de santé publique qu’est la MA et ses syndromes apparentés. 
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Alzheimer’s disease 
Alzheimer’s disease (AD) was identified more than 100 year ago and is the most 
common form of dementia, accounting for more than 50% of the cases. This disease 
predominantly affects elderly people, older than 65 years, and it was estimated in 2015 that 
about 30 million people worldwide were affected by this disease, and because of the 
increase in life expectancy and population ageing this number is expected to triple until 
2050. The healthcare cost, and the socio-economic burden, associated with AD (and 
dementia in general) is very high and increases with disease’s progression: AD is commonly 
associated to initial symptoms such as memory decline and cognitive impairment, followed 
by loss of motor functions and communication skills, all of which are progressive in severity 
until death (Alzheimer’s Association 2015; Winblad et al. 2016). 
AD is a complex, multifactorial and progressive neurodegenerative disorder, 
characterized by two main neuropathological hallmarks (H. Braak and Braak 1991): the 
formation of Amyloid-β peptide (Aβ) extracellular senile plaques and the development of 
intracellular neurofibrillary tangles (NFT), composed of abnormally hyperphosphorylated 
Tau, Figure 1; associated with progressive loss of synapse (Tackenberg et al. 2013; 
Eckermann et al. 2007) and leading to neuronal degeneration (Wenk 2003; Herrup 2015); 
with massive atrophy of the brain observed in severe AD patients, showing an extreme 
reduction on the hippocampus and cerebral cortex and an enlargement of the ventricles 
(Teipel et al. 2005; Van De Pol et al. 2006; Herrup 2015), Figure 2. 
The identification of mutations in the APP gene (Amyloid precursor protein) that 
promoted increased levels of Aβ forms, as well as the duplication of APP gene in Down 
syndrome, lead to the initial formulation of the Amyloid cascade hypothesis in 1992 (J. 
Hardy and Higgins 1992), which postulates that “the deposition of Aβ is the causative agent 
of Alzheimer’s pathology and that the neurofibrillary tangles, cell loss, vascular damage and 
dementia follow as direct result from this deposition”. Later on, the identification of 
mutations on the genes PSEN1 and PSEN2, coding the catalytic subunits of γ-secretase 
complex, Presenilin 1 and 2 (PSEN1 and PSEN2), responsible for cleavage of APP into Aβ, 
gave strength to this hypothesis (John Hardy and Selkoe 2002). The amyloid cascade 
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hypothesis played an influential role in the explanation of AD’s pathogenesis, prompting the 
research towards APP metabolism and Aβ toxicity.  
 
 
  
Figure 1 Photomicrograph of the temporal cortex of a patient with Alzheimer’s disease (modified Bielschowski stain; 
magnification, 400×), showing two senile plaques with a neurofibrillary tangle between them (Perl 2010). 
Figure 2 Schematic representation of transversal cut of preclinical and severe AD brain, depicting the regions with severe 
alterations. Adapted from ADEAR (Alzheimer's Disease Education and Referral Center, a service of the National Institute of 
Aging, National Institute of Health, USA; source http://www.nia.nih.gov/Alzheimers/Resources/MediaRoom.htm). 
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APP metabolism and Amyloid-β peptides 
Amyloid-β (Aβ) peptides derive from the cleavage of Amyloid precursor protein 
(APP), coded by a gene with the same name (APP) located on chromosome 21 in humans. 
APP has about 10 different isoforms, from 639 to 770 amino acids, generated by alternative 
splicing. APP is ubiquitously expressed in all human tissues, mostly isoforms APP751 and 
APP770, with higher expression in the central nervous system (CNS), due to the 
predominant expression of isoform APP695 in neurons, and all these three isoforms can 
generate Aβ (X. Wang et al. 2017). 
In neurons, APP has been associated with cell adhesion, cell-to-cell and cell-to-
substratum interactions (Reinhard, Hébert, and De Strooper 2005), the modulation of cell 
survival, growth, motility, and neurite outgrowth (O’Brien and Wong 2011), and the 
regulation of synapse formation (Hick et al. 2015). APP is cleaved by two main pathways 
during maturation and processing, the amyloidogenic and the non-amyloidogenic pathways. 
During the non-amyloidogenic pathway, in the plasma membrane of the cell surface, APP is 
cleaved by a α-secretase (e.g. ADAM10), creating a soluble extracellular fragment termed 
sAPPα that is released, and a transmembranar C-terminal fragment α, known as CTFα, that 
is subsequently cleaved by a γ-secretase (i.e. enzyme complex composed by nicastrin, APH-1, PEN-
2, and PSEN1 or 2), creating a fragment corresponding to APP intracellular domain (AICD) and 
a 3 kDa peptide corresponding to the amino acids between α- and γ-secretases cleavage 
(p3). The amyloidogenic pathway occurs in endosomes, where APP is cleaved by the β-
secretase BACE1, creating and releasing to the endosome lumen the sAPPβ, a soluble 
fragment slightly shorter than sAPPα, and the transmembranar CTFβ, which is further 
cleaved by a γ-secretase to produce the same AICD and a 4 kDa peptide resulting from the 
cleavage by β- and γ-secretases called Aβ (Nhan, Chiang, and Koo 2015; van der Kant and 
Goldstein 2015), Figure 3.  
Aβ can have several amino acids in length, due to N- or C-terminal truncation (Dunys, 
Valverde, and Checler 2018). Differences in the N-terminal are most commonly achieved by 
BACE1 cleavage of APP at two different sites: between Methionine 596 and Aspartate 597, 
giving origin to Aβ1-X, and between Tyrosine 606 and Glutamate 607, giving origin to Aβ11-
X (Zhang and Song 2013). The production of Aβ11-X or truncation of Aβ1-X’ N-terminal can 
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expose glutamate residues, located at positions 3 and 11, to cyclization by glutaminyl 
cyclase, and transform these residues into pyroglutamate (Gunn et al. 2016). The C-terminal 
of Aβ also varies in residue length, mostly due to γ-secretase differential endoproteolysis of 
the CTFβ: (i) γ-secretase cleavage starts at the endproteolytic ε sites, (between Leucine 49 
and Valine 50 or Threonine 48 and Leucine 49) to generate Aβ49 or Aβ48, (ii) followed by 
trimming of the C-terminal mostly every three amino acids called ζ sites, and (iii) finishing at 
the γ sites (following the sequences Aβ49-46-43-40 and Aβ48-45-42-38) to produce Aβ 
forms with 43 to 38 residues long; but how the ε sites are recognized by γ-secretase to start 
the endoproteolysis process is still poorly understood (De Strooper 2010; Fernandez et al. 
2016).  
 
Aβ40 and Aβ42 are the most common forms in human brain, existing in a proportion 
of 9:1, and it was reported that small changes in this ratio towards Aβ42 promote the 
formation of oligomers, synaptic toxicity and lead to cell death (Kuperstein et al. 2010). 
Other studies also showed that Aβ42 are the Aβ forms more prone to oligomerize (Dahlgren 
et al. 2002; Resende et al. 2008), and that Aβ42 oligomers are more toxic than monomers, 
fibrils, and other Aβ forms (Deshpande et al. 2006; Ferreira et al. 2012; T. L. Spires-Jones and 
Hyman 2014), thus it was proposed that Aβ42 oligomers are the main promoters of amyloid 
Figure 3 Schematic representation of APP canonical processing pathways (Hui Zheng and Koo 2011), showing the 
intermediate C-terminal fragments (APP-CTF) resulting from α- and β-cleavage and prior to γ-cleavage. EC extracellular, TM 
transmembrane, IC intracellular, Aβ domain is identified in red. 
 Introduction 
18 
plaques, existing in dynamic equilibrium with its monomeric species, toxic oligomeric 
species and fibrils (Benilova, Karran, and De Strooper 2012). However, in recent years, it has 
been demonstrated that pyroglutamate-Aβ peptides are more hydrophobic, form oligomers 
at lower concentrations, aggregate more quickly and enhance the aggregation and 
neurotoxiciy of Aβ42 (Pagano et al. 2018; Dammers et al. 2017; Dunys, Valverde, and 
Checler 2018; Gunn et al. 2016). 
Aβ oligomers have been reported to play a wide variety of roles in various culture 
and animal models of AD pathology such as synaptic degradation and plasticity dysfunction, 
Tau aberrant phosphorylation and axonal transport disruption, membrane receptor 
redistribution and insulin resistance, Ca2+ homeostasis, oxidative and endoplasmic 
reticulum stress, neuroinflammation, cell cycle re-entry and selective neuronal death (Cline 
et al. 2018). However, the multitude of experimental procedures used to produce or extract 
and characterize these oligomers makes it difficult to interpret and compare studies 
(Benilova, Karran, and De Strooper 2012). 
While genetic studies have strongly implicate amyloid as the initiating factor in AD, 
the correlation of tangles with neuronal loss in AD brain, together with the lack of neuronal 
loss and tangle formation in APP transgenic models contributed to the idea that Tau 
pathology is the major contributor to dementia (T. Spires-Jones and Knafo 2012). 
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Microtubule associated protein Tau 
Tau is part of the microtubule associated proteins (MAP) family, highly conserved in 
the animal kingdom, which have the canonical function of microtubule assembly regulation 
and stabilization, through direct binding of tubulin (Himmler et al. 1989; Al-Bassam et al. 
2002). Tau is almost exclusively expressed in neurons, especially in the axons, and Tau 
proteins are expressed in the human brain in 6 functional isoforms, resulting from the 
alternative splicing of the gene MAPT (microtubule associated protein Tau) (Buée et al. 
2000; G. Lee and Leugers 2012). These isoforms differ between them by the presence or 
absence of one or two inserts in the N-terminal part of the protein (0N, 1N, 2N), responsible 
for the interaction with other proteins of the cytoskeleton and plasma membrane, and the 
presence of three or four peptide repeats before the C-terminal part of Tau (3R, 4R), mainly 
responsible for the interaction with tubulin and identified as the microtubule binding 
domain (MBD). Linking the N-terminal region and the MDB, Tau has a proline-rich domain 
(PRD) between amino acids 151 and 244 (using as reference the longest isoform, 2N4R, with 
441 amino acids) and after the MDB, from amino acid 369 to 441, Tau has a conserved C-
terminal region, both of which are present in all Tau isoforms, Figure 4. The expression 
levels of Tau isoforms differ during neuronal development, brain region and between 
physiological and pathological conditions (Y. Wang and Mandelkow 2016; Guo, Noble, and 
Hanger 2017). 
The PRD of Tau contains 7 sequences of amino acids comprised by a Proline, any two 
amino acids and another Proline, known as PxxP motifs, which are commonly recognized by, 
and are the binding sites of, Src-homology 3 domain (SH3)-containing proteins (Reynolds et 
al. 2008; Morris et al. 2011). 
In neurons, Tau is predominantly axonal and plays a role in the stability and 
regulation of microtubule dynamics, regulation of axonal transport, and regulation of actin 
cytoskeleton; and has a plethora of partners and interactors, from microtubules and 
cytoskeleton proteins (tubulin and actin), passing by transport motor complexes (e.g. 
kinesin, p150), and protein kinases and phosphatases (e.g. Cdk5, Gsk-3β, PP2A, Calcineurin), 
to signal transduction proteins (e.g. 14-3-3) (G. Lee and Leugers 2012; Noble et al. 2013; Elie 
et al. 2015; Biswas and Kalil 2017). Tau is tightly regulated by phosphorylation: having about 
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eighty putative phosphorylation sites, it is targeted by several protein kinases and 
phosphatases; in combination with the isoform type, Tau phosphorylation modulate its sub-
cellular localization; Tau phosphorylation status changes during development, with shifts in 
the activity ratio of kinases and phosphatases, which modulate its properties and affinity 
towards its partners (Buée et al. 2000; G. Lee and Leugers 2012; Y. Wang and Mandelkow 
2016; Guo, Noble, and Hanger 2017). 
 
Besides phosphorylation, Tau is target of a wide range of post-translational 
modifications (PTM), including isomerisation, glycation, nitration, O-GlcNAcylation, 
acetylation, oxidation, polyamination, sumoylation, and ubiquitynation, Figure 5; that may 
regulate Tau interaction with other proteins, e.g. microtubules, and even with its own 
modulators, e.g. protein kinases and phosphatases, possibly exacerbating or reducing Tau 
phosphorylated state (Iqbal, Liu, and Gong 2016; Guo, Noble, and Hanger 2017). 
Tau, especially hyperphosphorylated Tau, is a hallmark of several neurodegenerative 
diseases including AD, commonly called tauopathies (G. Lee and Leugers 2012; Iqbal, Liu, 
and Gong 2016). For many years, the MAPT gene was a genetic risk factor of other 
tauopathies than AD, such as frontotemporal dementia (FTD) and FTD with parkinsonism 
Figure 4 The human MAPT gene and splicing isoforms of Tau in the human brain, (Y. Wang and Mandelkow 2016). Exon 
1 (E1), E4, E5, E7, E9, E11, E12 and E13 are constitutively expressed; whereas E2, E3 and E10 are subject to alternative 
splicing and generate the six human brain isoforms; and E4a, E6 and A8 are transcribed only in the peripheral tissue. The 
six brain isoforms differ according to the presence of 0,1 or 2 inserts in the N-terminal region of the protein, coded by E2 
and E3 (0N, 1N, 2N), and the absence or presence of repeat R2, coded by E10, in the C-terminal region (3R, 4R) of the 
protein. The proline-rich domain (PRD) is coded by E5, E7 and part of E9, and connects the N-terminal to the C-terminal 
regions of Tau proteins. 
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linked to chromosome 17 (FTDP-17) (Hutton et al. 1998) or progressive supranuclear palsy 
(Baker et al. 1999). However, it has been recently identified a possible association between 
a polymorphism in the MAPT region and AD (Jun et al. 2016). 
 
NFTs, the intracellular inclusions observed, and hallmark, in AD, are predominantly 
composed by paired-helical filaments (PHF) of hyperphosphorylated Tau protein (Grundke-
Iqbal et al. 1986). The mechanisms underlying Tau pathology in AD are not well understood, 
but it is currently accepted that at least two processes contribute to the development of Tau 
hyperphosphorylation and aggregation, neuronal toxicity and degeneration: an imbalance 
on Tau phosphorylation status and the detachment of Tau from the microtubules (Ballatore, 
Lee, and Trojanowski 2007; Iqbal, Liu, and Gong 2016). Tau abnormal phosphorylation is 
enough to induce Tau aggregation, without any other aggregation promoter (Despres et al. 
2017). On the other hand, Tau dissociation from the microtubules is by itself a destabilising 
event, prompting axonal transport dysregulation, Tau mislocalization, microtubule 
disassembly and synaptic dysfunction (Decker et al. 2015). Besides, it was shown that free 
Tau is more prone to phosphorylation at Threonine 231 than microtubule-bound Tau, and 
that phosphorylation at this site promotes the detachment of Tau from the microtubules 
(Sengupta et al. 2006). 
Figure 5 Distribution of known post-translational modification sites of Tau, throughout the largest human isoform, 2N4R 
with 441 amino acids (Guo, Noble, and Hanger 2017) 
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These two processes could occur consecutively, simultaneously, and/or in parallel, 
and several Tau PTM have been associated with their development: changes in the activity 
of certain protein kinases and phosphatases (e.g. PKA, CaMKII, GSK-3β, Cdk5, PP2A, 
calcineurin) was shown to promote Tau abnormal phosphorylation and reduce the 
interaction between Tau and microtubules; wile O-glycosylation reduces Tau 
phosphorylation, N-glycosylation, nitration and acetylation reduce Tau microtubule binding 
ability and prime Tau for phosphorylation; sumoylation and acetylation promote Tau 
aggregation; both abnormally phosphorylated and aggregated Tau fail to be degraded by 
the proteasome (Buée et al. 2000; J. Z. Wang et al. 2012; Iqbal, Liu, and Gong 2016; Guo, 
Noble, and Hanger 2017). 
Taken together, the wide variety of Tau partners (such as microtubules, actin, 
kinases, phosphatases, transport motor complexes) in combination with the wide variety of 
Tau PTMs present in physiological and/or pathological conditions (G. Lee and Leugers 2012; 
Guo, Noble, and Hanger 2017) makes it difficult to identify the most important pathways 
that lead to Tau modification and how they might be affected in pathology. 
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Interplay between Tau and Aβ 
One of the major questions of debate in AD research is regarding which of the 
pathologies, Tau or Aβ, appears first and/or is more important in AD pathology (Nisbet et al. 
2015; Selkoe and Hardy 2016). 
It is proposed that the development and progression of the two hallmarks have 
distinct and independent spatiotemporal progression (Brettschneider et al. 2015), with Aβ-
plaques accumulation starting several years prior to clinical symptoms in the neocortical 
region and progressing towards limbic regions, while NFT appears in association with 
neurodegeneration and develops initially in the locus coeruleus and entorhinal cortex 
(Iaccarino et al. 2018). Thus, it is accepted that AD starts much earlier than the detection of 
the first symptoms, which makes it very difficult to clinically identify and understand the 
biological mechanisms that lead to it (Heiko Braak and Del Tredici 2012; Villemagne et al. 
2013). 
Adding complexity to this question, Amyloid plaques were observed in the brains of 
“healthy” people, upon autopsy, and Tau is also hallmark of other neurodegenerative 
diseases. Tau was shown to be essential for Aβ-induced toxicity (Rapoport et al. 2002), 
either through interaction with Src kinase Fyn in the postsynaptic compartment of neurons 
(Ittner et al. 2010), and through CaMKII-AMPK pathway and Tau phosphorylation (Mairet-
Coello et al. 2013). Conversely, Aβ was shown to induce mislocalization of Tau and 
destabilization of synapses and microtubules (Zempel et al. 2013), and reported to induce 
and enhance the formation of NFT (J. Götz et al. 2001; Hurtado et al. 2010; Bennett et al. 
2017). 
Taken together, this information suggest that although the progression processes of 
AD hallmarks might be independent, the physiological mechanisms underlying them might 
cross paths at some point, and have synergistic effects that trigger AD pathology and 
progression (Armstrong 2011; Jack et al. 2013; Gulisano et al. 2018). However, neither these 
mechanisms nor their interplay are well understood, and further investigation aimed to 
decipher them is warranted. 
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Genetics of Alzheimer’s disease 
AD can be arbitrarily divided into two major categories, according to the age at 
which patients develop the first symptoms: the early onset forms of AD (EOAD), before 65 
years old, and the late onset forms of AD (LOAD), after the age of 65. Both types of AD can 
be further subdivided into autosomal dominant forms of AD, familial forms (FAD) and 
sporadic forms (SAD) (J. C. Lambert and Amouyel 2011), depending on the prevalence and 
hereditability of mutations in known genes, family history context and/or lack of both, 
Figure 6. 
The genes APP, PSEN1, PSEN2 are responsible for the rare monogenic forms of AD 
with autosomal dominant heritability, and the characterization of the mechanism that lead 
to these forms supported the amyloid cascade hypothesis. However, monogenic forms of 
AD only correspond to less than 1% of all clinically diagnosed AD cases (Piaceri et al. 2013). 
 
Figure 6 Percentages of early and late onset forms of AD (EOAD and LOAD, respectively), subdivided in familial (FAD), 
sporadic (SAD) and autosomal dominant forms of AD (Gentier and van Leeuwen 2015). 
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The aetiology of the remaining forms of AD cases is far more complex, resulting from 
the combination of environmental and genetic risk factors, such as lifestyle, mental and 
physical health, cognitive and physical activity, vascular and metabolic factors, aging, and 
several gene polymorphisms, but the way these determinants interact is unknown 
(Alzheimer’s Association 2015; Winblad et al. 2016; Reitz and Mayeux 2014). FAD is 
predominantly of early onset and characterized by the knowledge of diagnosed AD in first 
degree relatives, indicating a very strong genetic component. Most of the LOAD forms are 
considered SAD because there is not an obvious familial association, either due to the lack 
of known genetic transmission model or insufficient family history information (Piaceri et al. 
2013; Gentier and van Leeuwen 2015; J. C. Lambert and Amouyel 2011). Although the 
weight of the genetic component in these sporadic forms is still debatable, with genetic 
studies in twins showing that AD has an estimated heritability between 50 and 80 % (Gatz et 
al. 2006), it is currently accepted that that they involve a strong genetic predisposition and 
that the genetic component is complex and heterogeneous, with no simple model of disease 
transmission and with possible crosstalk between genetic risk factors and between genetic 
and environmental factors (J. C. Lambert and Amouyel 2011; Tanzi 2012). 
The apolipoprotein E (APOE) gene was the first identified and validated gene for 
which different polymorphisms modulated the risk of developing AD (W. J. Strittmatter et al. 
1993; Corder et al. 1993). APOE is a plasma protein involved in cholesterol transport and 
was shown to bind Aβ peptides (Warren J Strittmatter et al. 1993; W. J. Strittmatter et al. 
1993). APOE gene has 3 common alleles (ε2, ε3 and ε4), with different frequencies in the 
Caucasian population: the most common allele of APOE is ε3 with an averaged frequency of 
75%, followed by ε4 with an averaged frequency of 15%, and finally ε2 with a frequency of 
about 8%; that correspond to 6 different phenotypes. Genetic association studies of APOE 
alleles in AD and control cases reported that ε4 allele was significantly associated with AD, 
which means that persons carrying the APOE allele ε4 had higher risk of developing 
Alzheimer’s disease, independent of sex but with some differences according to the ethnic 
group, and that this risk is considerably increased with homozygosity and age (Farrer et al. 
1997; Genin et al. 2011). Interestingly, these studies also suggested that the presence of 
allele ε2, in homozygosity or heterozygosity with ε3, could decrease the risk of developing 
AD. 
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For years APOE was the sole genetic susceptibility or risk marker of LOAD, but the 
fact that this gene only accounted for about 20 % of LOAD’s estimated heritability, indicated 
that additional genetic factors should be involved in the risk of LOAD, and efforts were 
focused in the identification of these genes (Rosenthal and Kamboh 2014). Several genes 
have been proposed as contributors to the susceptibility or risk of LOAD through genetic 
association studies, in which allele frequencies for polymorphisms in loci (regions of interest 
in the genome) are compared between cases and controls: when frequencies differ 
significantly between the groups, the gene closest to that locus is identified as susceptibility 
gene for the disease. However, these genetic association studies only tested small number 
of genes at a time and employed modest populations in the evaluation. Advances in key 
technological and analytical areas, in the early 2000s, made possible to evaluate practically 
all the genome in a single experiment, and gave rise to a methodology called genome-wide 
association studies (GWAS) (Schellenberg and Montine 2012). With the advent of this 
methodology, more than 25 loci have already been identified and associated with AD, and 
the closest genes identified as genetic risk factors of AD (J.-C. Lambert et al. 2013; Sims et al. 
2017; J.-C. Lambert et al. 2009; Seshadri et al. 2010; Coon et al. 2007). 
Because the genetic association studies identify loci, more than one gene and/or 
more than one polymorphism could contribute to the detection of those loci. Hence it is of 
the utmost importance to identify the functional polymorphism(s) in each locus, identify the 
causal gene(s) in each locus, and understand the contribution of these genes to AD 
pathogenesis (Pierre Dourlen, Chapuis, and Lambert 2018). In recent years, several studies 
have been performed, in order to characterize the function of the polymorphism(s) 
identified through GWAS, and understand the relationship between (i) AD’s genetic risk 
factors, (ii) AD’s neuropathological hallmarks, and (iii) the pathophysiological processes 
leading to AD. These studies tried to identify the function of the polymorphism(s) identified 
(Nicolas et al. 2016; Bettens et al. 2012; Brouwers et al. 2012; Malik et al. 2013), employed 
diverse models to characterize or validate the gene(s), from cell lines to full organisms (J 
Chapuis et al. 2013; Tian et al. 2013; Y. Zhou et al. 2014), and some even involved cell-based 
and whole-organism screening strategies to assess the function of the gene(s) of interest in 
AD pathological process (Julien Chapuis et al. 2017; P. Dourlen et al. 2017). 
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In silico approaches have been invaluable, both in the identification of genes as risk 
factors of AD and their possible association with AD’s pathophysiological process. Taking 
advantage of the current knowledge of each gene function/pathway/process, researchers 
elaborated maps of these networks and developed bioinformatics tools, to cross-reference 
data obtained from high-throughput technologies with these network maps, known as 
pathway and network analysis approaches. The main objectives of these approaches are the 
(i) identification of relevant groups of related genes that are associated with specific 
signalling pathways, cellular processes or diseases; (ii) generation of new branches or gene 
clusters in these pathways and networks; and (iii) evaluation of the relationship between 
the various components in the same pathway or network. Altogether, these approaches 
have helped researchers to identify protein interactions, characterize cellular mechanisms, 
and propose biological roles for newly disease-associated genes, facilitating the generation 
of new research hypothesis (García-Campos, Espinal-Enríquez, and Hernández-Lemus 2015; 
Creixell et al. 2015). In the context of AD, network and pathway analysis have been useful to 
understand the relationship between genes associated with AD (Hu et al. 2017), identify 
cellular and molecular mechanisms that might be deregulated in the disease (McKenzie et 
al. 2017) or may be susceptible to the modulation of GWAS-defined genes (Krasemann et al. 
2017), and suggest genes that may be implicated in specific disease-related pathways 
(Camargo et al. 2015; Julien Chapuis et al. 2017). 
Although the mechanisms, by which most of the genetic risk factors of AD might be 
involved in AD pathological process, have not yet been unveiled, these genes can be 
grouped into three categories, according to their principal functions, all of which have been 
suggested to play some role in AD. Between the genes that regulate lipid metabolism we 
can find APOE, associated to binding and clearance of Aβ; ABCA7, associated with APP 
processing and Aβ deposition; and CLU, associated with Aβ clearance and fibril formation, 
and its protein was shown to interact with BIN1 and Tau (Y. Zhou et al. 2014). Regulating cell 
membrane processes (e.g. endocytosis and cell adhesion) we can find SORL1, associated 
with Aβ production; PICALM, shown to regulate γ-secretase endocytosis and CTF 
degradation, and was associated with Aβ clearance and loads; PTK2B, was shown to 
modulate Tau toxicity and co-localized with neurofibrillary degeneration markers (P. 
Dourlen et al. 2017); CD2AP, associated with APP endocytosis and blood-brain barrier 
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integrity; BIN1, associated with Aβ production and Tau oligomerization and toxicity, and also 
shown to interact with Tau (J Chapuis et al. 2013); and FERMT2, associated with APP 
metabolism and Aβ loads (Julien Chapuis et al. 2017), and possibly with Tau toxicity 
(Shulman et al. 2014). In the category of genes expressed in microglia and involved in 
immune response we have CR1, associated with the regulation of the complement system, 
the mechanism responsible for microglia phagocytosis of synapses; CD33, associated with 
the degradation of Aβ through microglia phagocytosis; and TREM2, responsible for the 
recognition of apoptotic neurons and APOE and CLU containing lipoprotein particles (shown 
to form complexes with Aβ) to undergo phagocytosis by the microglia, and is associated 
with Aβ deposition and microglia viability. These and other genetic risk factors of AD, Table 
1, may have more than one physiological role and share pathophysiological processes, 
hence it is still necessary to further map their pathological functions, for the better 
understanding of AD development at cellular and molecular level (Piaceri et al. 2013; 
Rosenthal and Kamboh 2014; Kanatsu and Tomita 2017; Pimenova, Raj, and Goate 2018). 
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Table 1 Known AD genetic risk factors and their possible association with AD pathophysiological process. Adapted from 
Pimenova, Raj, and Goate 2018. 
Gene 
Name 
Cell Type - 
Specific 
Expression 
Biological 
Processes 
Possible 
Association with 
AD 
Reference(s) 
ABCA7 Ubiquitous 
Lipid metabolism 
and phagocytosis 
APP processing 
and Aβ deposition 
(J.-C. Lambert et al. 
2013; Guennec et al. 
2016; Steinberg et al. 
2015; Satoh et al. 
2015) 
ABI3 Microglia Cell growth — 
 
(Sims et al. 2017) 
 
ADAM10 Ubiquitous Protein processing 
APP processing to 
Aβ 
(Kim et al. 2009; 
Saftig and 
Lichtenthaler 2015; 
Yuan et al. 2017) 
AKAP9 Ubiquitous Kinase signalling — 
 
(Logue et al. 2014) 
 
APOE 
Ubiquitous, 
major in 
astrocytes 
and microglia 
Lipid metabolism 
and phagocytosis 
Aβ binding and 
clearance 
(Corder et al. 1993; 
W. J. Strittmatter et 
al. 1993) 
APP Ubiquitous — 
APP processing to 
Aβ 
(Jonsson et al. 2012) 
BIN1 Ubiquitous Endocytosis 
Aβ production, Tau 
oligomerization 
and toxicity, also 
shown to interact 
with Tau 
(J.-C. Lambert et al. 
2013; J Chapuis et 
al. 2013; Ubelmann 
et al. 2017; Calafate 
et al. 2016) 
CD2AP — Endocytosis 
APP endocytosis 
and blood-brain 
barrier integrity 
(J.-C. Lambert et al. 
2013; Ubelmann et 
al. 2017; Cochran et 
al. 2015) 
CD33 Microglia 
Immune response 
and phagocytosis 
Aβ degradation 
(J.-C. Lambert et al. 
2013; Raj et al. 2014; 
Griciuc et al. 2013; 
Bradshaw et al. 
2013) 
CLU Astrocytes Lipid metabolism 
Aβ clearance and 
fibril formation, 
also interacts with 
BIN1 and Tau 
(J.-C. Lambert et al. 
2013; Bettens et al. 
2012; Y. Zhou et al. 
2014) 
CR1 Microglia 
Immune response 
and phagocytosis 
Synapse 
phagocytosis by 
microglia 
(J.-C. Lambert et al. 
2013; Brouwers et al. 
2012; S. Hong et al. 
2016; Crehan, 
Hardy, and Pocock 
2013) 
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Table 2 (continued) 
Gene 
Name 
Cell Type - 
Specific 
Expression 
Biological 
Processes 
Possible 
Association with 
AD 
Reference(s) 
FERMT2 — — 
APP metabolism 
and Aβ loads, and 
possibly with Tau 
toxicity 
(J.-C. Lambert et al. 
2013; Julien Chapuis 
et al. 2017; Shulman 
et al. 2014) 
MAPT Neurons 
Microtubule 
stability 
Tau 
oligomerization, 
toxicity and NFT 
formation 
(Jun et al. 2016; G. 
Lee and Leugers 
2012; Iqbal, Liu, and 
Gong 2016) 
MEF2C — 
Cell differentiation 
and synaptic 
regulation 
— 
(J.-C. Lambert et al. 
2013; Harrington et 
al. 2016)  
MS4A6A Microglia 
Chemosensory 
receptors 
— 
Lambert et al. 2013; 
Huang et al. 2017) 
PICALM — 
Endocytosis and 
sorting 
γ-secretase 
endocytosis and 
CTF degradation, 
also associated 
with Aβ clearance 
and loads 
(J.-C. Lambert et al. 
2013; Tian et al. 
2013; Kanatsu et al. 
2014) 
PLCG2 Microglia 
Phospholipase 
signalling 
— (Sims et al. 2017) 
PLD3 Ubiquitous — — 
(Cruchaga et al. 
2014) 
PTK2B — 
Cell adhesion and 
hippocampal long-
term depression 
Modulate Tau 
toxicity and co-
localize with NFT 
markers 
(J.-C. Lambert et al. 
2013; P. Dourlen et 
al. 2017; Hsin et al. 
2010) 
SORL1 Ubiquitous 
Endocytosis and 
sorting 
Aβ production 
(J.-C. Lambert et al. 
2013; Nicolas et al. 
2016; Kitago et al. 
2015) 
TREM2 Microglia 
Immune response 
and phagocytosis 
Aβ deposition and 
microglia viability 
(Jonsson et al. 2013; 
Guerreiro et al. 2013; 
Yeh et al. 2016; Jay 
et al. 2017) 
TREML2 Microglia Immune response — 
(Benitez et al. 2014; 
Honghua Zheng et 
al. 2016; de Freitas 
et al. 2012) 
UNC5C Neurons 
Response to 
neurotoxic stimuli, 
cell death 
— 
(Wetzel-Smith et al. 
2014) 
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Bridging integrator 1 
Genetic risk factors play a critical role in AD susceptibility, thus the comprehension of 
the mechanisms underlying LOAD associated genes has broaden researchers understanding 
of the pathways associated to AD progression, and shifted research attention from Aβ 
metabolism to other cellular pathways (Pimenova, Raj, and Goate 2018). One of the genetic 
risk factors identified through GWAS is the gene coding the protein bridging integrator 1 
(BIN1) (Seshadri et al. 2010), which was described as the second most associated genetic 
risk factor of AD, just after APOE (J.-C. Lambert et al. 2013). 
BIN1, which is also known as Amphiphysin II, is highly conserved, having high protein 
and DNA sequence homology between humans and other mammalian 
(https://www.uniprot.com/; https://www.ncbi.nlm.nih.gov/UniGene/), and has orthologs in 
several non-mammalian models (Prokic, Cowling, and Laporte 2014). BIN1 was initially 
described as Myc-binding protein able to suppress tumour growth present in (Sakamuro et 
al. 1996), followed by the characterization of a neuronal isoform (A. R. Ramjaun et al. 1997), 
and the identification of neuronal- and muscle-specific protein isoforms coded by the same 
gene (Butler et al. 1997). 
The BIN1 gene is ubiquitously expressed and BIN1 protein has 10 known tissue-
specific isoforms, , with tissue-specific expression levels and profiles due to alternative 
splicing (Tan, Yu, and Tan 2013; Prokic, Cowling, and Laporte 2014). All the isoforms are 
composed by a N-terminal BIN-Amphiphysin/Rvs domain (N-BAR) responsible for the 
curvature recognition and binding of plasma membrane (Peter et al. 2004), a Myc-binding 
domain (MBD) responsible for the interaction with Myc boxes and inhibition of c-Myc 
(Pyndiah et al. 2011), and a Src-homology 3 domain (SH3) in the C-terminal of the protein, 
responsible for the recognition and interaction with motifs rich in proline on target proteins 
(Leprince et al. 1997). Isoforms 1 to 7 have an extra exon 7 in the N-BAR domain, are the 
only ones that express alternative splicing products of the exons 13 to 16, encoding the 
Clathrin and AP2 binding domain (CLAP) (Antoine R. Ramjaun and McPherson 2002) 
associated to vesicle formation (Slepnev et al. 1998), and are exclusively expressed in the 
brain. Isoform 8 has a phosphoinositide binding motif (PI) coded in exon 11, is highly 
expressed in the muscle, predominantly in the T-tubules (E. Lee et al. 2002). The last two 
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isoforms, 9 and 10, do not possess PI motif or CLAP domain, differ in the splicing of exon 17 
coding MBD, and have ubiquitous expression (Wechsler-Reya, Sakamuro, et al. 1997), Figure 
7. 
 
BIN1 has been described to be involved in the most diverse functions, such as (i) cell 
cycle, DNA repair and apoptosis (Sakamuro et al. 1996; Wechsler-Reya, Elliott, et al. 1997; 
Pyndiah et al. 2011); (ii) membrane remodelling, endocytosis and recycling endosome 
regulation (Itoh and De Camilli 2006; Leprince et al. 1997; Pant et al. 2009); and (iii) 
cytoskeleton network remodelling (Meunier et al. 2009; Butler et al. 1997; Dräger et al. 
2017). 
Several studies have already shown that the reduction, alterations in expression or 
mutations on BIN1 are crucial for the development and/or progression of certain types of 
cancer and muscle related diseases. The underexpression or inhibition of BIN1 ubiquitous 
isoforms was shown to induce chemotreatment resistance in cancer cell lines through direct 
interaction with DNA repair proteins (Pyndiah et al. 2011); besides, the reduction of isoform 
9 and the presence of a similar isoform which possessed the amino acid sequence coded by 
Figure 7 BIN1 protein domains, gene organization and isoforms (Prokic, Cowling, and Laporte 2014). a) Protein domains: N-
BAR domain; PI motif; CLAP preceded by a Proline-Serine rich region; MBD; and SH3 domain. b) Gene organization of BIN1, 
with exons identification using the main nomenclature from NCBI and with the initial nomenclature above, in italic 
(Wechsler-Reya, Sakamuro, et al. 1997). Transcript isoforms found in c) brain, d) skeletal muscle, e) ubiquitously, and f) in 
melanoma. Alternative exons are indicated with “V”. 
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exon 12a (BIN1+12a+13) were identified in several types of cancer (Ge et al. 1999; Pineda-
Lucena et al. 2005), suggesting that the addition of this brain-specific sequence causes loss 
of Myc-binding function of ubiquitous BIN1 isoform. Aberrant splicing of BIN1 and 
mutations on BIN1 N-BAR domain were also identified in myopathies and were associated 
to T-tubule structural and location defects (Fugier et al. 2011; Toussaint et al. 2011; Böhm et 
al. 2013); whereas the decrease of BIN1’s muscle isoform (BIN1+10+13) expression was 
associated with arrhythmia and cardiomyopathies, knockout of BIN1 in mice lead to 
perinatal lethal cardiomyopathy (Prendergast et al. 2009; T. Hong et al. 2014; K. Zhou and 
Hong 2017). 
BIN1 loci was first associated with AD in GWAS through the polymorphism signal 
rs744373 (Seshadri et al. 2010), located 28kb upstream of BIN1 coding region. Fine mapping 
of this risk locus identified several single nucleotide polymorphisms and insertion/deletions, 
one of which, an insertion of three C bases (rs59335482), was associated with a higher risk 
of AD through the increase of BIN1 transcript levels, either experimentally and in the brains 
of AD patients (J Chapuis et al. 2013), and this polymorphism was also associated with a 
later age of onset and shorter disease duration (Karch et al. 2012). 
Following these observations, other studies reported that in AD brains the protein 
levels of BIN1 neuronal isoform are decreased (Glennon et al. 2013; Holler et al. 2014; De 
Rossi et al. 2016), while the levels of the ubiquitous isoform are increased (Holler et al. 
2014; De Rossi et al. 2016), which have higher expression in the white matter as compared 
to the grey matter (De Rossi et al. 2016). Consistently with this last report, 
immunohistochemistry of AD patient brains showed a decrease of BIN1 immunoreactivity in 
the neuropil region, with an increase in the neuronal soma (Adams et al. 2016), and a 
predominant immunoreactivity of oligodendrocytes and white matter (De Rossi et al. 2016). 
Although BIN1 loci polymorphisms had been associated with Tau loads (J Chapuis et 
al. 2013) and with Tau and phosphorylated Tau levels in cerebrospinal fluid (H.-F. Wang et 
al. 2016), there has been conflicting reports on BIN1 association with NFT and Tau 
pathology: some studies present no association (Adams et al. 2016) or co-staining between 
BIN1 and NFT (J Chapuis et al. 2013; De Rossi et al. 2017), and no correlation between BIN1 
protein levels and Tau pathology (Glennon et al. 2013); while other studies show a positive 
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correlation between the increase of BIN1 ubiquitous isoform levels and the number of NTF 
in AD brains (Holler et al. 2014), or a co-localization of the neuronal isoform of BIN1 and 
phosphorylated Tau in the cytoskeleton/insoluble fraction of AD brain lysates (Y. Zhou et al. 
2014). However, none of these studies identified any association between BIN1 and Aβ 
peptides or amyloid plaques. 
Similar to other GWAS-associated genes, the role of BIN1 in AD is not well 
understood and, based on previously described functions of BIN1, it was proposed that BIN1 
could modulate Tau pathology, endocytosis and recycling pathway, calcium homeostasis or 
inflammation (Tan, Yu, and Tan 2013), Figure 8. 
 
Previous studies have shown that the lack of BIN1 increases endocytosis (Muller et 
al. 2003) and disrupts recycling trafficking (Pant et al. 2009), suggesting that BIN1 regulates 
Clathrin-mediated endocytosis and the formation and/or transport of endocytic recycling 
vesicles. More recently, and in the context of AD, it was shown that the reduction of BIN1 
Figure 8 Summary of proposed roles for BIN1 in AD (Tan, Yu, and Tan 2013). 
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isoform 1 protein levels is linked with the increase of Aβ production via disruption of BACE1 
recycling (Miyagawa et al. 2016; Ubelmann et al. 2017) and with increase on Tau 
endocytosis and cell-to-cell propagation (Calafate et al. 2016). 
Other studies focussed on the association of BIN1 with Tau pathology and reported 
that BIN1 was able to directly interact with Tau, in vitro and in vivo, and that the silencing of 
BIN1 fly ortholog Amph was able to rescue Tau rough eye phenotype (J Chapuis et al. 2013; 
P. Dourlen et al. 2017), indicating that BIN1 is able to directly modulate Tau neurotoxicity. It 
has also been shown that BIN1 interacts with Tau through BIN1 SH3 domain, present in all 
BIN1 isoforms, and Tau PRD, also present in all Tau isoform, and that this interaction is 
modulated by Tau phosphorylation (Sottejeau et al. 2015). Additionally, it was shown that 
SH3 domain of BIN1 isoform 1 is naturally engaged in intramolecular interaction with its 
CLAP domain, due to the presence of a proline-rich motif in between residues 336 and 342, 
and that this domain is in competition with Tau-PRD for BIN1-SH3 binding site (Malki et al. 
2017). 
BIN1 has not been associated with any other neurodegenerative disease and was 
until recently the only genetic risk factor of AD directly associated with Tau pathology, 
therefore BIN1 could be the missing link between Tau pathology and LOAD development. 
Despite the research on BIN1 function in AD, the role of BIN1-Tau interaction in physiology 
or the pathophysiological process of AD it is not known, neither if it could be a potential 
therapeutic target for AD. 
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Animal models of Alzheimer’s disease 
Currently, there is no effective treatment for AD and part of the reduced therapeutic 
effectiveness lies in the difficulty to translate models of disease from one species to another 
and, as consequence, potential therapies that work in rodents often do not translate to 
humans (De Felice and Munoz 2016). One of the problems in the majority of the animal 
models of AD is the fact that these models are created based on the mutations or 
duplication of genes responsible for neurodegenerative diseases other than AD (e.g. Tau 
mutations responsible for FTD), or responsible for the rare monogenic forms of AD (i.e. APP, 
PSEN1 and PSEN2). Moreover, to replicate some of the events associated with AD, such as 
the development and distribution of AD’s neuropathological hallmarks, two or more of 
these mutated genes need to be expressed together (Jürgen Götz and Ittner 2008). 
Nevertheless, animal models are indispensable tools in biomedical research, not only 
being invaluable in the evaluation of novel therapeutic approaches, but also of the utmost 
importance in the identification and characterization of critical disease-related mechanisms. 
Thus, the development of models, animal and/or cellular, that better recapitulate the 
mechanisms that lead to the development or progression of human diseases, notably AD, 
has been the goal of many researchers (LaFerla and Green 2012). 
Such is the case of the 3xTg-AD mouse model, that was generated through the 
combined expression of APPSWE and TauP301L on a PSEN1M146V/– background mouse model, 
and closely recapitulates human AD pathology: development and distribution of senile 
plaques and NFT, synaptic transmission and long-term potentiation deficits, and learning 
and memory impairment (Oddo et al. 2003). Other models use non-mutated human genes, 
such as MAPT, to assess the development of hyperphosphorylated Tau, PHF and NFTs in 
mouse brains (Andorfer et al. 2003; Polydoro et al. 2009), or to evaluate the modulation of 
Tau toxic phenotype in vivo in fruit fly (J Chapuis et al. 2013). Although it could be argued 
that these models are more tauopathy models than AD’s, they allow the dissection of the 
pathways that lead to the development of NFTs and the associated toxicity, which is less 
known than the metabolism of APP. 
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Although several mouse models have been developed to study the mechanisms 
underlying APOE role in AD (Knouff et al. 1999; Sun et al. 1998; Youmans et al. 2012), and 
more recently TREM2 and ABCA7 (https://www.alzforum.org/research-models/alzheimers-
disease), the contribution of other GWAS-defined genes in the progression of AD has not yet 
been validated in mouse models. Only recently it was reported the development of a mouse 
model based on the overexpression of the human gene of BIN1 (Daudin et al. 2018). 
Another advantage of animal model is the wide range of studies that can be 
performed, such as behaviour, lifespan and viability studies, live imaging, cellular and 
molecular analysis. Although mouse models are the usually the models of choice for most 
researchers, the roundworm Caenorhabditis elegans and the fruit fly Drosophila 
melanogaster also have their advantages in translational research, notably of AD: both are 
easy to produce and maintain, have short lifespans and reproduce in large numbers, both 
possess orthologs of human genes associated with AD, little gene redundancy, and genetic 
mutations can easily be performed, to generate several transgenic lines simultaneously. 
While C. elegans is a perfect model to perform whole-organism screenings in microtiter 
plates, it is nearly impossible to perform behavioural studies. On the other hand, Drosophila 
has shown its potential as a model for a wide range of studies, and a powerful tool in the 
screening of modifiers that either enhance or suppress AD-associated pathology (Jürgen 
Götz and Ittner 2008; Jürgen Götz and Götz 2009). 
Currently, screening approaches are some of the most powerful tools to identify and 
study potential pathophysiological functions of GWAS-defined risk genes of AD (Pierre 
Dourlen, Chapuis, and Lambert 2018). Our lab possesses the knowhow and the tools to 
develop and perform cell-based and whole-organism (i.e. Drosophila) functional screenings. 
For instance, two studies have recently been published by our lab: one employed a high 
content screening (HCS) approach with siRNA, and associated FRMT2 to the metabolism of 
APP (Julien Chapuis et al. 2017); another used Drosophila to perform in vivo functional 
screening of AD risk loci, and identified PTK2B as a modulator and marker of Tau pathology 
(P. Dourlen et al. 2017). 
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High Content Screening 
High throughput screening (HTS) is a method commonly used in pharmaceutical 
research that allow the evaluation of large amounts of reagents to identify potential 
biological targets and/or biologically active compounds that can be used as drugs. Since the 
1970s, HTS has been used to biochemically characterize compounds against purified 
molecular targets, but the fact that these targets were isolated from their biological 
environment lead to the characterization of millions of compounds that had very little or no 
effect when tested in complex biological models. In the 1990s, cell-based assays started to 
be introduced in HTS in order to overcome the lack of physiological significance of basic 
biochemical assays. The introductions of cells in HTS pipelines introduced other levels of 
complexity to these assays: now researchers could (i) test not only thousands of compounds 
in parallel but also genes and/or their respective proteins, and (ii) analyse a wide range of 
cellular responses. To address these challenges, several readout techniques were developed 
and implemented to HTC, such as microscopy, leading to the development of high content 
screening (HCS) (Xia and Wong 2012). In recent years, both HTS and HCS techniques took 
advantage of the development and miniaturization of biochemical and cellular assays, liquid 
handling automation, and the development of automated quantitative readouts and 
analysis software (Varma, Lo, and Stockwell 2011; Jain and Heutink 2010). 
HCS can be considered as a cell-based multi-metric HTS, resulting from the merge of 
large cellular screening automated assays and multiple readout analysis, obtained from the 
development of microscopy techniques, equipment and resolution. HCS is a technology that 
does not require any prior knowledge of the molecular targets, being particularly useful in 
the characterization of unknown cellular mechanisms and molecular pathways, and is a 
huge advantage when compared to traditional cellular assays in which only few numbers of 
genes can be modulated, or compounds tested, at each experiment (Xia and Wong 2012; 
Mattiazzi Usaj et al. 2016). 
HCS is gaining its space in pharmaceutical industry and academia, applied and basic 
research, but it is still not frequently used as the major primary screening assay. Possibly this 
is due to the long development time, the high throughput microscopy and computational 
hardware and analysis software required, and the specialized expertise needed to carry it 
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out. Another reason for the reduced use of HCS as principal screening assay is the stiff 
statistical requirement to validate the assay’s quality in both HCS and HTS, normally using 
readouts that employ only one variable (e.g. Z’-factor or β-score (Bray and Carpenter 2013)), 
that not only can limit or arrest the development of a HCS assay, often due to the readout 
variability, but also weight in favour of a simpler and/or cell-based HTS instead of a HCS 
(Singh, Carpenter, and Genovesio 2014; Mattiazzi Usaj et al. 2016). 
HCS allows the identification, and possibly the characterization, of regulators and 
molecular pathways of biological, physiological and pathophysiological processes in an 
unbiased manner, using cellular models and microscopy imaging, in automated fashion. 
Most HCS studies are performed with immortalized cell lines, which are easier to 
maintain, manipulate and transfect, usually producing more homogenous cellular responses 
(Daub, Sharma, and Finkbeiner 2009), but in recent years there was an increase in the 
number of studies developed using more physiologically relevant cellular models, most 
notably primary neurons (Evans et al. 2008; Hattori et al. 2010; Charoenkwan et al. 2013; 
McDonough et al. 2017; van Deijk et al. 2017) and induced pluripotent stem cells (Sherman 
and Bang 2018; Ryan et al. 2016). Despite the multiple phenotypic measurements available, 
and sometimes analysed (such as cell number and categorization, neurite length, synaptic 
puncta, etc...), most of the HTS/HCS studies in the field of neurobiology tend to analyse 
almost exclusively cellular development, toxicity and degeneration, and pay little attention 
to the underlying cellular and molecular mechanisms (Cooper et al. 2017). 
To challenge the cellular models and develop any phenotypic modifications, HCS rely 
in three major types of libraries: (i) complementary DNA (cDNA) libraries for the study of 
gene overexpression, (ii) short hairpin and small interfering RNA (shRNA and siRNA) libraries 
to study gene loss-of-function, and (iii) chemical compound libraries that have been used 
since the initial development of HTS. The use of compound libraries enables the direct and 
fast identification of pharmacologically active molecules and new biological targets of 
known compounds, not only leading to the characterization of molecular pathways but also 
to a practical result translation in drug-discovery research. Another advantage of compound 
libraries is that they are fairly easy to automatize and deliver into the cells. On the other 
hand, the compounds active concentrations tend to vary across the library and experimental 
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model, and drugs with higher efficacies usually have multiple targets, potentially 
compensating for pathway redundancies, especially in the nervous system (Cooper et al. 
2017). 
Finally, in order to identify and evaluate those phenotypic changes two major 
approaches can be employed, in association with microscopy. Reporter peptides, such as 
fluorescent proteins (e.g. GFP, DsRed), can be used in live imaging to follow the dynamics of 
target proteins over-time, and even assess protein-protein interaction dynamics through 
techniques such as Förster resonance energy transfer (FRET); however, this approach 
requires the overexpression of modified target proteins. On the other hand, the 
endogenous protein levels and their location can be assessed with the use of antibodies; 
however, immunofluorescence (IF) is not compatible with the study of live cells and simple 
IF does not allow the detection of protein-protein interactions. In the last 15 years, a new 
technique, in situ proximity ligation assay (PLA), has been developed to study protein-
protein interactions at their endogenous levels through microscopy and shown to be a 
powerful tool to analyse protein interactions in physiological levels, in the presence or 
absence of genes and/or compounds of interest (Weibrecht et al. 2010). In fact, in situ PLA 
was even reported to be the major readout in a small-scale screening, using 96-well plate 
format, for the identification of compounds that inhibited the platelet-derived growth factor 
receptor (K.-J. Leuchowius et al. 2010). 
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Proximity Ligation Assay 
Since the development of microscopy several approaches were developed for the 
identification of cell types, detection of subcellular structures, their localization and even 
interaction. Traditional histochemistry and cytochemistry techniques have commonly been 
used to target a heterogeneity of biomolecules, detect cell populations and subcellular 
structures, while the application of antibodies allowed the detection of specific proteins in 
these structures. With the development of fluorescent microscopy, thanks to discovery of 
fluorescent molecules such as the green fluorescent protein (GFP), IF became very popular 
to detect endogenous proteins, identify of their subcellular localization and co-localization. 
This last one can be accomplished by superimposing images of fluorescent channels from 
different targets, but the microscopic resolution does not allow the differentiation of 
proteins co-localization from protein-protein interaction. The possibility to fuse these 
fluorescent molecules to target proteins allowed the development of several assays for the 
in vivo detection of proteins and their subcellular localization, and protein-protein 
interactions, e.g. FRET and bimolecular fluorescence complementation (BiFC). However, 
these techniques rely on the overexpression of proteins and cannot be used to study 
proteins interaction at their endogenous levels. On the other hand, proximity ligation assay 
(PLA) was specifically developed to allow the detection of protein interactions and protein 
PTM at endogenous levels (Weibrecht et al. 2010). 
Since it was first described in 2002, PLA has been used in association with techniques 
as diverse as western blot (WB), ELISA, q-PCR, flow cytometry and IF, to detect (or improve 
the detection of) proteins, PTMs and protein interactions, at endogenous levels. This 
methodologies have been applied in a range of biological systems, such as cell lines and 
primary cultures, tissue section and samples, purified in vitro protein suspensions and 
plasma, in the most diverse fields, including cancer research, immunology, virology, 
neurobiology, drug discovery, and PLA proved to be a useful tool in research and clinical 
diagnose (Blokzijl et al. 2014; K. J. Leuchowius, Weibrecht, and Söderberg 2011). 
In situ PLA is a development of the proximity ligation strategy that allows the 
detection of protein-protein interactions and protein post-translational modifications 
through microscopy with high selectivity and sensitivity, so long as the distance between the 
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target epitopes is inferior to 40 nm (Söderberg et al. 2006; Jarvius et al. 2007; Bagchi, 
Fredriksson, and Wallén-Mackenzie 2015). 
This technique combines the use of (i) specific antibodies targeting the protein(s) of 
interest, with the methods of (ii) proximity ligation, in which DNA strands attached to 
antibodies that bind the target molecule(s) are connected by enzymatic ligation, if the 
targeted molecule(s) are in close proximity, and (iii) rolling-circle amplification, in which a 
single strand of DNA is amplified with fluorescent-labelled oligonucleotides, using the 
ligation product as template, and generates a randomly coiled fluorescent product 
(Gustafsdottir et al. 2005; Weibrecht et al. 2010), Figure 9. Like an IF, in situ PLA can be 
performed using only antibodies targeting the protein(s) of interest or in association with 
secondary antibodies targeting the primary antibodies, and although the use of secondary 
antibodies requires extra steps of incubation and washing, it allows a broader choice of 
primary antibodies. As stated before, the use of antibodies allows the detection of proteins 
at endogenous levels, however this detection is highly dependent of the antibodies affinity, 
sensitivity and selectivity towards the target protein, as well as sample and/or tissue 
processing (fixation, permeabilization, saturation, storage and preservative, and section 
thickness). Another aspect of endogenous protein detection with antibodies is the fact that 
samples need to be fixed, producing only endpoint images of the biological processes of 
interest and not the temporal study of it (Stadler et al. 2013). 
From here on, in situ PLA will be simply referred to as PLA, Figure 10. 
Figure 9 Proximity Ligation Assay (PLA) steps. A) The two proteins of interest are targeted by specific primary antibodies, 
produced in different hosts. B) The two primary antibodies are targeted by secondary antibodies with strands of DNA 
covalently attached, called PLA probes. C) The DNA strands form a template for the ligation of additional oligonucleotides. 
D) The resulting DNA strand is used as template in a rolling circle amplification (RCA) reaction using fluorophores-labelled 
oligonucleotides, which can be visualized by microscopy as intense fluorescent spot.  
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Figure 10 Representative image of BIN1, Tau and BIN1-Tau interaction through PLA, in 14 DIV mixed PNC. Maximum 
intensity projection of images acquired using confocal microscope Zeiss LSM710, with 63x glycerol objective. Scale bar 
correspond to 10 µm. 
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Objectives 
BIN1 is AD’s second most associated genetic risk factor, and is the first to be directly 
associated with Tau. Our team has previously shown that (i) BIN1 risk allele was not only 
associated with higher BIN1 expression levels but also with Tau loads in AD patient brains 
(rs59335482), (ii) variation in the expression of BIN1 fly ortholog, Amph, modulated Tau 
toxic phenotype, and that (iii) BIN1 and Tau interacted in vitro and in vivo (J Chapuis et al. 
2013). 
Although some studies have explored BIN1’s physiological function in neurons and 
its possible role in AD pathophysiological process (Calafate et al. 2016; Ubelmann et al. 
2017; Miyagawa et al. 2016), these studies do not take into account the fact that BIN1 and 
Tau interact. In addition, the function of BIN1-Tau interaction it is not known, nor its role in 
the pathophysiological process of AD, which could be a potential therapeutic target. 
In order to better understand BIN1-Tau interaction, this project was developed with 
three major objectives: (i) identify the interaction sites between BIN1 and Tau, (ii) identify 
how the interaction could be modulated, (iii) highlight molecular pathways that could be 
involved in the modulation of BIN1-Tau interaction, and (iv) understand how BIN1-Tau 
interaction is involved in AD pathological process. 
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Results 
Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s 
proline-rich domain 
Tau is the main component of one of AD’s neuropathological hallmarks, associated 
with neurodegeneration, and BIN1 is a genetic risk factor of AD. Previous work carried out in 
our lab showed that (i) BIN1 risk allele rs59335482 was associated with higher BIN1 
expression levels and with Tau loads in AD patient brains, (ii) Tau toxic phenotype was 
modulated by variation in the expression of BIN1 fly ortholog, Amph, and that (iii) BIN1 and 
Tau interacted in vitro and in vivo (J Chapuis et al. 2013). Tau, besides being a microtubule 
associated protein, is also involved in cell signalling pathways via the recruitment of kinases 
and signalling adaptors through its PRD. Moreover, Tau is strongly regulated by 
phosphorylation, which is deregulated in AD (Guo, Noble, and Hanger 2017). BIN1 is a 
protein with roles in the regulation of the cytoskeleton, membrane remodelling and 
recycling, and endocytosis, mediated by its N-BAR, CLAP and SH3 domains, which bind to 
proline-rich motifs (Prokic, Cowling, and Laporte 2014). 
Therefore, we started by hypothesising that BIN1 and Tau interact through BIN1-SH3 
domain and Tau-PRD, and that Tau phosphorylation could regulate this interaction. Then we 
question if BIN1-Tau interaction is involved in the neuropathological process of a mouse 
model of tauopathy, and searched for the cellular processes and molecular pathways that 
are potentially involved in the modulation of BIN1-Tau interaction. 
Firstly, not only we demonstrated that the interaction between BIN1 and Tau occurs 
through the SH3 domain and the PRD but we also determined that the sequence of amino 
acids from T212 to T231, within the PRD, is involved in this interaction. Furthermore, our 
data indicate that BIN1-Tau interaction is modulated in vitro by Tau phosphorylation of PRD, 
particularly at T231. Upon the confirmation of this data in situ through proximity ligation 
assay (PLA) in primary neuronal cultures (PNC), it was observed a huge decrease of BIN1-Tau 
interaction when targeting Tau phosphorylation at T231, but not when targeting Tau 
phosphorylation at S396/404. This data is consistent with other studies that identified the 
PRD as the interaction site between Tau and its partners, notably those of Src family or that 
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possess SH3 domain, and that demonstrated that T231, but not S396/404, is important in 
the regulation of Tau interaction with Fyn-SH3 domain (Reynolds et al. 2008; Bhaskar, Yen, 
and Lee 2005). Tau is hyperphosphorylated in AD and the phosphorylation of T231 occurs in 
the earlier stages of the disease, before tangle formation (Augustinack et al. 2002). 
Then, we decided to further characterize BIN1-Tau interaction by looking at the 
subcellular localization of this interaction relative to markers of cellular compartments, 
essential to neuronal functions. Using PNC, we saw no co-localization between PLA and a 
marker of the endocytosis pathway, Clathrin, neither with pre- or post-synaptic markers, 
suggesting that BIN1-Tau interaction is not involved in the pathogenic pathways involving 
BIN1 in endocytosis and Tau at the synapse. Conversely, we found a considerable co-
localization between PLA and actin cytoskeleton, leading to the postulation that BIN1-Tau 
interaction might have a role at the interface between actin cytoskeleton and microtubule 
networks. Interestingly, it has been demonstrated that BIN1 and Tau, independently, 
regulate actin dynamics (Elie et al. 2015; Dräger et al. 2017). Furthermore, Tau was shown to 
interact with actin at the post-synaptic densities (Frandemiche et al. 2014) and at the axonal 
growth cone (Biswas and Kalil 2017), and to promote the development of actin bundles, 
when Tau is abnormally phosphorylated (Fulga et al. 2007), suggesting a possible interplay 
between actin cytoskeleton and BIN1-Tau interaction dynamics. 
Our results suggest a link between BIN1, Tau phosphorylation and AD-related 
pathways, and highlight the need for further researched aimed to understand the 
connection between BIN1, Tau, actin cytoskeleton and AD. 
 
This work was published in Acta Neuropathologica Communications in September 
2015, being presented here in its published form, and with the supplementary data (except 
“Additional file 11: A movie showing 3D images processed with IMARIS software”). 
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BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts 
with Tau through Thr348 phosphorylation 
In our previous work on BIN1-Tau interaction, we employed cellular and biochemical 
approaches to (i) identify the BIN1-SH3 domain and Tau-PRD as the domains involved on 
BIN1-Tau interaction, (ii) demonstrate that this interaction is regulated by (at least) 
phosphorylation of Tau at T231, and (iii) show that BIN1-Tau interaction occurs in the vicinity 
of actin cytoskeleton of cultured primary neurons (Sottejeau et al. 2015). Therefore, we 
decided to further characterize this interaction in vivo and in vitro. 
Is has been previously shown that the Drosophila ortholog of BIN1 could modulate 
Tau neurotoxicity in vivo, however the impact of BIN1 expression levels on cognitive function 
has not yet been investigated. To address this point, we crossed a mouse model of 
tauopathy that overexpress human MAPT, but not the murine Mapt, with a mouse model 
that overexpressed the full human BIN1 gene. We observed that the overexpression of BIN1 
induced short-term memory deficits earlier than the hTau mouse model but rescued this 
model long-term memory deficit. Similarly, the hBIN1 mouse model showed no deficit on 
long-term memory test. Although both short-term and long-term memory processes require 
the hippocampus, they take part in different cortical regions, i.e. lateral entorhinal and 
medial entorhinal cortex respectively (Van Cauter et al. 2013), indicating that BIN1 and Tau 
levels may differ in spatial and temporal dimensions, which could explain the opposite 
effects induced by BIN1 overexpression. Interestingly, BIN1 rescue of long-term memory 
deficits induced by hTau was associated with a strong decrease of phosphorylated Tau 
inclusions and a strong increase in BIN1-Tau interaction, in the hippocampus, suggesting that 
BIN1-Tau interaction may be protective against the formation of PHF, by blocking the re-
localization and accumulation of phosphorylated Tau. 
In addition, Tau overexpression was associated with myelin abnormalities at 18 
months and BIN1 overexpression rescued Tau phenotype. Tau had already been associated 
with potential myelin dysfunction (Sotiropoulos et al. 2014; Krämer-Albers and White 2011), 
and recently BIN1 has been described to be expressed in oligodendrocytes, but dysregulated 
in AD (De Rossi et al. 2016; McKenzie et al. 2017). 
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Taking this information together with the latest reports showing that the protein 
levels of the neuronal isoform of BIN1 are decreased in AD (Glennon et al. 2013; Holler et al. 
2014; De Rossi et al. 2016), we hypothesise that higher levels of BIN1 protein would be 
protective in AD, either through the regulation of BIN1-Tau interaction or through the rescue 
of myelin abnormalities induced by Tau. 
Focusing on the regulation of BIN1-Tau interaction, we proceeded to investigate the 
dynamics of this interaction during neuronal development, and observed a clear increase of 
neuronal isoform of BIN1 and Tau protein levels, a concomitant decrease of Tau 
phosphorylation levels, particularly in epitopes associated with T231 (which we had already 
described to negatively impact the interaction between BIN1-SH3 and Tau-PRD), and a 
decrease of BIN1-Tau interaction, but not in the same proportion of the total protein or Tau 
phosphorylation levels. Then we confirmed that the expression level of BIN1 is a modulator 
of BIN1-Tau interaction through the silencing or overexpression BIN1 neuronal isoform 
(BIN1iso1) and observed a decrease of BIN1-Tau interaction upon underexpression and an 
increase upon overexpression of BIN1iso1. This data suggests that, even if BIN1-Tau 
interaction is restricted to certain loci in neurons, such as the actin tips (as described 
before), and dependent of Tau phosphorylation levels, variation in BIN1iso1 levels definitely 
affect the dynamics of BIN1-Tau interaction (supporting the data obtained with the 
transgenic mice) and its subsequent physiological or pathophysiological functions. 
The fact that phosphorylation of Tau PRD (mainly at T231) inhibits its interaction with 
the BIN1 SH3 domain lead us to hypothesize that BIN1-Tau interaction dynamics is likely 
dependent on specific signaling pathways that regulate Tau phosphorylation. 
In order to identify the molecular pathways involved in the regulation of BIN1-Tau 
interaction we developed a novel, semi-automated HCS approached, based on PNC as 
cellular model and PLA as readout of BIN1-Tau interaction. For this work, we chose to 
challenge our cellular model with the compound library Tocriscreen™ Mini (#2890; Tocris 
Biosciences; Bristol, UK), a library of well-characterized biologically active compounds, 
suitable for HTS/HCS and chemical biology applications, with proven solubility, purity and 
stability. This library provides compounds that target enzyme coupled receptors, GPRs, ion 
channels, transporters, cytosolic and nuclear receptors, enzymes and enzymatic complexes 
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(between others); allowing the screening of a wide-range of cellular processes, such as 
inflammation, apoptosis, cell differentiation, signal transduction, intracellular transport; and 
the possibility to be used in different fields like neuroscience, cancer, endocrinology, 
epigenetics, stem cell and cardiovascular research. In addition to the compounds of this 
library we also tested 6 Sanofi proprietary compounds that targeted well characterized 
enzymes, suspected to be deregulated in AD, in a blind manner. 
Out of the 1126 tested compounds, 79 were excluded due to poor network quality. 
From the 1047, the strongest modulators of BIN1-Tau interaction were selected for the 
validation experiment. After dose-response curve (DRC) experiment, we retained 12 
compounds that consistently exhibited the strongest modulation of BIN1-Tau interaction 
throughout all the screening and validation steps, which corresponds to about 1 % of all the 
tested compounds. This hit rate is very interesting, due to the fact that not very HCS studies 
are performed using physiological conditions and endogenous protein levels, even less are 
performed with PNC (especially post-natal) which have much more heterogeneous 
responses than cell lines, and to our knowledge this is only the second study to employ PLA 
as a readout, and the first to do it in 384-well plate format. 
The 12 compounds selected from DRC experiments could be grouped into 5 
categories, according to their targets: we identified compounds that were associated with 
the (i) regulation of phosphorylation, such as Cyclosporin A (CsA), an inhibitor of Calcineurin 
phosphatase activity that increased the interaction levels, and U0126, a MEK1/2 inhibitor 
that decreased BIN1-Tau interaction levels; in the category of (ii) NO-synthase (NOS) 
targeting compounds we identified TRIM, a potent inhibitor of neuronal and inducible NOS, 
and Diphenyleneiodonium chloride, a GPR3 agonist that also inhibits NADPH oxidase and 
NOS, and both increased the interaction; as (iii) Ca2+ homeostasis targeting compounds we 
identified (±)-Bay K 8644, a L-type Ca2+ channel activator, and DHBP dibromide, an inhibitor 
of endoplasmic reticulum Ca2+ release, and both also increased the interaction; in the (iv) 
receptor targeting compounds we identified that BRL37344 sodium salt, a β3 agonist, and 
BU 226 hydrochloride, a potent and highly selective I2 ligand, increased the interaction, 
while SB 258585 hydrochloride, a potent and selective 5-HT6 antagonist, increased BIN1-Tau 
interaction at very low concentration followed by a decrease of this effect in a concentration 
manner, in agreement with the provided Ki for this compound; as compounds with (v) other 
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targets we identified that JLK6, an inhibitor of γ-secretase-mediated βAPP processing, and 
MNITMT, a non-toxic immunosuppressive agent, also increased the interaction, while 
Doxorubicin hydrochloride, a tumour suppressor drug shown to inhibit DNA topoisomerase II 
and reduce Tau cellular levels was able to decrease BIN1-Tau interaction. 
Knowing that BIN1-Tau interaction is modulated by Tau phosphorylation, we decided 
to further investigate the effect of CsA and U0126 on the modulation of BIN1-Tau 
interaction. We took especial interest on Calcineurin because it had not only been associated 
with AD and Tau dephosphorylation but also has been described to dephosphorylate 
Amphiphysin1, the homolog of BIN1 (Bauerfeind, Takei, and De Camilli 1997). Therefore, we 
postulated that Calcineurin could also target BIN1, and modulate BIN1-Tau interaction 
through its phosphorylation, but we had no simple way to address this suggestion. 
It had been previously reported that BIN1iso1 was involved in intramolecular 
interaction between its own PRD and SH3 domain (Malki et al. 2017), and we reported that 
phosphorylation on PRD lead to a decrease of PRD-SH3 interaction (Sottejeau et al. 2015). 
Furthermore, when comparing Amphiphysin 1 and BIN1 sequences we observed that their 
PRD in the CLAP domains appears to be highly conserved. Interestingly, a Threonine of 
Amphiphysin1, in this sequence, that had been shown to be target of Cdk5 (Liang et al. 2007) 
has a corresponding Threonine in BIN1 sequence (T348). Thus, we hypothesized that T348 of 
BIN1 might be able to regulate the intramolecular interaction between PRD and SH3 domain 
of BIN1, similarly to how T231 of Tau regulates its interaction with BIN1. 
To validate these two hypotheses, we developed and validated an antibody against 
BIN1 phosphorylated at T348, by assessing its sensitivity to Lambda protein phosphatase 
activity on crude protein extracts of PNC, and to cyclin-dependent kinases (Cdks) activity on 
purified recombinant protein. Then we used this antibody to assess the effect of CsA and 
U0126 on BIN1 phosphorylation, and observed a strong increase of BIN1 phosphorylated at 
T348 when incubating our PNC with CsA, and almost no effect when incubating with U0126. 
Conversely, Tau phosphorylation at T231 was strongly increased upon incubation of U0126, 
and was slightly affected upon incubation with CsA. Interestingly, T231 is not a target 
dephosphorylation site of Calcineurin (J. Z. Wang et al. 2012) and the modulation observed 
in the phosphorylation status of this epitope could be an off-target effect. Taken together 
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with the results from HCS, this data suggests that (i) the increase of BIN1-Tau interaction 
observed after inhibition of Calcineurin is due to an increase of BIN1 T348 phosphorylation, 
and (ii) the decrease of BIN1-Tau interaction upon inhibition of MEK1/2 was associated to an 
increase of Tau T231 phosphorylation. 
Therefore, the regulation of BIN1-Tau interaction might also be associated with 
Calcineurin/Cdk5 signalling and MAPK signalling pathway: Calcineurin and Cdk5 have been 
proposed as a phosphatase/kinase duplet, responsible for the regulation of phosphorylated 
and dephosphorylated states of proteins involved in synaptic vesicle endocytosis, notably 
Amphiphysin1, during neurotransmission (Bauerfeind, Takei, and De Camilli 1997; Tomizawa 
et al. 2003), and might have a similar role on BIN1; and, on the other hand, Tau T231 is 
phosphorylated by ERK2, which is downstream of MEK1/2 in the MAPK signalling pathway 
(Qi et al. 2016). 
We decided to further determine if the phosphorylation status of BIN1 at T348 could 
control the conformational dynamics of BIN1. Through nuclear magnetic resonance (NMR), 
we observed that (i) the SH3 domain of non-phosphorylated BIN1 is involved in 
intramolecular interaction with BIN1-CLAP-PRD, while the SH3 domain of BIN1 
phosphorylated by Cdk2 (hole protein phosphorylated) and of BIN1iso1 with Threonine 348 
mutated to glutamate (a phospho-mimetic mutation,  BIN1 T348E) was free; and that (ii) 
BIN1-SH3 domain had much less affinity for BIN1-CLAP domain phosphorylated at T348 than 
for non-phosphorylated BIN1-CLAP domain. Interestingly it had been previously reported 
that BIN1-SH3 domain had much less affinity for non-phosphorylated BIN1-CLAP domain 
than for Tau-PRD (Malki et al. 2017). In addition, we confirmed the regulatory role of BIN1 
phosphorylation at T348 by overexpressing BIN1iso1 and BIN1 T348E in PNC, and we 
observed a strong increase on BIN1-Tau interaction upon overexpression of BIN1 phospho-
mimetic construct, as observed by the increase of BIN1-Tau PLA levels. This data show that 
phosphorylation of T348 is enough to induce the opened form of BIN1, leaving the SH3 
domain available for interaction with the PRD of other proteins, including Tau, playing a 
central role in the regulation of BIN1-Tau interaction. 
The interaction between BIN1 and Tau is strongly regulated by phosphorylation: 
phosphorylation of Tau at T231 reduces the interaction, while phosphorylation of BIN1 at 
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T348 increases the interaction. We know that there is an imbalance in the regulation of 
kinase/phosphatase activity during AD and this leads to an increase of Tau phosphorylated 
at T231, since the earlier stages of AD pathophysiological process. Conversely, nothing is 
known about the phosphorylation levels of BIN1 T348 in the brains of AD patients. Here, we 
confirmed that BIN1iso1 protein levels are decreased in the brains of AD patients and, for 
the first reported time, we observed an increase of the BIN1 phosphorylation levels at T348, 
relatively to BIN1iso1. We propose that this relative increase of T348 phosphorylation levels 
might be a compensatory mechanism to increase BIN1 function and/or BIN1-Tau interaction 
levels, and protect against the reduction of the neuronal isoform of BIN1. 
In conclusion, our data supports the idea that BIN1 modulates the AD risk through an 
intricate regulation of its interaction with Tau, and that any modulation in BIN1 expression 
or activity may disrupt this regulatory balance with direct effects on learning and memory. 
 
This work has been communicated to the scientific community through submission to 
bioRxiv, being presented here in its submitted form, main manuscript and supplementary 
data. 
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Abstract 
The bridging integrator 1 gene (BIN1) is a major genetic risk factor for Alzheimer’s disease 
(AD). In this report, we investigated how BIN1-dependent pathophysiological processes 
might be associated with Tau. We first generated a cohort of control and transgenic mice 
either overexpressing human MAPT (TgMAPT) or both human MAPT and BIN1 
(TgMAPT;TgBIN1), which we followed-up from 3 to 15 months. In TgMAPT;TgBIN1 mice 
short-term memory deficits appeared earlier than in TgMAPT mice; however – unlike 
TgMAPT mice – TgMAPT;TgBIN1 mice did not exhibit any long-term or spatial memory 
deficits for at least 15 months. After sacrifice of the cohort at 18 months, 
immunohistochemistry revealed that BIN1 overexpression prevents both Tau mislocalization 
and somatic inclusion in the hippocampus, where an increase in BIN1-Tau interaction was 
also observed. We then sought mechanisms controlling the BIN1-Tau interaction. We 
developed a high-content screening approach to characterize modulators of the BIN1-Tau 
interaction in an agnostic way (1,126 compounds targeting multiple pathways), and we 
identified – among others – an inhibitor of Calcineurin, a Ser/Thr phosphatase. We 
determined that Calcineurin dephosphorylates BIN1 on a Cyclin-dependent kinase 
phosphorylation site at T348, promoting the open conformation of the neuronal BIN1 isoform. 
Phosphorylation of this site increases the availability of the BIN1 SH3 domain for Tau 
interaction, as demonstrated by nuclear magnetic resonance experiments and in primary 
neurons. Finally, we observed that the levels of the neuronal BIN1 isoform were decreased in 
AD brains, whereas phospho-BIN1(T348):BIN1 ratio was increased, suggesting a 
compensatory mechanism. In conclusion, our data support the idea that BIN1 modulates the 
AD risk through an intricate regulation of its interaction with Tau. Alteration in BIN1 
expression or activity may disrupt this regulatory balance with Tau and have direct effects on 
learning and memory. 
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Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is clinically 
characterized among others by memory deficits affecting first short term and then long term 
and spatial memory. AD constitutes a major public, medical, societal, and economic issue 
worldwide, with 35.6 million people suffering from the disease and a forecast of 106 million in 
2050 [41]. Responding effectively to this AD crisis necessitates a better understanding of this 
disease in order to improve diagnosis and therapy. 
AD is characterized by two main types of brain lesions: (i) amyloid plaques, resulting from 
the extracellular accumulation of amyloid beta (Aβ) peptides; (ii) neurofibrillar degeneration, 
due to the intracellular aggregation of abnormally hyperphosphorylated Tau proteins. This 
latter aggregation is associated with an ectopic localization of Tau from the axonal 
compartment to the somato-dendritic compartment [53]. 
The discovery of mutations in the APP, PS1 and PS2 genes (coding for amyloid precursor 
protein, APP, and presenilins 1 and 2), responsible for early-onset, autosomal-dominant 
forms of AD, has placed Aβ oligomer production at the center of the pathophysiological 
process [25]. A better understanding of the genetic component of the common, complex 
forms of AD, which is exceptionally high among multifactorial aging-related diseases [22], is 
required to decipher the pathophysiological processes of AD. Genome-wide association 
studies (GWAS) allowed for the identification of more than 30 loci associated with the late-
onset forms of AD [27,31,32,47], including the bridging integrator 1 gene (BIN1). A part of 
these genes pointed out a potential failure in Aβ clearance, leading to more insidious Aβ 
accumulation in the brain [30,47]. On the other hand, it is only recently that AD genetic risk 
factors have been also associated with Tau pathology, following the development of 
systematic screenings in Drosophila which allowed for the identification of genetic modifiers 
by assessing eye roughness and eye size as readouts of Tau neurotoxicity [19,45,46] and 
their associations with endophenotypes related to Tau [6,16,19]. Such observations are of 
high importance since, contrary to amyloid plaques, neurofibrillary tangles (NFTs) are well 
correlated with cognitive impairment both in humans [39] and in animal models [28]. 
Among the genes described to genetically interact with human Tau transgene in Drosophila, 
BIN1 was further described to directly interact with the Tau protein by NMR spectroscopy 
using recombinant proteins, in vitro glutathion S-transferase (GST) pull-down from HEK293 
lysates, as well as reciprocal co-immunoprecipitation from mouse brain synaptosome 
homogenates [14]. In addition, a genome-wide significant functional risk variant in the vicinity 
of BIN1 locus has been associated with Tau loads (but not with Aβ loads) in AD brains [19]. 
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The BIN1 gene codes for Amphiphysin 2, also called BIN1, a ubiquitously expressed protein 
involved in membrane remodeling. BIN1 comprises a N-BAR domain involved in membrane 
curvature sensing, an SH3 domain that binds to proline-rich motifs present in a number of 
proteins including itself, and a clathrin- and AP2-binding domain (CLAP) specific of the 
neuronal isoform 1 [42]. In the central nervous system (CNS), BIN1 is mostly found in the 
axon initial segment, at the nodes of Ranvier [11], and at the synapse [44,17], and was also 
associated with myelinated axons and oligodendrocytes in the white and grey matter [18]. 
However, little is known about its function in the CNS. We recently described the 
consequences of increased human BIN1 expression in the mouse brain, which exhibits early 
alterations in the neuronal tract between the entorhinal cortex and the dentate gyrus of the 
hippocampus, leading to impaired novel object recognition and aging-related changes [17]. 
Altogether, BIN1 overexpression affects the aging brain and induces neurodegeneration 
[17]. 
Little is also known about BIN1 in the context of AD. Several teams evaluated potential links 
between AD and BIN1 and determined: (i) BIN1 may regulate BACE1 intracellular trafficking 
through multiple mechanisms and subsequently alter Aβ peptide production [37]; (ii) BIN1 
may have a role in plasma membrane remodeling during myelination, which is known to be 
affected in AD [18,36]; (iii) BIN1 may participate in the neuron-to-neuron propagation of Tau 
prion strains [12]; and (iv) BIN1 may directly interact with Tau and interfere with Tau 
neurotoxicity via unknown mechanisms [19,35]. In this study, we developed a 
multidisciplinary approach encompassing molecular, cellular, and behavioral experiments to 
determine how BIN1 is involved in the pathophysiological processes of AD. To this end we 
assessed for the first time the impact of human BIN1 overexpression in a mouse model of 
tauopathy and further dissected the interaction between Tau and BIN1 at the molecular and 
cellular levels. 
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Materials and Methods 
Animal ethics 
Animal experiments were approved by the Com’Eth (project file: 2014-056) and accredited 
by the French Ministry for Superior Education and Research in accordance with the Directive 
of the European Parliament: 2010/63/EU. For all tests described, mice were kept in specific 
pathogen free conditions with free access to food and water, and were bred with littermates. 
The light cycle was controlled as 12 h light and 12 h dark (lights on at 7AM). Before all 
behavioral experiments, handling was done every day for one week before the beginning of 
the experiment.  
Mouse lines and genotyping 
We used several mouse lines carrying the inactivation of Mapt: B6.Cg Mapttm1(EGFP)Klt/+, noted 
here Mapt+/- [50], a line overexpressing human Tau: B6.Cg Mapttm1(EGFP)Klt/tm1(EGFP)Klt 
Tg(MAPT)8cPdav/J, named here hTau [2], and another line overexpressing human BIN1: B6 
Tg(Bin1)U154.16.16Yah, named here TgBIN1/0 [17]. In order to generate cohorts of animals 
carrying hTau alone, hTau;TgBIN1, and Mapt+/- as control littermates, we crossed Mapt+/-
;Tg(MAPT)8cPdav/J with Mapt+/-;TgBIN1. All animals were crossed on C57BL/6J 
background. Primer sequences are available in Table S1. 
Design of behavioral experiments 
Animals studied in behavioral tasks were both males and females. Same animals were 
longitudinally tested at 3, 6, 9, 12, and 15 months. All animals were killed at 18 months for 
histology and molecular biology experiments.  
Open field paradigm 
For the open field paradigm, mice were tested in a 55 cm-diameter white round box. Mouse 
activity was recorded with the Ethovision video tracking system (Noldus, Paris, France) 
during a single session of 30 min. The arena was placed in a room homogeneously 
illuminated at 50 lux. Each mouse was allowed to explore the apparatus freely for 30 min 
with the experimenter out of the animal’s sight. The distance travelled and time spent in the 
central and peripheral regions were recorded over the test session. 
Novel object recognition task 
This task was performed in the same conditions as in the open field paradigm (see above). 
The objects to be discriminated were a glass marble (2.5 cm in diameter) and a plastic dice 
(2 cm). The animals were first habituated to the open field for 30 min. The next day, they 
were submitted to a 10 min acquisition trial during which they were placed in the open field in 
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the presence of two similar objects (object A; marble or dice). The time the animal took to 
explore the object A (when the animal’s snout was directed towards the object at a distance 
≤ 1 cm) was recorded manually. A 10 min retention trial was performed 1 h later. During this 
trial, one of the familiar objects in the open field was replaced with a new one (object B), and 
the time periods that the animal took to explore the two objects were recorded (tA and tB for 
objects A and B, respectively). Two exclusion criteria were applied to select those animals 
that had memorized the objects: (i) during the acquisition trial, mice exploration should be 
longer than 3 s, and (ii) during the retention trial, mice exploration should also be longer than 
3 s. The exploration index for object B was defined as (tB / (tA + tB)) × 100. Memory was 
defined by the percentage of time animals spent investigating the novel object statistically 
different from the chance (50%). To control for odor cues, the open field arena and the 
objects were thoroughly cleaned with 50% ethanol, dried, and ventilated between sessions. 
All animals were tracked with the Ethovision software. 
Morris water maze task 
The Morris water maze was used to test spatial learning and memory. Each session was 
performed one week after NOR task and constituted the last behavioral experiment. The 
water maze is a circular pool (150 cm in diameter, 60 cm in height), filled with water up to 40 
cm mark that is maintained at 20-22°C, and made opaque using a white aqueous emulsion 
(Acusol OP 301 opacifier). The surface was split into 4 quadrants: South-East (SE), North-
West (NW), North-East (NE), and South-West (SW). The escape platform, made of rough 
plastic, was submerged 1 cm below the water’s surface. Experiments were performed to 
study reference memory through a spatial search strategy that involved finding the hidden 
platform. The spatial memory session consisted of a 6-day (J1 to J6) learning phase with 
four 90 s trials per day. Each trial started with mice facing the interior wall of the pool and 
ended when they climbed onto the platform located on the SE quadrant, or after a maximum 
searching time of 90 s. The starting position was changed pseudo-randomly between trials. 
Mice were left undisturbed in their home cage for 90 min intertrial intervals. On the 7th day, 
mice were given the 60 s probe test, in which the platform had been removed. The distances 
traveled in each quadrant (NW, NE, SW, and SE) were recorded, as well as the time spent 
in the target quadrant. At 6, 9 and 12 months of age, the platform was located in the NE 
quadrant, whereas at 15 months of age, the platform was located in the SW quadrant. All 
animals were tracked with the Ethovision software. 
Brain protein extraction and Western blotting 
Mice were killed by cervical dislocation and brains were quickly removed and dissected. 
Structures were immediately frozen in liquid nitrogen, and conserved at -80°C. For protein 
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extraction we used fresh extraction buffer with pH adjusted to 7.5 (20 mM Tris at pH = 7.5; 
50 mM NaCl; 2 mM EGTA; 1% Triton X-100; 10 mM NaF; 1 mM Na3VO4; 2 mM β 
Glycerophosphate; cOmplete™ EDTA-free protease inhibitor cocktail). Tissues were lysed 
using Precellys apparatus and centrifuged at 33,000 ×g for 30 min. Protein quantification 
was performed using the BCA protein assay (Thermo Scientific; Waltham, MA). 10-20 μg of 
total protein from extracts were separated in SDS–polyacrylamide gels (10%) and 
transferred to nitrocellulose membranes. Depending on the target protein, we used bovine 
serum albumin or milk (5% in Tris-buffered saline with 0.1% Tween-20, TTBS; 1 h at RT) to 
block non-specific binding sites of phosphorylated and non-phosphorylated proteins, 
respectively. Immunoblotting was carried out with primary antibodies (Table S2) for 1 h at 
RT. Then membranes were washed 5 times in TTBS, followed by incubation with secondary 
antibodies conjugated with horseradish peroxidase (Table S2). Immunoreactivity was 
visualized using ECL chemiluminescence system (SuperSignal™, Thermo Scientific). 
Chemiluminescence was captured with Amersham Imager and signals were quantified with 
ImageJ (NIH; Bethesda, MD). 
Immunofluorescence in brain slices 
Mice were anesthetized with 5% ketamine and 10% xylazine and perfused first with PBS and 
then with 4% paraformaldehyde (PFA) in PBS. After removal, brains were immerged in 4% 
PFA overnight at 4°C, followed by multiple rinses with PBS, and put in 30% sucrose in PBS 
until they sink. Once they sink, they were embedded in O.C.T. tissue freezing compound 
(Scigen; Gardena, CA), and stored at -80°C until they were cut with a cryostat at 10 µm 
thickness. For immunofluorosence, slices were first permeabilized with 0.1% Triton in PBS, 
with 10% horse serum and 5% BSA for 30 min. The primary antibody (Table S2) was then 
applied overnight at 4°C in the permeabilization buffer. After multiple rinses with PBS, the 
secondary antibody (Table S2) in 0.1% Triton was applied for 1 h at RT. After multiple 
rinses, slices were stained with 1:1000 Hoechst (Sigma; St. Louis, MO). After multiple rinses, 
slices were mounted in Fluorsave (Merck Millipore; Darmstadt, Germany). Slices were 
imaged with NanoZoomer slice scanner (Hamamatsu Photonics; Massy, France).  
Electron microscopy of brain slices 
Mice were PFA-fixed as described. After removal, brains were immerged in 4% PFA and 4% 
glutaraldehyde in PBS overnight at 4°C. Coronal sections were obtained with Leica VT1000 
vibratome (Leica Biosystems; Nanterre, France), and the tissue was cut to expose the dorsal 
fornix and the upper part of the hippocampus. The tissues were post-fixed in 1% osmium 
tetroxide, dehydrated through graded ethanol (50, 70, 90, and 100%) and propylene oxide 
for 30 min each, and embedded in Epon 812 (EMS; Hatfield, PA). Semithin sections were 
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cut at 2 µm on an ultra-microtome (Ultracut UCT; Leica) and ultrathin sections were cut at 70 
nm, contrasted with uranyl acetate and lead citrate, and examined at 70 kV using a 
Morgagni 268D electron microscope (Thermo Scientific). Images were captured digitally by 
Mega View III camera (Soft Imaging System; Münster, Germany).  
Primary neuronal culture 
Culture media and supplements were from Thermo Scientific, unless mentioned otherwise. 
Primary hippocampal neurons were obtained from P0/P1 rats, according to previously 
described procedures with minor modifications [5,29]. Briefly, cortices and hippocampi were 
isolated from new-born rats, washed with ice-cold dissection medium (HBSS supplemented 
with HEPES, sodium pyruvate, and penicillin/streptomycin), and trypsinized (2.5%; 10 min; 
37°C). Trypsin was inactivated with dissociation medium (MEM supplemented with 
inactivated FBS, Glutamax, D-glucose (Sigma), MEM vitamins, and penicillin/streptomycin), 
followed by DNase (5 mg/ml; Sigma) incubation for 1 min and wash with dissection medium. 
Media was replaced by dissociation medium and tissue was triturated with a fire-polished 
cotton-plugged Pasteur pipette to obtain a homogenous cell suspension, followed by 
centrifugation (200 ×g for 5 min) and wash with dissociation medium. Cells were 
resuspended in culture medium (Neurobasal A supplemented with Glutamax and B27 neural 
supplement with antioxidants), counted, and plated in 384-well plates (Greiner bio-one; 
Kremsmünster, Austria) at a density of 50,000 cells/cm2 for HCS, on Ø13 mm coverslips in 
24-well plates at a density of 25,000 cells/cm² for proximity ligation assay (PLA), or directly in 
24-well plates without coverslips at density 100,000 cells/cm2 for immunoblots. Coverslips 
and plates were pre-coated with poly-L-lysine (Alamanda Polymers; Huntsville, AL) overnight 
at 37°C and rinsed thoroughly with water. After 20-24 h, culture media was replaced with 
supplemented Neurobasal A medium and cultures were maintained in a tissue culture 
incubator (Panasonic; Osaka, Japan) at 37°C and 5% CO2 for 7, 14, or 21 days. 
Viral transductions 
Primary neuronal cultures (PNC) were transduced on DIV8 with lentiviral constructs for 
silencing (MOI = 4) using Mission pLKO,1-puro-CMV-shRNA vectors (Sigma), non-targeting 
(05191520MN) and shBIN1 (TRCN0000380439). Overexpression constructs were obtained 
from Gene Art (Thermo Fisher) based on pLenti6/Ubc/v5-DEST vectors (Life Technologies, 
Carlsbad, CA): BIN1iso1 (NM_009668), BIN1iso1 phosphomimetic T348E (cDNA with 
Thr348→Glu), BIN1 isoform 9 (NM_139349), and an overexpression control vector (mock). 
The transduction was performed according to a previously described procedure with minor 
modifications [34]: For PNC in 24-well plates, viral constructs at multiplicity of infection (MOI) 
2 were added to pre-warmed supplemented Neurobasal A media with Polybrene (0.1% final 
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concentration; Sigma) at 10× concentration. Half of the culture media from multi-well plates 
were collected and stored. The transduction mixture was added to each well to reach 250 µl 
final volume and neurons were incubated for 6 h. At the end of this period, wells were topped 
with 250 µl collected media and neurons were maintained in the incubator until fixation or 
protein harvest. Transduced neurons were either fixed or harvested on DIV14.  
Immunoblotting 
PNC were harvested in minimum volume of 40 µl/well in ice-cold lysis buffer as described 
elsewhere [13]. Lysates were mixed with 4× LDS (Novex; Life Technologies) and 10× 
reducing agent (Novex) loaded on pre-cast NuPage 4-12% bis-Tris acrylamide 10 well gels 
(Novex) and transferred to nitrocellulose membranes using the BioRad Trans-blot transfer 
system kit (BioRad, Hercules, CA). Membranes were blocked in 5% non-fat milk in 1x TNT 
buffer. Primary antibodies were diluted in SuperBlock T20 (TBS) blocking buffer (Thermo 
Fisher) and kept at 4°C overnight: mouse BIN1-99D (clone 99D; 1:1,000; cat. no. 05-449, 
Merck Millipore), rabbit TauC (1:10,000), mouse beta-actin (1:10,000; Sigma), rabbit 
phospho-BIN1 Thr 348 (1:10,000; custom made by Biotem, Apprieu, France), mouse Tau 1 
non-phospho Ser 195-Ser 202 (aa197-205) (1:10,000; Merck Millipore), mouse AT180 
phospho Thr 231 (1:500, Thermo Fisher), mouse RZ3 Thr 231 (1:500), and mouse PHF1 
phospho Ser396/404 (1:1000). The last two antibodies were kind gifts from Peter Davies. 
We further confirmed the specificity of this antibody for the neuronal isoform by silencing 
BIN1 and overexpressing BIN1iso1 or BIN1iso9 (Fig. S1). Detection was performed using 
horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000, Jackson) for 1-2 h 
at RT. The membrane was revealed through chemiluminescence (Luminata CrescendoTM, 
EMD Merck Millipore) and imaged with Amersham Imager 600 (GE Healthcare, 
Mississauga, Canada). The images were quantified with ImageQuantTL Software (GE 
Healthcare). 
Analysis of neuropathological human sample cohort 
Assessment of AD-related neurofibrillary pathology (Braak stage) was performed for 14 
individuals after death (Table S3) with immunostaining of paraffin sections with AT8 
antibody, which detects hyperphosphorylated Tau [7]. Protein extractions from the frozen 
temporal lobe tissue samples were performed as previously described [38]. Protein 
quantification was performed using BCA protein assay. Total proteins (20 µg/lane) were 
separated on 4-12% Bis-Tris-polyacrylamide gel electrophoresis (PAGE; Invitrogen) under 
reducing conditions and subsequently blotted onto polyvinylidene difluoride membranes 
using iBlot 2 Dry Blotting System (Thermo Scientific). Primary antibodies against phospho-
BIN1 Thr 348 (1:1,000), total BIN1 (1:1,000) and β-actin (1:1,000; cat. no. ab8226, Abcam) 
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were used for immunoblotting. After incubation with the appropriate HRP-conjugated 
secondary antibodies, the protein bands were detected using ImageJ.  
Lambda protein phosphatase assay 
Crude protein extracts were incubated with Lambda protein phosphatase (New England 
Biolabs; Ipswich, MA), following supplier’s instructions with minor changes. DIV21 PNC were 
harvested on ice in 40 µl ice-cold lysis buffer per well without protein phosphatase inhibitors, 
lysates were sonicated, centrifuged for 10 min at 1,000× g and the supernatant was 
distributed into 2 new tubes; volumes were adjusted to 40 μl with MilliQ H2O, and 
supplemented with 5 µl of 10× NEBuffer and 5 µl of 10 mM MnCl2 (provided with the 
enzyme); 1 μl of lambda protein phosphatase (λ-PP) was added to one of the tubes and both 
tubes were incubated for 30 min at 30°C. 4× LDS and 10× reducing agent were added to the 
tubes, samples were boiled at 95°C for 10 min and immunoblotted as described before. 
In vitro assay with recombinant proteins  
BIN1 phosphorylation in vitro was assessed in kinase buffer containing 20 mM MOPS, pH 
7.4, 5 mM MgCl2, 100 μM ATP, and 1 mM DTT. Purified GST-BIN1 (500 ng) was incubated 
with recombinant GST-tagged Cdk5/p35 (100 ng) at RT for 1h. The reaction was terminated 
by the addition of boiled SDS sample buffer. After electrophoresis of the samples were run 
on SDS-PAGE. In addition, Cdk2/CycA3 kinase [52] was used to obtain Bin1iso1 
phosphorylated on T348 residue. The capacity of the kinase to phosphorylate T348 was first 
verified using the CLAP (334-355) peptide as substrate and mass spectrometry to assess 
the addition of a phosphate group. In addition, the phosphorylated peptide was detected 
using the antibody directed against pT348 (Fig. S2a, inset). For NMR experiments, 100 µM 
15N-BIN1iso1 was incubated with recombinant Cdk2/CycA3 kinase (molar ratio 1/100), for 3 
h at 37°C, in the presence of 2 mM ATP, 2.5 mM MgCl2, 2 mM EGTA, 2 mM DTT, 30 mM 
NaCl and protease inhibitors in 50 mM HEPES, pH 8.0 (Fig. S2). Control experiment was 
performed in the absence of ATP. Phosphorylation of Bin1Iso1 at T348 was verified using 
western blot analysis with an antibody directed against pT348. 
NMR spectroscopy 
NMR experiments were recorded at 20°C on Bruker 900-MHz spectrometer. NMR 
measurements were performed in 50 mM sodium phosphate buffer, pH 7.3, 30 mM NaCl, 3 
mM DTT and 10% D2O. BIN1iso1, BIN1iso1-CLAP-T348E and Cdk2-phospho-BIN1iso1 
1H-
15N HSQC spectra were all recorded with a TXI probe at a protein concentration of 100 µM. 
These 2D spectra were acquired with 3072 points in the direct and 180 points in indirect 
dimensions for spectral width of 13 ppm and 26 ppm, respectively, and with 512 scans. 
BIN1-SH3 domain 1H-15N HSQC spectrum was recorded with a cryogenic probe with 3072 
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points in the direct and 256 points in indirect dimensions for spectral width of 14 ppm and 26 
ppm, respectively, and with 48 scans. Spectra were processed using TopSpin software 
(Bruker). BIN1-SH3 domain backbone assignments were previously reported [35]. The NMR 
titration data were obtained by adding aliquots of 4 mM stock solutions of unlabeled peptides 
Q L R K G P P V P P P P K H T P S K E V K Q CLAP (334-355) or phospho-T348 CLAP 
(334-355), phosphorylated residue in bold in the sequence, to 100 µM 15N-labeled BIN1-SH3 
domain, using HSQC spectra to monitor changes in amide and tryptophan indole chemical 
shift values. Kd were calculated based on these data (see Supplementary Information for 
details). 
Semi-automated high-content screening for modulators of BIN1-Tau interaction  
A compound screen was setup by combining a commercial library of 1,120 compounds (10 
µM; #2890; Tocris Biosciences, Bristol, UK), 6 Sanofi proprietary compounds (0.1, 1, and 10 
µM; Sanofi; Chilly-Mazarin, France), Okadaic acid (1 µM; Merck Millipore) as a control 
compound, and DMSO (0.1%; VWR; Radnor, PA). Tocriscreen™ Mini is a library of well-
characterized biologically active compounds that allows the screening of a wide-range of 
cellular processes, such as inflammation, apoptosis, cell differentiation, signal transduction, 
intracellular transport. 1000× stock compounds were transferred into intermediate 384-well 
plates using Echo 550 liquid Handler (Labcyte; San Jose, CA), and plates were sealed and 
kept at -20°C. Neurons cultured in 384-well plates were maintained for 21 days and 
transferred to HCS platform incubator (Liconic instruments; Mauren, Liechtenstein) on the 
day of screening. Compounds in intermediate plates were resuspended in 30 µl Neurobasal 
A, to reach 5× concentration, followed by a 2 min-long centrifugation at 100 ×g. 10 µl of 
resuspended compounds were then added into respective wells in PNC plates using Bravo 
automated liquid handling platform (Agilent; Santa Clara, California, USA), containing 40 µl 
of culture media, and plates were returned to the incubator. To achieve equal treatment 
duration for all plates, the compounds were resuspended and transferred with 10 min 
intervals between plates. Neurons were incubated with compounds for 2.5 h and fixed with 
4% paraformaldehyde (EMS; Hatfield, PA) in PBS (Dutscher; Brumath, France) for 20 min at 
RT, permeabilized with 0.3% Triton-X (Sigma) in PBS for 10 min at RT, and blocked with 5% 
normal donkey serum (Jackson ImmunoResearch, Ely, UK) and 0.1% Triton-X in PBS for 1 
h at RT. Alternatively, neurons in 384-well plates were blocked with 2.5% BSA (Sigma) and 
0.1% Triton-X in PBS, up to 14 days at 4°C. Neurons were washed with PBS at RT between 
each step. 
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Proximity ligation assay (PLA) 
All components of PLA (Duolink PLA probes and in situ detection reagents) apart from the 
primary and secondary antibodies were from Sigma. PLA was performed following 
manufacturer’s instructions with minor modifications [3,48]. After protein blocking, neurons 
were incubated with the following primary antibodies overnight at 4°C: BIN1-99D (mouse 
monoclonal IgG, 1:200; Merck Millipore), Tau (rabbit polyclonal IgG, 1:500; Dako-Agilent), 
MAP2 (chicken polyclonal IgG, 1:500; Synaptic Systems; Göttingen, Germany), and GFAP 
(chicken polyclonal IgG, 1:300; Synaptic Systems). Samples were washed with a solution of 
0.15 M NaCl (Merck Millipore), 0.01 M Tris (Sigma), 0.05% Tween-20 (Sigma), at pH 7.4 
(Buffer A), incubated with PLA probes Mouse-minus and Rabbit-plus (secondary antibodies 
labeled with complementary DNA strands) in Duolink antibody diluent for 1 h at 37°C, and 
washed with Buffer A. This was followed by the enzymatic ligation of the two DNA strands, 
provided that they were in close proximity (< 30 nm) [48], for 30 min at 37°C and another 
wash with Buffer A. This was followed by the enzymatic rolling-circle amplification of DNA 
and hybridization of Cy3-labelled oligonucleotides (PLA orange) for 100 min at 37°C. 
Samples were then washed with a solution of 0.1 M NaCl and 0.2 M Tris, at pH 7.5 (Buffer 
B). After the PLA process, samples were incubated with the following secondary antibodies 
for 1 h at RT: AlexaFlour488 donkey-anti-chicken, AlexaFlour488 donkey-anti-mouse, 
AlexaFlour647 donkey-anti-rabbit, and DyLight405 donkey-anti-chicken (1:500 for coverslips 
and 1:1000 for 384-well plates; Jackson ImmunoResearch; West Grove, PA). Coverslips 
were washed with PBS and mounted in glycerol. 384-well plates were washed with PBS and 
sealed. 
PLA in brain slices was performed with additional modifications [24]. Slices were first 
permeabilized with 0.3% Triton in PBS for 30 min and blocked with Duolink blocking solution 
for 2 h at 37°C. Slices were next treated with the IgG blocking reagent overnight at 4°C and 
with the protein concentrate, according to manufacturer’s instructions (M.O.M. Basic Kit; 
Vector Laboratories, Burlingame, CA). Primary antibodies BIN1-99D (1:80), Tau (1:200), and 
α-tubulin (mouse monoclonal, 1:200; clone DM1A; Sigma) were diluted in the Duolink 
antibody diluent and incubated overnight at 4°C. Samples were washed with Buffer A, 
incubated with PLA probes Mouse-minus and Rabbit-plus in Duolink antibody diluent for 1 h 
at 37°C, and washed with Buffer A. This was followed by DNA ligation for 30 min at 37°C 
and another wash with Buffer A. This was followed by the enzymatic amplification and PLA 
hybridization for 2 h at 37°C. Samples were then washed with Buffer B and 1:5000 Hoechst 
(H3569, Thermo Scientific). After the PLA process, samples were incubated with the 
secondary antibodies AlexaFlour488 donkey-anti-mouse and AlexaFlour647 donkey-anti-
rabbit (1:200) for 2 h at RT, followed by several washes with Buffer B. To reduce 
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autofluorescence, the brain slices were treated with 0.1% Sudan Black B (Sigma) in 70% 
ethanol for 15 min. Samples were then washed with Buffer B and mounted in 90% glycerol. 
Image acquisition and analysis 
Coverslips were imaged with LSM 710 confocal microscope (Zeiss, Oberkochen, Germany) 
using a 40× 1.6 NA objective. Images were acquired at zoom 2 in z-stacks of 0.3 µm 
interval. 10-13 images per condition were acquired for each of the three independent 
experiments. Images were deconvoluted using AutoQuantX3 Software (Bitplane, Zurich, 
Switzerland) and analysed with Imaris Software (Bitplane), using the ―surfaces‖ tool for 
defining PLA spots, Tau network, and BIN1 puncta in three dimensions. Imaris results were 
analyzed using a custom MATLAB (MathWorks; Natick, MA) code that removes outliers 
based on ±3 median absolute deviations (MAD).  
384-well plates were imaged using IN Cell Analyzer 6000 Cell Imaging System (GE 
Healthcare; Little Chalfont, UK) equipped with a Nikon 60× 0.95 NA objective and a CMOS 
camera. 16 images (2,048 × 2,048 pixels) per well were acquired in four channels (DAPI, 
dsRed, FITC, and Cy5) using appropriate filter sets and with following acquisition 
parameters: 2×2 binning; bias = 96.9; gain = 1.0 (Fig. S3). Images were analyzed with 
Columbus image data storage and analysis system (Perkin Elmer; Waltham, MA) with 
analysis scripts optimized via a custom MATLAB code (Fig. S3B). Optimal analysis scripts 
were determined separately for each plate. 
Brain slices were imaged with Axio Scan Z1 (Zeiss) using a 40× 0.95 NA objective. Images 
were acquired in 12 z-stacks of 1 µm interval. Regions of interest were marked around the 
hippocampus during acquisition in each of the 3 independent experiments. PLA spots were 
analyzed with Imaris using the ―surfaces‖ tool. Imaris results were analyzed using MATLAB 
after removing outliers based on ±3 MAD. 
HCS script optimization and plate validation 
Before image transfer, IN Cell image registration and transfer files were manually edited to 
import images only from control wells to Columbus, thereby generating the so-called control 
plates for script optimization and plate validation. Analysis scripts consisted of a series of 
Columbus commands that determine (i) total Tau staining area and (ii) total area of PLA 
spots within the Tau network, for each well (Fig. S3A). Four optimization parameters were 
defined: (i) Tau area threshold in terms of standard deviation (SD) of Tau intensity; (ii) 
sensitivity parameter for PLA spot detection; (iii) background correction parameter for PLA 
spot detection; and (iv) minimum PLA spot contrast. Analysis scripts were created by 
assigning distinct values to each optimization parameter. For example, assigning three 
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distinct values per parameter resulted in 34 = 81 combinations; hence the optimization was 
performed by running Columbus with 81 separate analysis scripts. 
Measured values were corrected for spatial bias (horizontal) using the slope of the line that 
fits the column averages in the control plate based on the least-squares method. Three 
values typically used in HCS analysis [8] were evaluated: (i) strictly standardized mean 
difference (β factor, ); (ii) Z factor ( ); 
and (iii) signal-to-background ratio (S/B = ), where µ and σ are mean and standard 
deviation, and p and n indicate positive and negative controls. Optimal analysis script was 
determined as the one with the highest β factor (β ≥ 2), provided that it produced S/B of at 
least 10. Additional rounds of parameter optimization were performed as deemed necessary. 
Plate analysis and hits selection 
Full plates were analyzed with optimal analysis scripts after correcting for local bias in terms 
of total Tau area, total MAP2 area, and total area of PLA spots within Tau area (Fig. S3C): 
First the local median of 5x5 wells surrounding the target well calculated and normalized with 
the plate median excluding edge wells, i.e., corrected value = raw value / (local median / 
plate median). For each plate, compounds affecting network quality, defined as being 
outside median ± 3 median absolute deviations (MAD) in terms of Tau area or Tau:MAP2 
area ratio (edge wells were excluded from these calculations), were excluded (Fig. S4). For 
each well, corrected PLA:Tau area ratio was normalized by plate mean, excluding edge 
wells and wells with compounds affecting network quality. After all screenings were 
performed, mean and SEM of normalized, corrected PLA:Tau area ratio were calculated for 
each compound, for compounds that did not affect network quality in at least 2 screenings. 
Compounds potentially affecting BIN1-Tau interaction were determined as those belonging 
to the top or bottom 5% tiers. 
Validation of selected compounds 
Hit validation was performed in a two-step procedure: first, dose-response curves were 
generated for selected compounds to identify specific effects; second, the impact of selected 
compounds on BIN1 phosphorylation was assessed through immunoblotting. Since several 
of the selected compounds had multiple protein targets at 10 µM concentration used in our 
screen, dose-response experiments were designed to validate the specific effects of the 
compounds and/or to identify relevant target proteins. Dose-response experiments were 
performed for 72 selected compounds that induced similar effect on PLA density in all three 
screens using the same protocol as for the compound screen. Selected compounds were 
diluted four log scales to obtain a dose-response curve (10nM, 100nM, 1µM and 10µM) and 
 Results 
92 
 
each compound and concentration was tested in three separate plates. Script optimization, 
plate validation, plate analysis, and well correction and exclusion processes were performed 
as described above. For each well, corrected PLA:Tau area ratios were normalized by the 
mean obtained from DMSO-treated wells of the same plate. The means of each compound 
at 10 µM were compared with the results from screening (conducted at 10 µM), and 
compounds that had similar effects in both sets of experiments were retained for further 
analysis. For each compound, dose-response curves were fit with 4-parameter or 3-
parameter (where Hill slope is 1) nonlinear regression models, based on the extra sum-of-
squares F test using GraphPad Prism 7 (La Jolla, CA). PNC on DIV21 were incubated with 
selected compounds at 10 µM for 2.5 h and BIN1 and Tau phosphorylation was assessed 
through immunoblotting. 
Statistical analysis 
Statistical analyses were performed in GraphPad Prism 7 or in Matlab. When variables were 
normally distributed, parametric analyses were applied: one- or two-way analysis of variance 
(ANOVA), followed by Bonferroni-corrected post hoc tests, Student’s t-test, or one sample t-
test. When variables were non-normally distributed, we conducted non-parametric analysis: 
Kruskal-Wallis ANOVA, followed by Dunn’s test or Wilcoxon signed rank test with Tukey-
Kramer correction. 
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Results 
BIN1 overexpression modulates hTau phenotypes in short- and long-term memory 
Although a genetic interaction between Bin1 and MAPT has been shown in Drosophila and 
the corresponding proteins have been described to physically interact [14,35], the impact of 
BIN1 expression levels on cognitive function has not yet been investigated in a mammalian 
tauopathy model. For this purpose, we crossed the hTau mouse, a tauopathy model that 
overexpresses human MAPT (but does not express endogenous murine Mapt [40]) with the 
TgBIN1 mouse that overexpresses human BIN1 under the control of its own promoter and 
recapitulates the tissue-specific expression of different BIN1 isoforms (Fig. S5) [17]. Briefly, 
generation of mice were obtained on C57BL/6J genetic background by crossing Mapt+/-
;TgMAPT/0 [2] and Mapt+/-;TgBIN1/0 [17] to obtain Mapt+/- as control littermates, Mapt-/-
;TgMAPT/0 (noted here hTau) as the tauopathy model [40], and, finally, Mapt-/-
;TgMAPT/0;TgBIN1/0 as the double transgenic model (noted here hTau;TgBIN1). Notably, in 
the TgBIN1 mouse, brain Mapt expression is similar to that observed in the WT mouse (Fig. 
S5). Expression of human BIN1 is able to rescue the perinatal lethality of Bin1-/- mice [15], 
and Bin1-/-;TgBIN1 mice had normal locomotor activity at 4 months in the open field 
paradigm (Fig. S5). 
To assess if BIN1 overexpression affected the short-term, non-spatial memory deficit in the 
hTau mice, a novel object recognition (NOR) task was performed longitudinally at 3, 6, 9, 12, 
and 15 months. MAPT overexpression induced short-term memory deficits in males and 
females from 9 months on, characterized by their inability to discriminate between familiar 
and novel objects (Fig. 1a). Strikingly, hTau;TgBIN1 mice displayed short-term memory 
deficits earlier than hTau mice, by 3 months, both in males and females. Notably, Mapt 
heterozygous deletion alone had no impact on this task and TgBIN1 males present NOR 
deficits only starting from 6 months [17]. There was no place or object preference, 
regardless of genotype or sex (Fig. S6). In conclusion, hTau phenotypes in the NOR task 
appeared at an earlier age upon BIN1 overexpression. 
In parallel with the NOR test, we assessed in this mouse cohort (non-naïve animals) the 
effect of BIN1 and MAPT overexpression on long-term spatial memory using Morris water 
maze (MWM) tasks at the same relative ages. All groups were able to achieve the same 
performance in reducing the distance needed to reach the hidden platform (Fig. 1b-e and 
S7). The hTau mice displayed a deficit in recalling the platform location 24 h after the last 
training session by 12 months (Fig. 1b-e and S8). However, hTau;TgBIN1 males were able 
to perform this task at all ages tested up to 15 months, indicating that BIN1 overexpression 
rescued the long-term and spatial memory of the hTau mice (Fig. 1b-e). The hTau;TgBIN1 
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females displayed a delayed deficit at 15 months compared to the hTau mice (Fig. S8). 
Notably, 15-month-old TgBIN1 mice did not have a deficit in this task (Fig. S9). To validate 
that the memory deficit observed for hTau mice were not due to a visual or locomotor deficit, 
we measured the distance and time required by the 15 month old mice to reach the visible 
platform. No difference was noted in the swimming velocities of different genotypes (Fig. 
S10). Overall, BIN1 overexpression modulates hTau phenotypes by exacerbating short-term 
memory deficits and preventing long-term memory deficits. 
Human BIN1 expression prevents Tau intracellular inclusions and increases BIN1-Tau 
complexes in the hippocampus 
The hTau mice have been described to develop detectable Tau aggregation and intracellular 
inclusions in the hippocampus and entorhinal cortex by 9 months [1,40]. We therefore tested 
the hypothesis that the mechanism underlying the rescue of the long-term and spatial 
memory deficits in hTau males through BIN1 overexpression may be linked to an alteration 
of this aggregation. We sacrificed our cohort at 18 months and performed immunolabeling 
with antibodies specifically targeting Tau phosphorylation at both Ser202 and Thr205 (AT8 
antibody) and at Thr231 (AT180 antibody) in the hippocampus (Fig. 2). As expected, no 
staining was evident in control mice. In hTau mice, Tau was mislocalized to the somatic 
compartment and formed prominent intracellular inclusions in the hippocampus (dentate 
gyrus, CA3, CA2, and CA1) (Fig. 2a). However, in hTau;TgBIN1 mice the number of cells 
with intracellular inclusions decreased by 5.9-fold or by 4.3-fold in the hippocampus when 
labeled with AT8 or AT180 antibodies, respectively (Fig. 2a-c). Since it is known that 
hyperphosphorylation of soluble Tau precedes Tau somatic inclusion [10], we determined if 
reduction of Tau inclusions upon BIN1 overexpression is due to an alteration of Tau 
phosphorylation pattern or of soluble Tau levels. However, no difference in soluble 
phosphorylated Tau protein was observed between hTau and hTau;TgBIN1 mice in the 
hippocampus (Fig. S11), indicating that BIN1 does not potentially regulate the level of 
soluble phosphorylated Tau protein or its phosphorylation pattern. 
It has been previously described that BIN1 is able to physically interact with Tau [14,49]. We 
assessed if BIN1 overexpression altered the amount and/or localization of BIN1-Tau 
complexes. For this purpose we used proximity ligation assay (PLA) in brain slices from 
sacrificed animals (Fig. 2d) and quantified the PLA density as a read-out of the BIN1-Tau 
interaction. We observed a strong increase in the PLA signal for the hTau;TgBIN1 mice 
when compared to both hTau mice and controls (2.7-fold and 6.2-fold in spot density, 
respectively) (Fig. 2d-f). As a positive control, we also used PLA to assess the interaction 
between α-tubulin and Tau and detected an increase in this interaction in hTau and 
hTau;TgBIN1 mice relative to controls (Fig. S12). Taken together, these data indicate that 
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BIN1 overexpression increases the amount of BIN1-Tau complexes in the hippocampus and 
prevents Tau mislocalization and somatic inclusion, notably in the brain regions involved in 
long-term and spatial memory.  
BIN1 expression in neurons modulates the BIN1-Tau interaction 
Our data in transgenic mice support the idea that the BIN1-Tau interaction is relevant for the 
pathophysiological functions of Tau in AD and potentially in neurons. To gain further insight 
into the regulation of BIN1-Tau interaction, we monitored its dynamics during neuronal 
maturation in hippocampal primary neuronal cultures (PNC) at 7, 14, and 21 days in vitro 
(DIV), using western blots and PLA (Fig. 3). We first observed an increase in BIN1 and Tau 
amounts with time (Fig. 3a-b), whereas Tau phosphorylation was lower at certain epitopes, 
in particular, at Thr231 (Fig. 3c). Of note, this phosphorylation site has been described to 
inhibit the interaction between Tau’s proline-rich domain (PRD) and BIN1’s SH3 domains 
[49]. The relative density of BIN1-Tau PLA in the neuronal network was highly variable at 
DIV7 due to the low network density and it decreased with neuronal maturation from DIV14 
to DIV21 (Fig. 3d-e). The BIN1-Tau PLA signal was highly correlated with the Tau signal 
irrespective of DIV (Fig. 3f), suggesting a uniform distribution of PLA signals in the network. 
We then assessed the impact of BIN1 expression on the PLA signal at DIV14, by 
downregulating BIN1 or overexpressing BIN1 neuronal isoform 1 (BIN1iso1) at DIV8 via 
transduction of lentiviruses expressing shRNA against BIN1 or the corresponding cDNA, 
respectively (Fig. 3g-i and S13). BIN1 downregulation led to a decrease in PLA signal; 
conversely, BIN1iso1 overexpression led to an increase in PLA signal (Fig. 3g and 3i). 
These data indicate that even if the BIN1-Tau interaction occurred at restricted loci in 
neurons (e.g., at microtubule tips, as previously described [49]), the BIN1-Tau complex 
formation depends on the global amount of BIN1 in neurons, as observed in the transgenic 
mice. Together, our data support the notion that variation in BIN1 expression affects the 
dynamics of BIN1-Tau complexes and their subsequent physiological and/or 
pathophysiological functions. 
Identification of signaling pathways modulating the BIN1-Tau interaction in neurons 
In addition to the BIN1 expression level as a modulator of the BIN1-Tau interaction, we had 
previously shown that phosphorylation of the Tau PRD domain (mainly at T231) inhibits its 
interaction with the BIN1 SH3 domain [49]. This suggested that BIN1-Tau interaction 
dynamics likely depends on specific signaling pathways that regulate Tau phosphorylation. 
However, the cell signaling pathways susceptible to modulate the dynamic BIN1-Tau 
interaction remained unknown. To answer this question, we developed an agnostic strategy 
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and set-up a semi-automated high-content screening (HCS) approach, using PNC as cellular 
model and PLA volume as readout for BIN1-Tau interaction (Fig. 4a).  
We tested a library of 1,126 compounds (at 10 μM) known to mainly target key elements of 
canonical pathways (see the Materials and Methods section for a full description of the HCS 
design). In brief, HCS was made in triplicate (one well per compound in each screen) using 
independent cultures. 79 compounds showed potential toxicity, as assessed by Tau and 
MAP2 network densities (Fig. 4b), and were excluded. We then applied several selection 
criteria to identify most promising compounds: (i) only compounds showing an effect in the 
same direction in all three independent screens were retained for further investigation; (ii) we 
selected the 10% of compounds showing the strongest variations (5% increasing PLA and 
5% decreasing PLA). This led to 72 compounds for validation in dose-response experiments 
(Fig. 4c). Following this validation step, we were able to retain 12 compounds (marked red in 
Fig. 4d) that consistently exhibited the strongest variations in PLA signals. We grouped the 
targets of these compounds into 5 categories: (i) phosphorylation; (ii) nitric oxide synthase; 
(iii) Ca2+ homeostasis; (iv) membrane receptors; and (v) others (see Fig. S14 for the dose-
response curves). As BIN1-Tau interaction has been shown to be modulated by 
phosphorylation [49], we decided to focus on two compounds whose targets are regulators 
of phosphorylation: (i) the Calcineurin (CaN) inhibitor Cyclosporin A (CsA), which, at 10 nM, 
increased PLA:Tau ratio by 42.6%; and (ii) the MEK inhibitor U0126, which, at 10 μM, 
decreased PLA:Tau ratio by 36.2% (Fig. 4e). In conclusion, our results show that CaN and 
MEK-dependent signaling pathways – among others – are able to modulate the complex 
dynamics of the BIN1-Tau interaction in neurons. 
The conformational change in BIN1 neuronal isoform 1 upon phosphorylation 
modulates BIN1-Tau interaction  
Of particular interest, CaN is a Ser/Thr phosphatase which has been described to 
dephosphorylate Amphiphysin 1 (AMPH1), the homolog of BIN1 [4]. We thus postulated that 
CaN may also target BIN1 and sought potential phosphorylation sites within BIN1 explaining 
the increase in the PLA signal observed after CaN inhibition. Interestingly, we had previously 
characterized a conformational change in BIN1iso1 between open and closed forms. This 
involves an intramolecular interaction between the SH3 and CLAP PRD of BIN1iso1, making 
the SH3 domain unavailable for intermolecular interactions for instance with Tau [35]. Since 
phosphorylations in the PRD have already been described to inhibit PRD/SH3 domains [49], 
we postulated that phosphorylation in the CLAP PRD domains of BIN1iso1 may favor BIN1’s 
open form and increase the BIN1-Tau interaction and consequently the PLA signal. When 
the protein sequences of AMPH1 and BIN1 are compared, their CLAP PRD domains appear 
to be highly conserved (Fig. 5a). Considering that AMPH1 T310 (corresponding to BIN1 
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T348) has been described to be phosphorylated by Cdks [21], we hypothesized that T348 (in 
the vicinity of the PRD sequence interacting with the BIN1-SH3 domain [35]) may be 
controlling the open/closed conformation of BIN1iso1. 
We first developed an antibody against BIN1 phosphorylated at T348 to determine if the 
BIN1 T348 phosphorylation occurred in neurons. Treating neuronal protein extracts with a 
protein phosphatase pool decreased BIN1 T348 phosphorylation (Fig. 5b). As control, Tau 
T231 phosphorylation was also decreased (Fig. S15a). Next, since T348 is within a 
consensus sequence recognized for phosphorylation by cyclin-dependent kinases (Cdks), 
we tested if Cdks were able to phosphorylate BIN1 T348. By using recombinant Cdk2 or 
Cdk5 and BIN1iso1, we showed that both kinases are able to directly phosphorylate T348 
(Fig. 5c), as well as Tau T231 in vitro (Fig. S15b) confirming previous results [49]. We finally 
tested CsA and U0126 in PNC for their effect on BIN1 T348 and Tau phosphorylation. We 
observed that CsA – but not U0126 – was able to significantly increase BIN1 T348 
phosphorylation in PNC (85±26% vs. 4±26%, respectively) suggesting that CaN is indeed 
able to dephosphorylate BIN1 at T348 (Fig. 5d-e). Remarkably, CaN inhibition did not impact 
Tau T231 phosphorylation, which we had previously described as a major modulator of the 
BIN1-Tau interaction [49,33], suggesting that the BIN1 T348 phosphorylation alone drives 
the impact of CsA on PLA. Conversely, U0126 likely modifies the BIN1-Tau interaction 
through Tau T231 phosphorylation, without any impact on BIN1 T348 (Fig. 5d-e). Notably, 
we had previously characterized T231 as one of the 15 Ser/Thr sites where Tau gets 
phosphorylated by ERK2, downstream of MEK [43]. 
To determine if phospho-T348 may control the dynamics of the open/closed conformation of 
BIN1iso1, we used nuclear magnetic resonance (NMR). We first tested whether this 
phosphorylation could impact the intramolecular interactions of BIN1 SH3 in the context of 
full BIN1iso1 protein. Signal from the BIN1-SH3 domain was observed in the spectra of 
Cdk2-phosphorylated recombinant BIN1iso1, whereas these same signals were barely 
detectable in the spectra of non-phosphorylated BIN1iso1 under identical acquisition and 
processing conditions (Fig. S2). Detection of these signals in the context of the large 
BIN1iso1 protein showed that the BIN1-SH3 domain kept some mobility and that the 
equilibrium was less in favor of the intramolecular interaction once the BIN1-CLAP domain 
was phosphorylated compared to the non-phosphorylated BIN1iso1 protein. However, since 
we detected multiple phosphorylation sites in the Cdk2-BIN1iso1 by NMR (Fig. S2), we 
generated a recombinant BIN1iso1 with T348E (BIN1-CLAP-T348E) to mimic the single 
phosphorylation event. Signals from the BIN1-SH3 domain were also detected in the spectra 
of the mutated BIN1iso1 T348E (Fig. S16), suggesting that phosphorylation at T348 is 
sufficient to shift to the BIN1iso1 open form (Fig. 5f). Finally, to further validate this 
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observation, 15N-labeled BIN1 SH3 domain was titrated with CLAP (334-355) or phospho-
CLAP (334-355) peptides and the titration was monitored using 1H-15N heteronuclear single 
quantum coherence (HSQC) spectroscopy of 15N-BIN1 SH3, one spectrum being recorded 
at each titration point (Fig. S17). The Kd values, obtained by fitting the chemical shift values 
measured in the spectra series to the saturation equation, were 71±13 µM for CLAP (334-
355) peptide and 736±70 µM for phospho-CLAP (334-355) peptide, showing a 10-fold 
increase in Kd due to a single phosphorylation event in the peptide (Fig. 5g). Cumulatively, 
these results indicate that phosphorylation of T348 in the BIN1 CLAP domain is able to shift 
the dynamic equilibrium of the BIN1iso1 conformation towards the open form, thereby 
increasing the availability of the BIN1 SH3 domain for other interactions. 
We next assessed whether the open/closed dynamics may impact the formation of the BIN1-
Tau complex by controlling the availability of the BIN1iso1 SH3 domain in neurons and thus 
its ability to interact with Tau. For this purpose, we transduced at DIV8 hippocampal PNC 
with lentiviruses overexpressing wild-type BIN1iso1 and its mutated form, BIN1iso1-T348E, 
which, as previously demonstrated, leads to a systematically open form of BIN1iso1. We 
observed a 2.1-fold increase in PLA volume in PNC transduced with BIN1iso1-T348E when 
compared to BIN1iso1 (after normalization with respective BIN1 immunofluorescence) (Fig. 
5h-i). This observation is in accordance with the increased availability of the BIN1iso1-T348E 
SH3 domain for Tau.  
Finally, we quantified the amount of total and phospho-BIN1 (T348) neuronal isoforms in 
protein extracts from 14 brain samples with increasing neurofibrillary pathology (Braak 
stages 0 to 6). The relative amounts of total and phosphorylated BIN1 exhibited a trend to 
decrease with increasing Braak stage (Fig. 6a-c). Surprisingly, the phospho-Bin1:BIN1 ratio 
exhibited a trend to increase with increasing Braak stage (Fig. 6d). Among the 14 
individuals, 4 were controls and 12 were diagnosed with AD. After stratification based on the 
AD status, we observed a statistically non-significant decrease in total BIN1 in AD cases 
compared to controls (p = 0.05), but not in phospho-BIN1 (p = 0.71) (Fig. 6d-e). Interestingly, 
phospho-BIN1:BIN1 ratio was significantly increased in the brains of AD cases (p = 0.02) 
(Fig. 6g). Altogether, these data indicate that, in pathological conditions, the global level of 
the neuronal isoform of BIN1 is decreased, but a higher fraction of this BIN1 population is 
phosphorylated. 
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Discussion 
There is no longer any doubt that BIN1 is a major genetic risk factor for AD [32]. However, 
as for other GWAS-defined genes, it is often difficult to determine the implication of such 
genes in pathophysiological processes (or even in physiological ones in organs of interest). 
In this study, we aimed to determine if the BIN1-Tau interaction is involved in the 
neuropathological process of a mouse tauopathy model and to decipher the cellular 
processes and signaling pathways potentially regulating it. 
To determine if BIN1 could interfere with Tau pathology in vivo, we first developed a 
mammalian tauopathy model overexpressing BIN1 isoforms including neuron-specific forms 
in the brain. We observed that BIN1 overexpression in the hTau mice expedited the 
appearance of short-term memory deficits from 9 to 3 months, but prevented spatial and 
long-term memory deficits up to 15 months, the highest age tested. Remarkably, the rescue 
of spatial and long-term memory by BIN1 overexpression was associated with a strong 
increase in the BIN1-Tau interaction in the neuronal network and a strong decrease in 
phosphorylated Tau inclusions within the neuronal somata in the hippocampus. Next, we 
analyzed the BIN1-Tau interaction in the physiological context. BIN1 expression level 
appeared to be a strong modulator of the BIN1-Tau interaction in PNC. To identify signaling 
pathways modulating the BIN1-Tau interaction in neurons, we developed an agnostic HCS 
approach and determined a number of potential targets; one of best hits being an inhibitor of 
CaN, a Ser/Thr phosphatase. This observation led us to identify BIN1 phosphorylation at 
T348 as both a CaN target and a major regulator of the BIN1-Tau interaction. We 
determined that BIN1 phosphorylation at T348 increased the availability of the BIN1-SH3 
domain to interact with Tau and consequently led to an increase in this interaction in 
neurons. Finally, we determined that neuronal BIN1 isoforms (mainly isoform 1) decreased 
in the brains of postmortem AD patients compared to control cases, whereas – surprisingly – 
phospho-BIN1(T348):BIN1 ratio increased, suggesting that this site may also be involved in 
the AD process. Overall, we hypothesize that increased BIN1 expression and its 
phosphorylation on T348 protects hTau mice against spatial and long-term memory deficits 
(Fig. 7). 
Altogether, our data support that a complex and dynamic regulation of the BIN1-Tau 
interaction is involved in the development of the AD pathophysiological process. However, 
the protective or deleterious effect of this interaction may vary depending on cognitive 
functions. Indeed, BIN1 overexpression modulates MAPT phenotypes by exacerbating short-
term memory deficits and by preventing long-term memory deficits. Both of these processes 
require the hippocampus, but the cortical regions involved are different, i.e., lateral entorhinal 
cortex and medial entorhinal cortex, respectively [9,51]. The equilibrium between Tau and 
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BIN1 levels may be slightly different in these cortical brain regions and in temporality, 
potentially explaining the opposite effects observed. In addition, signaling pathways 
controlling the phosphorylation of BIN1 and Tau, and subsequently the BIN1-Tau interaction 
may also differ temporally and regionally. However, since we developed a cohort study, it 
was not possible to evaluate such temporal and regional variations at each time of 
behavioral tests. It is nevertheless worth noting that the rescue of spatial and long-term 
memory by BIN1 overexpression was associated with a strong decrease in phosphorylated 
Tau inclusions within the neuronal somata and a strong increase in the BIN1-Tau interaction 
in the hippocampus. Remarkably, in hTau mice, the BIN1-Tau interaction was lower than in 
both control and htau;TgBIN1 mice. These observations thus suggest that the BIN1-Tau 
interaction may be protective by blocking the relocalization and accumulation of 
phosphorylated Tau in the neuronal somata, a major hallmark of AD. 
The hypothesis that a dynamic regulation of the BIN1-Tau interaction is involved in AD 
process also implies that a high level of BIN1 expression would be protective. However, we 
previously found that total BIN1 mRNA is over-represented in the brains of AD cases 
compared to controls [13], but did not evaluate at that time the isoform-dependency of the 
BIN1 expression. Subsequent publications reporting protein levels showed that unlike the 
overexpression of ubiquitous isoforms, the neuronal isoforms were specifically 
underexpressed in the AD brains [23,26]. We validated this observation in brain samples and 
showed that this decrease was dependent on the Braak stage (Fig 6). Since the neuronal 
isoforms are the main isoforms that are overexpressed in the brain of our transgenic mice 
model (Fig. S5), these data corroborate the idea that specific overexpression of the neuronal 
BIN1 isoforms may be protective. We may thus postulate that the overexpression of 
neuronal BIN1 isoforms in the TgBIN1 mouse reverses a neuropathological process that 
occurs in AD brains. This protective effect could be explained by the BIN1-Tau interaction in 
neurons. However, we cannot exclude other potential mechanisms. Indeed, we observed 
that at 18 months MAPT over-expression is associated with myelin abnormalities, and a 
significant rescue of this phenotype was observed in hTau;TgBIN1 mice (Fig. S18). Of note, 
the over-expression of BIN1 alone did not induce any myelin abnormalities (Fig. S19; also 
see supplementary results). Thus, the memory impairments observed in the behavioral 
analyses of the hTau mice may also be associated with myelin disorganization in the fornix, 
and be rescued upon BIN1 overexpression. Interesting, BIN1 has been described to be 
strongly expressed in oligodendrocytes [18] and Tau has been also previously linked with 
potential myelin dysfunction in tauopathies [20]. 
Identifying the signaling mechanisms controlling the BIN1-Tau interaction is of high interest 
to understand the pathophysiological processes in AD. These pathways could be either 
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protective or deleterious, by favoring or abrogating the BIN1-Tau interaction, respectively. In 
this report we characterized a key regulatory element, which is the phosphorylation of BIN1 
at T348. Remarkably, we determined that the phospho-BIN1(T348):BIN1 ratio increased with 
increasing Braak stage in the brains of AD cases. These findings suggest that a higher 
fraction of brain BIN1 isoforms is phosphorylated at T348 in AD brains, where the global 
level of neuronal BIN1 isoforms is decreased. This may imply that the relative increase in 
BIN1 T348 phosphorylation occurs to compensate in part the decrease in the neuronal BIN1 
isoforms in order to maintain the BIN1-Tau interaction. Altogether, these observations 
suggest that BIN1 T348 phosphorylation is involved in the development of AD. 
Our data thus indicate that the BIN1-Tau interaction is complex and dynamic, potentially 
controlled by numerous actors modifying the level of phosphorylation of both BIN1 and Tau, 
including Cdks and CaN. Indeed, we had previously shown that the phosphorylation of Tau 
at T231 was a major regulator of the BIN1-Tau interaction, but in the opposite direction, i.e., 
leading to a decrease in this interaction. Importantly, the increase in Tau phosphorylation at 
T231 is considered as an early marker of the development of AD [10]. This dual BIN1/Tau 
regulation is illustrated in our HCS screening, which revealed that inhibiting CaN favors the 
BIN1-Tau interaction by increasing BIN T348 phosphorylation, whereas inhibiting MEK 
hinders it by increasing Tau T231 phosphorylation. Cdks – particularly Cdk5 – highlight this 
complexity, since these kinases are able to phosphorylate both BIN1 T348 and Tau T231, 
but with opposite effects on the abilities of Tau and BIN1 to interact with each other: 
increased Cdk5 activity would increase BIN1’s affinity for Tau through phosphorylation of 
BIN1 at T348, and, conversely, would decrease Tau’s affinity for BIN1 through 
phosphorylating Tau at T231 (Fig. 7). This complex interplay between actors modulating 
BIN1 and Tau phosphorylation may be a limitation for developing drugs to favor or prevent 
the BIN1-Tau interaction. A better understanding of the mechanisms involved will thus be 
needed to identify potential cell signaling pathways and drug targets that would uncouple the 
BIN1-Tau phosphorylation crosstalk. In this context, CaN-dependent pathways may be of 
therapeutic interest, since we observed that only BIN1 T348 is modulated by CaN, but not 
Tau T231.  
In conclusion, we reveal the impact of overexpression of BIN1, a major genetic risk factor of 
AD, in a tauopathy model. Our data also reinforce the hypothesis that a potential protective 
impact of this overexpression on the AD process may be linked to the direct interaction of 
BIN1 and Tau, and depends strongly on the phosphorylation statuses of both proteins. 
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Figure Captions 
Fig. 1 BIN1 overexpression worsens hTau phenotypes in short-term memory and rescues 
long-term memory deficit due to MAPT overexpression in hTau males. a. Discrimination 
indices for novel object recognition with one hour of retention at 3, 6, 9, 12, and 15 months 
are shown for control, hTau, and hTau;TgBIN1 mice. Dashed lines represent object 
preference by chance. Blue dots, males; pink dots, females. One-sample t-test compared to 
chance at 50%; *p<0.05, **p<0.01. b. Distance traveled to reach the platform of the Morris 
water maze for 12-month-old hTau and hTau;TgBIN1 males. Data represent mean ± SEM 
for consecutive days of acquisition (control, n=11; hTau, n=11; hTau;TgBIN1, n=13). c. 
Probe test without platform at 12 months, performed 24 h after the last training session. 
Dashed line represents chance. Data represent mean ± SEM for each quadrant (control, 
n=11; hTau, n=11; hTau,TgBIN1, n=13). Underlined quadrant marks original platform 
location. d. Distance traveled to reach the platform for 15-month-old hTau and hTau;TgBIN1 
males. Data represent mean ± SEM for consecutive days of acquisition (control, n=11; hTau, 
n=10; hTau;TgBIN1, n=13). e. Probe test without platform at 15 months, performed 24 h 
after the last training session. Dashed line represents chance. Data represent mean ± SEM 
for each quadrant (control, n=11; hTau, n=10; hTau,TgBIN1, n=13). Underlined quadrant 
marks original platform location. One-sample t-test compared to chance at 25%; *p<0.05, 
**p<0.01. 
 
Fig. 2 BIN1 overexpression prevents Tau inclusions and increases BIN1-Tau interaction in 
hTau hippocampi. a. Immunohistofluorescence of different phospho-Tau proteins in 
hippocampi of control, hTau and hTau;TgBIN1 males at 18 months. Antibodies used were 
detecting p-Ser202/p-Thr205 Tau (AT8) or p-Thr231 Tau (AT180). Insets show zooms of the 
hilus areas encompassing the neuronal cell bodies; intracellular inclusions are visible for 
hTau, but barely for hTau;TgBIN1. Scale bars = 500 µm; insets, 50 µm. b-c. Quantification 
of the number of cells with intracellular Tau inclusions per mm2 in control, hTau and 
hTau;TgBIN1 mice labeled with the two phospho-Tau antibodies (control, n=4; hTau, n=4; 
hTau;TgBIN1, n=5). d. BIN1-Tau PLA (cyan), and BIN1 (yellow), Tau (magenta), and 
Hoechst (white) stainings in the hippocampi of the same mice. Zoomed areas show PLA and 
Tau channels only. See Fig. S12 for Tubulin-Tau PLA, conducted as technical control. e-f. 
Quantification of BIN1-Tau PLA density. Data expressed as PLA spot number per tissue 
area (E) or total PLA spot volume per tissue area (F), normalized with control mean (control, 
n=9; hTau, n=11; hTau;TgBIN1, n=12 hemispheres for spot number; control, n=10; hTau, 
n=12; hTau;TgBIN1, n=12 hemispheres for volume). Red bars and black squares indicate 
sample median and mean, respectively. Kruskal-Wallis ANOVA, followed by multiple 
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comparisons test with Tukey-Kramer correction; *** p < 0.0001; * p < 0.05. N/S, not 
significant. Scale bars = 500 µm; zooms, 50 µm. 
 
Fig. 3 Characterization of BIN1-Tau interaction in primary neuron cultures (PNC). a. 
Representative immunoblots from neuronal extracts obtained at DIV7, DIV14, and DIV21 (in 
duplicate) showing BIN1 and total and phosphorylated forms of Tau (Tau1 for non-phospho 
Ser195/Ser198/Ser199/Ser202; PHF1 for p-Ser396/Ser404; RZ3 and AT180 for p-Thr231). 
b-c. Relative changes in BIN1 and Tau protein levels and in Tau phosphorylation during 
neuronal maturation. d. Representative images of PNC showing PLA spots and Tau 
immunolabeling during neuronal maturation. e. Change in PLA density during neuronal 
maturation. N = 3 independent experiments. f. Correlation between total PLA volume and 
total Tau volume in a representative experiment. Each dot represents a confocal image. g. 
Representative images of PNC under- and overexpressing BIN1, showing PLA and Tau and 
BIN1 immunolabeling. shNT: non-targeting shRNA. h-i. Total BIN1 volume and PLA density 
in PNC under- and overexpressing BIN1, normalized with respective controls (shBIN1 with 
shNT and BIN1iso1 with Mock). N = 3 independent experiments. In box plots, red bars and 
black squares indicate sample median and mean, respectively. Wilcoxon rank-sum test; * p 
< 0.05; ** p < 0.01; *** p < 0.001; N/S: not significant. 
 
Fig. 4 High-content screening (HCS) with PLA:Tau volume ratio in the Tau network as 
readout identifies the regulators of the BIN1-Tau interaction. a. The HCS workflow consists 
of compound screen (DIV21; 10 μM; 2.5 h) in PNC cultured in 384-well plates, plate-by-plate 
image segmentation and analysis, hit selection, and hit validation via dose-response 
experiments. b. Exemplary images from the HCS showing U0126 and Cyclosporin A (CsA) 
that decreased and increased PLA density, respectively. Scale bars = 50 μm. c. PLA:Tau 
area ratio for 1,047 compounds that did not induce damage in the neuronal network. Mean ± 
SD from 3 independent screens. d. Top and bottom 5% modulators (72 compounds) were 
retained for dose-response experiments. 12 compounds were validated in dose-response 
experiments are shown in red. e. Dose-response curves of U0126 and CsA (see Fig. S14 for 
all validated compounds). Mean ± SD from 3 independent experiments. 
 
Fig. 5 BIN1 phosphorylation at T348 regulates BIN1-Tau interaction by modulating 
open/closed conformation of BIN1. a. Alignment of Amphiphysin 1 and BIN1iso1; domains 
not to scale. The underlined sequence indicates the BIN1 PRD sequence interacting with the 
BIN1 SH3 domain. b. Lambda protein phosphatase (λ-PP) treatment dephosphorylates 
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BIN1; 2 lanes per condition. c. In vitro phosphorylation assays with recombinant proteins 
show that Cdk2 and Cdk5 phosphorylate BIN1 at T348. Also see Fig. S2. d-e. Immunoblots 
and quantification showing the effects of U0126 and CsA (10 μM; 2.5 h) on BIN1 and Tau 
phosphorylation. Inset shows the effect of 10 nM CsA on BIN1 phosphorylation. Mean ± SD 
from 3 independent experiments. One-way ANOVA and paired t-test; * p < 0.05; ** p < 0.01. 
f. Behavior of BIN1-SH3 domain in the whole BIN1 isoform 1 protein as a function of 
phosphorylation by Cdk2 or of a mutation at threonine (T) 348 to glutamate (E) as monitored 
by 1H-15N HSQC spectra of BIN1iso1 CLAP T348E protein (in blue), Cdk2-phospho-
BIN1iso1 (superimposed in red), and BIN1iso1 protein (superimposed in green). Also see 
Fig. S16. g. Titration of BIN1-SH3 domain with concentration of CLAP (334-355) or 
phospho-T348 CLAP (334-355) peptides. Normalized saturation curves (shown for residue 
559), built from the gradual chemical shift changes (normalized; 1 denotes the largest 
change), are shown as pink stars for CLAP (334-355) and red stars for phospho-CLAP (334-
355). Saturation curves are in cyan and green for CLAP (334-355) and phospho-CLAP (334-
355), respectively. Also see Fig. S17. h. Representative images of PNC overexpressing 
BIN1iso1 and the BIN1iso1 T348E, its systematically open form, showing PLA signals and 
Tau and BIN1 immunolabeling. i. PLA density after normalization with respective BIN1 
immunofluorescence in PNC overexpressing BIN1iso1 and BIN1iso1 T348E (for clarity, 
datasets were further normalized with the mean of BIN1iso1). N = 3 independent 
experiments. Red bars and black squares indicate sample median and mean, respectively. 
Wilcoxon rank-sum test; *** p < 0.001. 
 
Fig. 6 BIN1 amount and phosphorylation status in post-mortem AD brains. a. Western blots 
showing total BIN1 (99D antibody), BIN1 phosphorylated at T348 (p-T348), and β-actin in 
the temporal lobes of 14 individuals with increasing neurofibrillary pathology (Braak stage; 
see Table S3 for demographic details and pathological statuses). b-d. Quantification of the 
BIN1:β-actin, BIN1-p-T348:β-actin, and BIN1-p-T348:BIN1 signals, normalized with the 
mean of the control group (Braak stage = 0). Dashed red lines indicate exponential fits; p-
values refer to the Kolmogorov-Smirnov test for the normal distribution of residuals. Data 
marked in green indicate non-AD cases according to neuropathological diagnosis. e-g. 
Comparison of BIN1:β-actin, BIN1-p-T348:β-actin, and BIN1-p-T348:BIN1 signals between 
non-AD and AD cases. Red bars and black squares indicate sample median and mean, 
respectively; p-values refer to the Wilcoxon rank-sum test. 
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Fig. 7 Complexity and dynamics of the BIN1-Tau interaction in neurons. a. At the molecular 
level, the open/closed conformation of BIN1 regulates the BIN1-Tau interaction in neurons 
under the control of the BIN1 T348 phosphorylation by CaN and Cdks. In addition, 
phosphorylation of Tau at T231 decreases the BIN1-Tau interaction. b. In healthy neurons, 
the BIN1-Tau interaction occurs at physiological levels. c. In AD pathology, a decrease in 
BIN1iso1 leads to a decrease in BIN1-Tau interaction, potentially favoring the formation of 
neurofibrillary tangles (NFT), in spite of potential compensation through BIN1 T348 
phosphorylation. d. In tauopathy, overexpression of BIN1iso1 in neurons (as in the case for 
hTau;TgBIN1 mice) leads to an increase in the BIN1-Tau interaction and correlates with the 
disappearance of Tau somatic inclusions. 
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Supplementary Materials and Methods 
HCS image segmentation in Columbus 
HCS was performed in the IN Cell platform. IN Cell image registration and transfer files 
(.xdce files) were manually edited to import images to Columbus only from control wells, 
thereby generating the so-called ―control plates‖ for script optimization and plate validation. 
HCS image analysis was performed using Columbus software (Fig. S3). In order to improve 
the detection of Tau and MAP2 areas, somatic regions were excluded from the Tau (Cy5 
channel) and MAP2 (FITC channel) images by removing the Hoechst signal (DAPI channel), 
using the formula , where A is the Cy5 or the FITC 
channel and B is the DAPI channel. Tau and MAP2 areas were calculated after thresholding 
using the formula , where A is the somata-excluded Cy5 
or FITC channels and q1 is area threshold coefficient in terms of SD. For the FITC channel 
(MAP2), the parameter q1 had a constant value of 0.1. For the Cy5 channel (Tau), q1 was 
one of the optimization parameters determined through an iterative process, i.e., script 
optimization. PLA spots (dsRed channel) in the thresholded Tau area using the Find Spots 
and Select Population building blocks of Columbus following Method D. Here, the Splitting 
Coefficient was kept constant at 0.9, Spot Area was restrained between 15 and 60 px2, and 
the upper threshold of Spot Contrast was kept constant at 0.9. In addition, three parameters 
of this building block were determined through script optimization: q2, threshold of Detection 
Sensitivity; q3, threshold of Background Correction; and q4, lower threshold of Spot Contrast. 
Iterative process to determine optimum parameters for image segmentation script 
Each control plate was used to optimize the image segmentation parameters to be used to 
analyze the corresponding full plate. Multiple Columbus analysis scripts were created by 
assigning distinct values combinatorially to each of the optimization parameter (q1-q4). For 
example, assigning three distinct values per parameter results in 34 = 81 combinations; 
hence the optimization was performed by running Columbus in the Batch Analysis mode, 
using 81 analysis scripts. This resulted in 81 result files per control plate, which were then 
analyzed in MATLAB. Data obtained for each well of the control plate were corrected for 
spatial bias (horizontal), using the slope of the line that fits the column averages based on 
the least-squares method. For each control plate, three values typically used in HCS 
analysis (Bray and Carpenter, 2013) were calculated: (i) strictly standardized mean 
difference, β factor, ; (ii) Z prime factor 
; and (iii) signal-to-background ratio (S/B = ), where µ 
and σ are mean and standard deviation, and p and n indicate positive and negative controls 
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(PLA conducted without the BIN1 primary antibody or without the Mouse-minus probe). The 
optimal parameter set for analysis script was determined to be the one with the highest β 
factor (β ≥ 2), provided that it produced S/B of at least 10. Additional rounds of parameter 
optimization were performed when necessary. 
Full plate analysis and identification of hits 
Full plates were analyzed in Columbus with the corresponding optimal analysis script. For 
each well, Tau area, MAP2 area, and PLA spot area within Tau area were corrected for local 
bias by normalizing the raw values by the ratio of the local median (median of the 
surrounding wells in the 5×5 neighborhood) to the plate median (excluding edge wells), i.e., 
. For each plate, compounds affecting network 
quality, defined as not having Tau area or Tau:MAP2 area ratio within median ± 3 median 
absolute deviations (MAD), were excluded (Fig. S4). Edge wells were not taken into account 
when calculating median and MAD. Corrected PLA:Tau area ratio for each well was then 
normalized by the mean of non-excluded wells. Finally, normalized, corrected PLA:Tau area 
ratio obtained from 3 screens were pooled to calculate mean and SEM for each compound 
that were not excluded from at least 2 screenings. Compounds potentially affecting BIN1-
Tau interaction were determined as those belonging to the top or bottom 5% tiers.  
Validation of selected compounds 
Hit validation was performed by generating dose-response curves for selected compounds 
to identify specific effects on BIN1-Tau interaction. Since several of the selected compounds 
had multiple protein targets at 10 µM concentration (as used in the HCS) dose-response 
experiments were designed to determine if the effects were specific and/or to identify 
relevant targets. Dose-response experiments were performed for 72 compounds from the 
top and bottom 5%, which gave similar results in all 3 screens. Compounds were diluted four 
log scales to obtain a dose-response curve (10 nM, 100 nM, 1 µM and 10 µM) and each 
compound and concentration was tested in three separate plates under identical conditions 
as in HCS. Script optimization, plate validation, plate analysis, and well correction and 
exclusion steps were executed as described above. The DMSO-normalized mean of each 
compound at 10 µM was compared with the screen result (also at 10 µM), and compounds 
that had similar effects in both sets of experiments were retained for further analysis. For 
each compound, dose-response curves were fit with 4-parameter or 3-parameter (where Hill 
slope is 1) nonlinear regression models, based on the extra sum-of-squares F test using 
GraphPad Prism 7 (La Jolla, CA). 
Kd determination using NMR data 
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The 1H,15N combined chemical shift changes, ∆δ(1H,15N), were calculated using the following 
equation: ∆δ(H,N) = (∆δ2H + ∆δ
2
N × 0.159)
1/2, where H and N are the chemical shift (δ) 
changes for 1H and 15N, respectively. Dissociation constants were obtained by fitting the 
chemical shift perturbation data to the following equation: obs = max (a + b + Kd – ((a + b + 
Kd)
2 – 4ab)1/2) / 2a, where obs is the weighted average of the chemical shifts in the free and 
bound states and max is the maximal signal change upon saturation (bound state). Kd is the 
dissociation constant, a and b are the total peptide and BIN1 SH3 concentrations, 
respectively. Kd was calculated based on chemical shift perturbations of each resonance 
with ∆δ(H,N) > 0.01 ppm when comparing the bound and free states, and averaged. 
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Supplementary Results 
Myelin alterations in the fornix 
The degree of fornix alteration is correlated with memory impairments. Coronal visualization 
of the fornix at 18 months in hTau and hTau;TgBIN1 mice was performed using electron 
microscopy. MAPT overexpression is associated with myelin abnormalities. Indeed, most 
nerve fibers in the hTau mice presented multiple myelin rings (Fig. S18, arrowheads); 
however, a significant rescue of this phenotype was observed in hTau;TgBIN1 mice. The 
overexpression of BIN1 alone did not induce any myelin abnormalities (Fig. S19). Thus, the 
memory impairments observed in the behavioral analyses of the hTau mice may be also 
associated with myelin disorganization in the fornix, and were rescued upon BIN1 
overexpression. Finally, as spatial memory was perturbed in hTau mice, ultrastructural 
analysis of proximal axons projecting from the CA3 was also conducted via electron 
microscopy. No obvious ultrastructural defects were observed and, notably, the microtubule 
network appeared well aligned and distributed inside the nerve fibers in hTau, TgBIN1, and 
hTau;TgBIN1 mice (Fig. S20). 
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Supplementary Tables  
Table S1. Primer sequences 
Primer 5’ 3’ 
Mapt KI WT UP  CTCAGCATCCCACCTGTAAC  
Mapt KI WT DW CCAGTTGTGTATGTCCACCC  
Mapt KI Tg UP AAGTTCATCTGCACCACCG  
Mapt KI Tg DW  TGCTCAGGTAGTGGTTGTCG  
TgMAPT (mut) UP  ACTTTGAACAGGATGGCTGAGCCC  
TgMAPT (mut) DW  CTGTGCATGGCTGTCCACTAACCTT  
TgMAPT (WT) UP  CTAGGCCACAGAATTGAAAGATCT  
TgMAPT (WT) DW  GTAGGTGGAAATTCTAGCATCATCC  
TgBIN1 UP  CGAGGCCTGCGCCGCGATGGC  
TgBIN1 DW  CGCAGCCTGGGGACCTCGAAG  
 
Table S2. Antibodies used in brain slices 
 
  
Antibody Reference 
Tau [E178]  Abcam, ab32057  
BIN1 [C99D]  Sigma, B9428  
Phospho Tau Thr231 [AT180]  Thermo Scientific, MN1040  
Phospho Tau Ser202 [AT8] Thermo Scientific, MN1020  
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Table S3. Demographic details of the neuropathological cohort. 
 
  
Individual 
 
Braak 
stage 
Gender 
 
Age at 
death 
Post-mortem 
delay (h) 
Brain 
weight (g) 
Neuropathological 
diagnosis 
1 0 M 61 7 900 Non-AD 
2 0 F 52 8 1190 Non-AD 
3 1 F 82 7 950 AD 
4 1 M 84 7 1130 Non-AD 
5 2 F 84 5 1100 AD 
6 2 F 82 4 1110 AD 
7 3 F 76 4 990 AD 
8 3 F 92 18 1060 Non-AD 
9 4 F 76 24 1165 AD 
10 4 F 85 4 1070 AD 
11 5 F 85 4 800 AD 
12 5 M 80 5 1000 AD 
13 6 F 78 5 995 AD 
14 6 F 85 4 1035 AD 
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Supplementary Figures: 
 
Fig. S1 Specificity of BIN1 p-T348 antibody to the neuronal isoforms of BIN1 in PNC. 
Western blot of neurons transduced with shNT, shBIN1, Mock, BIN1iso1 (containing T348), 
and BIN1iso9 (without the CLAP domain or T348) constructs. BIN1 p-T348 signal is 
modulated as a function of BIN1iso1 under- and overexpression. No BIN1 p-T348 signal was 
detected at the molecular weight of BIN1iso9, while endogenous BIN1iso1 was seen in all 
but the shBIN1-expressing neurons. 
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Fig. S2 NMR measurements confirm that Cdk2 phosphorylates BIN1 CLAP at T348. a. 
Maldi-TOF analysis of CLAP (334-355) peptide before (red) and after (blue) incubation with 
Cdk2/CycA3 kinase. Incubation of the peptide with the kinase (molar ratio 1/100) at 37°C for 
3 h, in the presence of 2 mM ATP, 2.5 mM MgCl2, 2 mM EGTA, 2 mM DTT, 30 mM NaCl 
and protease inhibitors in 50 mM HEPES, pH 8.0, resulted in a mass increase compatible 
with the incorporation of one phosphate group. T238 is the only Pro-directed site compatible 
with the kinase specificity in the peptide. Inset: BIN1 p-T348 antibody recognizes the BIN1 
CLAP (334-355) peptide upon Cdk2 phosphorylation. b. 1H-15N HSQC spectra of BIN1Iso1-
CLAP-T348E protein (blue), Cdk2-phospho-BIN1Iso1 (superimposed in red) and BIN1Iso1 
protein (superimposed in green). Boxed resonances, superimposed in the blue and red 
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spectra, correspond to some of the resonances of the BIN1-SH3 domain, and are only 
detected in the presence of T348 phosphorylation or the T348E mutation of the CLAP 
domain (see also Fig. S16). Circled resonances, only detected in the red spectrum (or Cdk2-
phospho-BIN1) correspond to resonances with typical H-N chemical shift values for pS/pT 
residues. Inset: Multiple sites of Cdk2-BIN1 were thus modified in the conditions of this 
assay, as also shown by the characteristic gel-shift observed by SDS-PAGE. 
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Fig. S3 HCS image analysis and quantification procedures. a. Details of image acquisition, 
segmentation and PLA detection processes: Acquisition of 16 fields per well in four 
wavelengths using IN Cell Analyzer 6000; exclusion of somatic regions from FITC and Cy5 
channels and delimitation of MAP2 and Tau areas in the Columbus software; detection of 
PLA spots in non-somatic Tau areas and their filtering based on area and contrast (green 
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spots in the last image). b. Schematic showing the iterative process for selecting the 
optimum analysis script separately for each plate. c. Demonstration of data analysis in a 
representative plate layout. Yellow wells are used to correct for spatial bias. Blue wells and 
the corresponding 5×5 neighborhood (black outlines) illustrate the correction for local bias. 
Red wells were excluded based on network quality and the remaining (green) wells were 
used to calculate plate means for normalization. 
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Fig. S4 Distribution of Tau area (a) and Tau:MAP2 area ratio (b) of all 1,126 compounds in 
the three screenings, after plate-by-plate normalization (excluded data points shown in red). 
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Fig. S5 MAPT and BIN1 expression in the TgBIN1 mouse. a. Drawing of the BAC RP11-
437K23 encompassing the BIN1 locus and upstream sequences. b. RNA was extracted from 
hippocampus of TgBIN1 mice, reverse-transcribed, cloned and sequenced. Human exons 
present in hippocampus and corresponding protein domains are displayed with 
corresponding colors. BAR, BIN-Amphiphysin-Rvs; CLAP, Clathrin and AP2 binding domain; 
MBD, Myc binding domain; SH3, Src homology domain. c. Isoform 1 was the main human 
BIN1 isoform detected, whose sequence is shown. d. Quantification of neuronal and 
muscular BIN1 isoforms by RT-qPCR from brain and quadriceps of TgBIN1 mouse. e. 
Quantification of total murine Bin1 and human BIN1 RNA by RT-qPCR from brain of WT and 
TgBIN1 mice. f. Western blots of total Tau in the brains of WT and TgBIN1 mice. g. Distance 
traveled by WT and TgBIN1 mice in the open field test.  
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Fig. S6 Validation of lack of object preference. Percentage of time spent by the 3-, 6-, 9-, 12- 
, or 15-month-old control, hTau and hTau;TgBIN1 mice with objects located in the right or left 
positions, during the acquisition phase. 
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Fig. S7 Spatial and long-term memory in 12- and 15-month-old TgBIN1 males assessed with 
Morris water maze. a. Time to reach the platform (PT) at 12 months. b. Velocity during task 
acquisition. c. Time to reach the platform (PT) at 15 months. d. Velocity during task 
acquisition. Data represent mean ± SEM for consecutive days of acquisition (control n=11; 
hTau n=11; hTau;TgBIN1 n=13). Two-way ANOVA followed by Bonferroni post hoc test at 
each day of acquisition. § p < 0.05, §§ p < 0.01 for control vs hTau. * p < 0.05, ** p < 0.01 for 
hTau vs hTau;TgBIN1. 
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Fig. S8 Long-term memory deficits due to MAPT overexpression in hTau females is rescued 
by BIN1 overexpression at 12 but not 15 months. Spatial and long-term memory in 12- and 
15-month-old control, hTau and hTau;TgBIN1 mice assessed with Morris water maze. a. 
Distance traveled to reach the platform at 12 months. Data represent mean ± SEM for 
consecutive days of acquisition (control, n=11; hTau, n=9; hTau;TgBIN1, n=11). b. Probe 
test without platform at 12 months, performed 24 h after the last training session. Dashed 
line represents chance. Data represent mean ± SEM for each quadrant (control, n=11; hTau, 
n=9; hTau;TgBIN1, n=11). Underlined quadrant marks original platform location. c. Distance 
traveled to reach the platform at 15 months. Data represent mean ± SEM for consecutive 
days of acquisition (control, n=11; hTau, n=9; hTau;TgBIN1, n=11). d. Probe test without 
platform at 15 months, performed 24 h after the last training session. Dashed line represents 
chance. Data represent mean ± SEM for each quadrant (control, n=11; hTau, n=9; 
hTau;TgBIN1, n=11). Underlined quadrant marks original platform location. One sample t-
test compared to chance at 25% for the time spent in quadrants, *p<0.05, **p<0.01. Two-
way ANOVA for the distance travelled, **p<0.01.  
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Fig. S9 BIN1 overexpression does not affect long-term memory. Spatial and long-term 
memory in 15-month-old TgBIN1 males assessed with Morris water maze. a. Distance 
traveled to reach the platform. Data represent mean ± SEM for consecutive days of 
acquisition (WT, n=15; TgBIN1, n=13). b. Time to reach the platform (PT). Data represent 
mean ± SEM for consecutive days of acquisition (WT, n=15; TgBIN1, n=13). c. Velocity 
during task acquisition. Data represent mean ± SEM for consecutive days of acquisition 
(WT, n=15; TgBIN1, n=13). d. Probe test without the platform, performed 24 h after the last 
training session. Dashed line represents chance. Data represent mean ± SEM for each 
quadrant (WT, n=15; TgBIN1, n=13). Underlined quadrant marks original platform location. 
One sample t-test compared to chance at 25%; * p < 0.05. 
  
 Results 
137 
 
 
Fig. S10 Absence of visual or motor deficits in 15-month-old males and females for the 
Morris water maze. a. Distance traveled to reach the visible platform (PT) for males (control, 
n=11; hTau, n=11; hTau;TgBIN1, n=13). b. Time to reach the visible platform for males 
(control, n=11; hTau, n=11; hTau;TgBIN1, n=13). c. Distance traveled for females to reach 
the visible platform (PT; control, n=10; hTau, n=10; hTau;TgBIN1, n=11). d. Time to reach 
the visible platform for females (control, n=10; hTau, n=10; hTau;TgBIN1, n=11). Data 
represent mean ± SEM. One-way ANOVA followed by Bonferroni post hoc test. 
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Fig. S11 BIN1 does not impact the levels of soluble phospho-Tau proteins. a. Western blots 
of hippocampal lysates from 18-month-old hTau and hTau;TgBIN1 male mice, labeled with 
antibodies detecting total Tau protein (total Tau), p-Ser202/p-Thr205 Tau (AT8) or p-Thr231 
Tau (AT180), and GAPDH. Quantification of phospho-Tau over total Tau signal intensities 
for AT8 (b) and AT180 (c) antibodies. 
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Fig. S12 Tubulin-Tau PLA in brain slices. a. Tubulin-Tau PLA (cyan), and Tubulin (yellow), 
Tau (magenta), and Hoechst (white) stainings in the hippocampi of control, hTau and 
hTau;TgBIN1 males at 18 months. Zoomed areas show PLA and Tau channels only. Scale 
bars = 500 µm; zooms, 50 µm. b-c. Quantification of the Tubulin-Tau PLA density. Data 
expressed as PLA spot number per tissue area (B) or total PLA spot volume per tissue area 
(C), normalized with control mean (control, n=2; hTau, n=2; hTau;TgBIN1, n=2). 
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Fig. S13 Expression of BIN1 after transduction with BIN1 constructs. Representative 
Western blots showing BIN and β-actin protein levels in PNC at DIV14 after transduction at 
DIV8. Bands showing shNT and shBIN1 are from the same membrane as the other 
constructs, but with longer exposure to reveal the shBIN1 band. 
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Fig. S14 Dose-response curves for the 12 shortlisted compounds grouped according to their 
targets. See Fig. 4 for details. Phosphorylation targeting compounds: Cyclosporin A, an 
inhibitor of Calcineurin (through forming a blocking complex with Cyclophilin); U0126, a 
potent MEK inhibitor. NO-synthase targeting compounds: TRIM, a potent inhibitor of 
neuronal and inducible NO-synthases; Diphenyleneiodonium chloride, a GPR3 agonist that 
also inhibits NO-synthase and NADPH oxidase. Ca2+ homeostasis targeting compounds: (±)-
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Bay K 8644, a L-type Ca2+ channel activator; DHBP dibromide, an inhibitor of endoplasmic 
reticulum Ca2+ release. Receptor targeting compounds: BRL37344 sodium salt, a β3 
agonist; BU 226 hydrochloride, a potent and highly selective I2 ligand; SB 258585 
hydrochloride, a potent and selective 5-HT6 antagonist. Other compounds: JLK6, an inhibitor 
of γ-secretase-mediated βAPP processing; MNITMT, a non-toxic immunosuppressive agent; 
Doxorubicin hydrochloride, a tumor suppressor drug shown to inhibit DNA topoisomerase II 
and reduce Tau cellular levels.  
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Fig. S15 Modulation of Tau phosphorylation in vitro. a. Reduction of Tau phosphorylation at 
Thr 231 after 30 min incubation of PNC crude extracts with lambda protein phosphatase (λ-
PP). b. In vitro phosphorylated recombinant Tau at Thr 231 is observed after incubation with 
recombinant Cdk5 for 1 h. Cdk2 dependent phosphorylation of Tau at Thr 231 has been 
published previously (Ref. 49). 
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Fig. S16 Additional signals in BIN1iso1-CLAP-T348E matched signals from BIN1 SH3 
domain. Overlays of 1H-15N HSQC spectra of (a) BIN1iso1-CLAP-T348E protein (in red) and 
BIN1iso1 protein (superimposed in blue) or of (b) BIN1iso1-CLAP-T348E protein (in red) and 
BIN1 SH3 domain (superimposed in green). In BIN1iso1 spectrum, in blue, due to the large 
size of the BIN1iso1 protein, only signals corresponding to mobile disordered regions are 
detected. These signals show a typical poor dispersion on the 1H scale (ca. 7.5-8.5 ppm). 
Due to this intrinsic need of mobility to detect protein NMR signals, the SH3-BIN1 resonance 
are only detected when the domain behaves independently of the full protein, as is observed 
for BIN1iso1-CLAP-T348E (in red). Signals from the SH3-BIN1 domain show a good 
dispersion on the 1H scale (ca. 6.5-9.5 ppm), as expected for globular domain signals. The 
additional signals observed in BIN1iso1-CLAP-T348E, in red, matched signals from the SH3-
BIN1 domain, in green.  
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Fig. S17 Titration of 15N-BIN1-SH3 with CLAP peptides. Detail of overlayed 1H-15N HSQC 
spectra of BIN1-SH3 domain, in the presence of increasing amount of (a) CLAP (334-355) 
peptide, molar ratios 0.25 to 8 (color scale, from red to violet), or of (b) phospho-CLAP (334-
355) peptide, molar ratios 1 to 20 (color scale, from red to violet). One spectrum was 
recorded for each titration point. The gradual change of the chemical shift value for each 
resonance was then used to build a saturation curve (see Fig. 5g). Data were averaged to 
estimate the Kd values. Note that a larger excess of phospho-CLAP (334-355) peptide was 
needed to reach saturation, due to its lower affinity for BIN1-SH3 domain, compared to the 
non-phosphorylated peptide.  
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Fig. S18 Myelin alterations following hTau overexpression was prevented upon BIN1 
overexpression. a-c. Electron microscopy analysis of the myelinated axons in the fornices of 
18-month-old control (A), hTau (B), and hTau;TgBIN1 (C) males. d-f. Serial magnification of 
the marked areas. Arrowheads point to myelin abnormalities defined by multiple myelin 
rings. Micrographs are representative of 2 animals per genotype. Scale bars = 5 µm (a-c) 
and 2 µm (d-f). 
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Fig. S19 Myelin structure is unaffected following BIN1 overexpression. a-b. Electron 
microscopy analysis of the myelinated axons in the fornices of 18-month-old Mapt-/-;TgBIN1 
(A) and TgBIN1 (B) males. c-d. Serial magnification of the marked areas. Micrographs are 
representative of 2 animals per genotype. Scale bars = 5 µm (a-b) and 2 µm (c-d). 
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Fig. S20 Axonal ultrastructure is unaffected in transgenic mice. Electron microscopy analysis 
of axon fibers in the hippocampal CA1 region of 18-month-old control, hTau, and 
hTau;TgBIN1 males. Micrographs are representative of 2 animals per genotype. Scale bars 
= 2 µm. 
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Discussion and Conclusions 
To better understand the interaction between BIN1 and Tau, we aimed to identify 
the interaction sites between BIN1 and Tau and how the interaction could be modulated, 
highlight the molecular pathways that could be involved in the modulation of BIN1-Tau 
interaction, and understand how BIN1-Tau interaction is involved in AD pathophysiological 
process. 
Here, we reported that BIN1 and Tau interact through the binding of BIN1-SH3 
domain and Tau-PRD, that this interaction is dependent of BIN1 and Tau phosphorylation 
levels and BIN1 protein levels and conformation, and that BIN1-Tau interaction occurs in the 
vicinity of actin cytoskeleton. We show that the previously reported conformational change 
observed in the neuronal isoform of BIN1 (Malki et al. 2017) is regulated by the 
phosphorylation of BIN1 at T348, a residue in the PRD of BIN1-CLAP domain: 
phosphorylation of BIN1 T348 releases BIN1-SH3 domain from its intramolecular interaction 
with BIN1-CLAP-PRD, leading to an open conformation of BIN1iso1 and subsequent 
availability to interact with other proteins, e.g. Tau. Similarly, phosphorylation of Tau at 
T231, in the PRD of Tau, abolishes the interaction between BIN1-SH3 and Tau-PRD. 
Interestingly, we observed that Cdk5, a kinase known to be deregulated in AD (Shukla, 
Skuntz, and Pant 2012), was able to phosphorylate both BIN1 T348 and Tau T231 in vitro, 
suggesting that the interaction between BIN1 and Tau is highly dynamic and probably 
subject to complex regulation. 
In order to identify molecular pathway that could be involved in BIN1-Tau 
interaction, we developed a novel, semi-automated, HCS compound-based approach that 
used PNC as cellular model and PLA as the readout of BIN1-Tau interaction, and identified a 
few compounds that targeted molecular pathways such as NO-synthase activity, Ca2+ 
homeostasis, MAPK signalling pathway, and Calcineurin signalling. We decided to further 
validate the compounds Cyclosporin A (CsA), an inhibitor of Calcineurin phosphatase activity 
and U0126, an inhibitor of MEK1/2, and observed that while CsA increased the interaction 
by increasing BIN1 phosphorylation at T348, U0126 decreased BIN1-Tau interaction by 
increasing Tau phosphorylation levels at T231. Once again, the phosphorylation of BIN1 and 
Tau PRDs had opposite effect in regulation of BIN1-Tau interaction. 
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Using a mouse model of tauopathy, we observed that the overexpression of BIN1 
neuronal isoforms, although exacerbated short-term memory deficits since young age, 
rescued the Tau induced behavioural phenotypes in long-term and spatial memory at the 
later age. This rescue was associated with a clear reduction of intracellular inclusions of Tau 
and with a drastic increase of BIN1-Tau interaction in the hippocampus. These results 
suggest a potential protective impact of the overexpression of BIN1 neuronal isoforms in the 
pathophysiological processes of AD, possibly linked with the increase of BIN1-Tau 
interaction. Finally, we showed that BIN1 neuronal isoform is decreased in brains of post-
mortem AD patients, as previously reported (De Rossi et al. 2016; Holler et al. 2014; 
Glennon et al. 2013), and (surprisingly) the levels of BIN1 phosphorylated at T348, relative 
to BIN1iso1, were increased when compared to controls, suggesting that this site might also 
be involved in AD process. 
Altogether, our data indicate that BIN1-Tau interaction is complex, dynamic, loci 
specific, and its regulation, especially through the phosphorylation of BIN1 and Tau, is 
somehow involved in the pathophysiological process of AD, but it is not yet clear if this 
interaction is protective or deleterious. The fact that BIN1 overexpression modulated Tau 
phenotype by increasing short-term memory deficits and rescuing long-term deficits suggest 
a potential equilibrium between BIN1 and Tau levels may differ in spatial and temporal 
dimensions. Indeed, both short- and long-term memory processes require the 
hippocampus, but they take part in different cortical regions, i.e. lateral entorhinal and 
medial entorhinal cortex respectively (Van Cauter et al. 2013). Interestingly, the rescue of 
long-term memory deficits by BIN1 overexpression was associated with the strong reduction 
of Tau inclusions and a strong increase of BIN1-Tau interaction. Since we developed a cohort 
study, it was only possible to evaluate the levels of Tau phosphorylation and BIN1-Tau 
interaction after the behavioural experiments (18 months). Although we observed that BIN1 
overexpression had no impact on soluble phosphorylated Tau at this age of the mouse 
model, it has been previously shown that this hTau mouse model develop inclusions of 
phosphorylated Tau in the hippocampus as early as 4 months (Polydoro et al. 2009), and 
supplementary cytochemical and biochemical analysis, at earlier age of this mouse model, is 
necessary to fully understand the role of BIN1 expression on Tau phosphorylation, before 
tangle formation. Nonetheless these results suggest that the increase of BIN1 Tau 
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interaction levels may be protective against the re-localization and accumulation of 
phosphorylated Tau, a major hallmark of AD. 
Although it had previously been demonstrated that BIN1 mRNA levels were 
increased in the brains of AD patients carrying the polymorphism rs59335482, when 
compared to controls (J Chapuis et al. 2013), that observation had not been associated with 
any specific isoform of BIN1, and posterior publications reported the underexpression of 
BIN1 neuronal isoform and the overexpression of the ubiquitous isoform of BIN1 in the 
post-mortem brains of AD patients (Glennon et al. 2013; Holler et al. 2014; De Rossi et al. 
2016), which suggests that this increase in mRNA levels of BIN1 could lead to an increase of 
the ubiquitous and not the neuronal isoform. In line with those findings, we observed that 
the protein levels of BIN1 neuronal isoform were reduced in the brains of AD patients, when 
compared with controls. Since the main isoforms of BIN1 expressed in our mouse model are 
the neuronal isoforms, this data strengthens the idea that the specific overexpression of the 
neuronal isoforms of BIN1 might be protective, and we may thus postulate that the 
overexpression of brain isoforms in the TgBIN1 mouse reverses, or at least arrests, a 
neuropathological process that occurs in AD brains. Unfortunately, neither this study nor 
previous publications assessed the presence of BIN1 polymorphisms in the samples used to 
assess BIN1 protein levels, so the association between BIN1 mRNA and protein isoforms 
levels cannot be confirmed. 
Noteworthy, BIN1’s protective effect could be partially explained by other 
mechanisms than BIN1-Tau interaction in neurons. In fact, we observed that BIN1 
overexpression also rescued myelin abnormalities, present in the tauopathy mouse model, 
and had no effect on myelin when overexpressed alone. Thus, the memory deficits observed 
when overexpressing Tau may also be associated with these myelin abnormalities and 
rescued with BIN1 overexpression, in line with previous works linking Tau to potential 
myelin dysfunctions in tauopathies (Ferrer 2018) and reporting that BIN1 was strongly 
expressed in oligodendrocytes (De Rossi et al. 2016). In this last study, the authors used 
combinations of antibodies that do not recognise BIN1 neuronal isoform with antibodies 
that recognize almost all the isoforms of BIN1 and show, through IF and WB, that BIN1 iso9 
is predominantly expressed in oligodendrocytes and is more expressed in AD cases than in 
control patients. Although they were not assessed in this study, we cannot exclude that the 
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mechanisms associated with the physiological roles of BIN1 in the regulation of endocytosis 
and recycling endosome pathway, shown to be associated with Tau propagation and Aβ 
production (Miyagawa et al. 2016; Ubelmann et al. 2017; Calafate et al. 2016), could also be 
deregulated in our animal models of tauopathy and be rescued by BIN1 overexpression, 
leading to the phenotypical and behavioural changes observed. 
Moving forward from these possibilities, identifying the molecular mechanisms that 
regulate BIN1-Tau interaction might be highly important to understand the 
pathophysiological process of AD. In this regard, we defined the BIN1-SH3 domain and the 
Tau-PRD as the interaction sites of these proteins, and identified two major regulatory 
elements of BIN1-Tau interaction, the phosphorylation of BIN1 at T348 and the 
phosphorylation of Tau at T231, with opposite impacts on this interaction: while 
phosphorylation of Tau at T231 abrogates BIN1-Tau interaction, phosphorylation of BIN1 at 
T348 promotes its occurrence. 
Tau T231 seems to play a central role in the regulation of Tau phosphorylation state: 
phosphorylation at S235 primes phosphorylation of T231 (Li et al. 2006); T231 is more easily 
phosphorylated when free than in association with microtubules and it is enough to 
dissociate Tau from the microtubules (Sengupta et al. 2006); phosphorylation at T231 
inhibits dephosphorylation of S202/T205 (Landrieu et al. 2011); and phosphorylation of 
S202/T205 can induce Tau aggregation (Despres et al. 2017). Besides, enzymes that control 
this phosphorylation(s) (e.g. Cdk5, Gsk-3β, PP2A) are clearly deregulated during AD process 
(Iqbal, Liu, and Gong 2016). 
On the other hand, the phosphorylation of BIN1 at T348 has never been described 
and its role is not known. However, it has recently been shown that the neuronal isoform of 
BIN1 is involved in intramolecular interaction between its SH3 domain and its CLAP 
domains, notably with a proline-rich region (Malki et al. 2017). In this work, we demonstrate 
that phosphorylation of BIN1 at T348 is enough to abolish that intramolecular interaction 
and promote the interaction of BIN1 with Tau. Moreover, we detected an increase of the 
relative levels of BIN1 phosphorylated at T348, in the brain samples of AD patients and 
increasing with Braak sage. Interestingly these findings indicate that while the global levels 
of BIN1 neuronal isoform is decreased, a higher fraction of this isoform is phosphorylated at 
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T348 in AD brains, thus suggesting that this increase in phosphorylation may occur as an 
attempt to compensate the decrease of BIN1 neuronal isoform and maintain the interaction 
between BIN1 and Tau. Independently of the mechanisms potentially involved, these 
observations suggest that phosphorylation of BIN1 at T348 may be involved in the 
pathophysiological process of AD. 
Using an HCS approach, we identified several compounds that were able to 
modulate BIN1-Tau interaction in a concentration dependent manner, thus suggesting that 
these compounds were modulators of this interaction, either directly or through their target 
pathways. Noteworthy, several of the targets identified in our HCS approach are known to 
be deregulated in AD, such as NO-synthase (NOS) activity, Ca2+ homeostasis, Calcineurin, 
MEK1/2, Aβ production and Tau (L. Zhou and Zhu 2009; Norris 2018; O’Day, Eshak, and 
Myre 2015; Nisbet et al. 2015; Pei et al. 2002). Moreover, several of these targets seem to 
interact or at least share pathways, such as the case of the NOS regulation by Ca2+ levels via 
Calmodulin (Tricoire and Vitalis 2012), the β3-adrenergic receptor regulation of NOS activity 
in myocytes (Watts et al. 2013), and the Calcineurin association to dephosphorylation of Tau 
and NOS (Rameau, Chiu, and Ziff 2003; O’Day, Eshak, and Myre 2015). This data, together 
with the identification of Tau T231 and BIN1 T348 as key regulatory elements of BIN1-Tau 
interaction, corroborate the idea that this interaction is highly complex, both in its 
regulation and its function, in physiology and AD process, potentially controlled by 
numerous actors capable of modify the phosphorylation levels of both BIN1 and Tau. Thus, 
further investigation on the signalling mechanisms involved in BIN1-Tau interaction is 
warranted. 
The divergent role of BIN1 and Tau phosphorylation in their interaction is highlighted 
in our HCS approach, which revealed that the inhibition of MEK1/2 leads to a decrease in 
BIN1-Tau interaction through the increase of Tau T231 phosphorylation levels, whereas the 
inhibition of Calcineurin phosphatase activity favours it by increasing the phosphorylation 
levels of BIN1 at T348. The complexity involved in the regulation of BIN1-Tau interaction can 
be further illustrated by the regulation of phosphorylation through cyclin-dependent 
kinases, especially Cdk5: Cdk5 is able to phosphorylate both BIN1 at T348 and Tau at T231 
and we showed that he phosphorylation of these two epitopes had opposite effects on 
BIN1-Tau interaction. Thus, we proposed that Cdk5 phosphorylates BIN1 at T348, allowing 
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BIN1 to change its conformation and increase its affinity towards Tau, then Tau interacts 
with BIN1 and is subsequently phosphorylated by Cdk5 at T231, abolishing the interaction 
and releasing phosphorylated BIN1 and phosphorylated Tau. 
This proposed pathway illustrates the challenge for the development or testing of 
drugs targeting the modulation of BIN1-Tau interaction: in this case, targeting the kinase 
alone could have very little or no effect in the modulation of the interaction. On the other 
hand, the inhibitor of Calcineurin phosphatase activity, CsA, is a compound of interest to 
study the modulation of BIN1-Tau interaction: upon inhibition of Calcineurin activity we 
observed a strong increase of the interaction associated with the increase of BIN1 T348 
phosphorylation, but not so much of Tau T231. Therefore, a better understanding of the 
mechanisms involved in BIN1-Tau interaction is needed. 
Of notice, Cdk5 is deregulated in AD (Shukla, Skuntz, and Pant 2012), and it has been 
shown that free Tau phosphorylated at T231 could initiate a cascade of phosphorylation, 
and/or inhibition of dephosphorylation, of other epitopes in Tau protein that would lead to 
Tau abnormal phosphorylation. Therefore, a thigh regulation of BIN1-Tau interaction levels, 
and of BIN1 T348 and Tau T231 phosphorylation levels, could be influential in avoiding the 
development of pathophysiological processes of AD. 
In this regard, it has been shown that the neuronal isoforms of BIN1 exist in 
phosphorylated state in resting nerve terminals and, in order to interact with its endocytic 
partners, is rapidly dephosphorylated by Calcineurin upon membrane depolarization and/or 
stimulation of exo/endocytosis (Patrick Wigge and McMahon 1998; Marks and McMahon 
1998; P Wigge et al. 1997), and this dephosphorylation is enhanced in a Ca2+-dependent 
manner when a burst of endocytic activity is needed (Bauerfeind, Takei, and De Camilli 
1997; Slepnev et al. 1998). Although the phosphorylation sites of BIN1 neuronal isoform 
involved in this process have never been identified, it was shown that the phosphorylation 
of Amphiphysin I by Cdk5, at T310 and other sites, was implicated in membrane binding and 
endocytosis (Tomizawa et al. 2003; Liang et al. 2007). Since the sequence surrounding T310 
of Amphiphysin I is very similar to the sequence around T348 of the neuronal isoform of 
BIN1, we could postulate that this phosphorylation site could be involved not only in the 
regulation of BIN1-Tau interaction but also be involved in modulating BIN1’s availability to 
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regulate endocytosis. Thus, it would be interesting to know if Calcineurin alone would be 
able to dephosphorylate BIN1 during its interaction with Tau or if it needed a disruption of 
BIN1-Tau interaction in order to dephosphorylate BIN1 and initiate its regulation of 
endocytic pathway. 
These extrapolations, together with the partial co-localization of BIN1-Tau 
interaction with actin suggest that BIN1-Tau interaction may play a role in the interface 
between actin cytoskeleton and the recycle and endocytic machinery. The fact co-
localization of BIN1-Tau interaction with endocytic and synaptic markers was not observed 
indicates that the interaction is not involved in the formation, or at least stabilization, of 
these structures. However, the participation of BIN1-Tau interaction in recycling and 
endocytic pathways cannot be completely excluded because the cells were not stimulated 
and the interaction might have not been required at that time. Interestingly it was shown 
that underexpression of BIN1 iso1 increased Clathrin-mediated endocytosis and promoted 
Tau pathology propagation (Calafate et al. 2016), but nothing was assessed regarding the 
development of Tau pathology. Moreover, it was also shown that underexpression of BIN1 
iso1 increased the amounts of BACE1 and Aβ formation (Miyagawa et al. 2016) and that this 
effect was due to the accumulation of BACE1 on axonal early endosomes (Ubelmann et al. 
2017), which could be a mechanism leading to the development of AD. 
This work aimed to shed light onto the role of BIN1-Tau interaction through the 
identification of its modulators and molecular pathways involved in it. 
Although it was not yet possible to unveil the role of BIN1-Tau interaction in 
physiology and/or in AD pathophysiological process, it is possible to clearly say that BIN1-
Tau interaction and its regulation is somehow involved in the pathophysiological process of 
AD. We identified the protein domains involved in BIN1-Tau interaction and that the 
phosphorylation of both proteins modulated the interaction with opposite effects: 
phosphorylation of BIN1 at T348 leads to a conformational shift of the protein, increasing its 
affinity towards Tau and, increasing the interaction, whereas Tau phosphorylation at T231 
reduces the affinity of BIN1-SH3 domain towards Tau PRD, decreasing the interaction. 
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This is the first time that the impact of the overexpression of BIN1, a major genetic 
risk factor of AD, is characterized in a model of tauopathy, and our data also suggests that 
the overexpression of BIN1 might have a protective impact on the AD process. However, 
whether this potential protective effect is linked with BIN1-Tau interaction or associated to 
a function of BIN1 (e.g. regulation of endocytosis and recycling endosome pathway) is still to 
be assessed; but it is definitely and strongly dependent on the phosphorylation statuses of 
both BIN1 and Tau proteins. Furthermore, it is recommended to perform 
immunohistochemical and biochemical analysis in younger animals of this model, to 
understand the role of BIN1 overexpression at earlier stages of AD development and to 
discriminate between causal and consequential events. 
Although HCS approaches require extensive work and time dedicated to protocol 
and analysis optimization, they quickly provide large amounts of data that allow the 
simultaneous analysis of hundreds to thousands of experimental conditions, and 
minimize/optimize the number of hypotheses to be further tested, being one of the 
strongest tools currently available to study the role of AD-associated GWAS-defined genes. 
Thus, we developed a novel, semi-automated HCS approach, employing PNC as cellular 
model and PLA as readout of BIN1-Tau interaction (the first time these techniques are 
employed together with HCS), to identify molecular mechanisms that may be involved in 
BIN1-Tau interaction, such as NOS activity, Ca2+ homeostasis, Calcineurin and MEK1/2 
signalling. Interestingly, all these molecular pathways are dysregulated in AD, and their 
involvement in BIN1-Tau interaction, in physiology or in the AD context, are worth of further 
investigation. 
There is no more doubt that BIN1 is a major genetic risk factor of AD, but there is still 
much more to learn about its role and the role of BIN1-Tau interaction in the 
pathophysiological process of AD. Therefore, future work in the lab will involve the 
development of imaging strategies that will allow the identification of BIN1-Tau interaction 
relative position in the neurons, and the setting up of experiments to dissect molecular 
pathways, identified in our HCS approach, with possible involvement in BIN1-Tau 
interaction. 
 
 Bibliography 
157 
 
Bibliography 
Adams, Stephanie L., Kathy Tilton, James A. Kozubek, Sudha Seshadri, and Ivana Delalle. 
2016. “Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral 
Cortex During the Progression of Alzheimer Disease Pathology.” Journal of 
Neuropathology & Experimental Neurology 75 (8):779–90. 
https://doi.org/10.1093/jnen/nlw056. 
Al-Bassam, Jawdat, Rachel S. Ozer, Daniel Safer, Shelley Halpain, and Ronald a. Milligan. 
2002. “MAP2 and Tau Bind Longitudinally along the Outer Ridges of Microtubule 
Protofilaments.” Journal of Cell Biology 157 (7):1187–96. 
https://doi.org/10.1083/jcb.200201048. 
Alzheimer’s Association. 2015. “2015 Alzheimer’s Disease Facts and Figures.” Alzheimer’s & 
Dementia. Vol. 11. Elsevier Ltd. https://doi.org/10.1016/j.jalz.2015.02.003. 
Andorfer, Cathy, Yvonne Kress, Marisol Espinoza, Rohan De Silva, Kerry L. Tucker, Yves Alain 
Barde, Karen Duff, and Peter Davies. 2003. “Hyperphosphorylation and Aggregation of 
Tau in Mice Expressing Normal Human Tau Isoforms.” Journal of Neurochemistry 86 
(3):582–90. https://doi.org/10.1046/j.1471-4159.2003.01879.x. 
Armstrong, R a. 2011. “The Pathogenesis of Alzheimer’s Disease: A Reevaluation of the 
‘Amyloid Cascade Hypothesis’.” International Journal of Alzheimer’s Disease 2011 
(January). Hindawi Publishing Corporation:630865. 
https://doi.org/10.4061/2011/630865. 
Augustinack, Jean C., Anja Schneider, Eva Maria Mandelkow, and Bradley T. Hyman. 2002. 
“Specific Tau Phosphorylation Sites Correlate with Severity of Neuronal Cytopathology 
in Alzheimer’s Disease.” Acta Neuropathologica 103 (1):26–35. 
https://doi.org/10.1007/s004010100423. 
Bagchi, Sonchita, Robert Fredriksson, and Åsa Wallén-Mackenzie. 2015. “In Situ Proximity 
Ligation Assay (PLA).” Methods in Molecular Biology 1318 (January):149–59. 
https://doi.org/10.1007/978-1-4939-2742-5_15. 
Baker, Matt, Irene Litvan, Henry Houlden, Jennifer Adamson, Dennis Dickson, Jordi Perez-
Tur, John Hardy, Timothy Lynch, Eileen Bigio, and Mike Hutton. 1999. “Association of 
an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy.” Human 
Molecular Genetics 8 (4):711–15. https://doi.org/10.1093/hmg/8.4.711. 
Ballatore, Carlo, Virginia M.Y. Lee, and John Q. Trojanowski. 2007. “Tau-Mediated 
Neurodegeneration in Alzheimer’s Disease and Related Disorders.” Nature Reviews 
Neuroscience 8 (9):663–72. https://doi.org/10.1038/nrn2194. 
Bauerfeind, Rudolf, Kohji Takei, and Pietro De Camilli. 1997. “Amphiphysin I Is Associated 
with Coated Endocytic Intermediates and Undergoes Stimulation-Dependent 
 Bibliography 
158 
 
Dephosphorylation in Nerve Terminals.” Journal of Biological Chemistry 272 
(49):30984–92. https://doi.org/10.1074/jbc.272.49.30984. 
Benilova, Iryna, Eric Karran, and Bart De Strooper. 2012. “The Toxic Aβ Oligomer and 
Alzheimer’s Disease: An Emperor in Need of Clothes.” Nature Neuroscience 15 (3). 
Nature Publishing Group:349–57. https://doi.org/10.1038/nn.3028. 
Benitez, Bruno a., Sheng Chih Jin, Rita Guerreiro, Rob Graham, Jenny Lord, Denise Harold, 
Rebecca Sims, et al. 2014. “Missense Variant in TREML2 Protects against Alzheimer’s 
Disease.” Neurobiology of Aging 35 (6). 
https://doi.org/10.1016/j.neurobiolaging.2013.12.010. 
Bennett, Rachel E., Sarah L. DeVos, Simon Dujardin, Bianca Corjuc, Rucha Gor, Jose 
Gonzalez, Allyson D. Roe, et al. 2017. “Enhanced Tau Aggregation in the Presence of 
Amyloid Β.” The American Journal of Pathology 187 (7):1601–12. 
https://doi.org/10.1016/j.ajpath.2017.03.011. 
Bettens, Karolien, Nathalie Brouwers, Sebastiaan Engelborghs, Jean Charles Lambert, 
Ekaterina Rogaeva, Rik Vandenberghe, Nathalie Le Bastard, et al. 2012. “Both Common 
Variations and Rare Non-Synonymous Substitutions and Small Insertion/deletions in 
CLU Are Associated with Increased Alzheimer Risk.” Molecular Neurodegeneration 7 
(1):1–12. https://doi.org/10.1186/1750-1326-7-322248099. 
Bhaskar, Kiran, Shu Hui Yen, and Gloria Lee. 2005. “Disease-Related Modifications in Tau 
Affect the Interaction between Fyn and Tau.” Journal of Biological Chemistry 280 
(42):35119–25. https://doi.org/10.1074/jbc.M505895200. 
Biswas, Sayantanee, and Katherine Kalil. 2017. “The Microtubule Associated Protein Tau 
Mediates the Organization of Microtubules and Their Dynamic Exploration of Actin-
Rich Lamellipodia and Filopodia of Cortical Growth Cones.” The Journal of Neuroscience 
38 (2):2281–17. https://doi.org/10.1523/JNEUROSCI.2281-17.2017. 
Blokzijl, A., R. Nong, S. Darmanis, E. Hertz, U. Landegren, and M. Kamali-Moghaddam. 2014. 
“Protein Biomarker Validation via Proximity Ligation Assays.” Biochimica et Biophysica 
Acta - Proteins and Proteomics 1844 (5). Elsevier B.V.:933–39. 
https://doi.org/10.1016/j.bbapap.2013.07.016. 
Böhm, Johann, Nasim Vasli, Marie Maurer, Belinda Cowling, G. Diane Shelton, Wolfram 
Kress, Anne Toussaint, et al. 2013. “Altered Splicing of the BIN1 Muscle-Specific Exon in 
Humans and Dogs with Highly Progressive Centronuclear Myopathy.” PLoS Genetics 9 
(6). https://doi.org/10.1371/journal.pgen.1003430. 
Braak, H., and E. Braak. 1991. “Neuropathological Stageing of Alzheimer-Related Changes.” 
Acta Neuropathologica 82 (4):239–59. https://doi.org/10.1007/BF00308809. 
Braak, Heiko, and Kelly Del Tredici. 2012. “Where, When, and in What Form Does Sporadic 
Alzheimer’s Disease Begin?” Current Opinion in Neurology 25 (6):708–14. 
https://doi.org/10.1097/WCO.0b013e32835a3432. 
 Bibliography 
159 
 
Bradshaw, Elizabeth M., Lori B. Chibnik, Brendan T. Keenan, Linda Ottoboni, Towfique Raj, 
Anna Tang, Laura L. Rosenkrantz, et al. 2013. “CD33 Alzheimer’s Disease Locus: Altered 
Monocyte Function and Amyloid Biology.” Nature Neuroscience 16 (7). Nature 
Publishing Group:848–50. https://doi.org/10.1038/nn.3435. 
Bray, Mark-anthony, and Anne Carpenter. 2013. Advanced Assay Development Guidelines 
for Image-Based High Content Screening and Analysis. Assay Guidance Manual. Eli Lilly 
& Company and the National Center for Advancing Translational Sciences. 
https://doi.org/NBK126174 [bookaccession]. 
Brettschneider, Johannes, Kelly Del Tredici, Virginia M.-Y. Lee, and John Q. Trojanowski. 
2015. “Spreading of Pathology in Neurodegenerative Diseases: A Focus on Human 
Studies.” Nature Reviews Neuroscience 16 (2). NIH Public Access:109–20. 
https://doi.org/10.1038/nrn3887. 
Brouwers, N., C. Van Cauwenberghe, S. Engelborghs, J. C. Lambert, K. Bettens, N. Le Bastard, 
F. Pasquier, et al. 2012. “Alzheimer Risk Associated with a Copy Number Variation in 
the Complement Receptor 1 Increasing C3b/C4b Binding Sites.” Molecular Psychiatry 
17 (2). Nature Publishing Group:223–33. https://doi.org/10.1039/c3ee42799d. 
Buée, Luc, Thierry Bussière, Valérie Buée-Scherrer, André Delacourte, and Patrick R. Hof. 
2000. “Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative 
Disorders.” Brain Research Reviews 33 (1):95–130. https://doi.org/10.1016/S0165-
0173(00)00019-9. 
Butler, Margaret Husta, Carol David, Gian Carlo Ochoa, Zachary Freyberg, Laurie Daniell, 
Detlev Grabs, Ottavio Cremona, and Pietro De Camilli. 1997. “Amphiphysin II (SH3p9; 
BIN1), a Member of the amphiphysin/Rvs Family, Is Concentrated in the Cortical 
Cytomatrix of Axon Initial Segments and Nodes of Ranvier in Brain and around T 
Tubules in Skeletal Muscle.” Journal of Cell Biology 137 (6). Rockefeller University 
Press:1355–67. https://doi.org/10.1083/jcb.137.6.1355. 
Calafate, Sara, William Flavin, Patrik Verstreken, and Diederik Moechars. 2016. “Loss of Bin1 
Promotes the Propagation of Tau Pathology.” Cell Reports 17 (4). 
ElsevierCompany.:931–40. https://doi.org/10.1016/j.celrep.2016.09.063. 
Camargo, Luiz Miguel, Xiaohua Douglas Zhang, Patrick Loerch, Ramon Miguel Caceres, Shane 
D. Marine, Paolo Uva, Marc Ferrer, et al. 2015. “Pathway-Based Analysis of Genome-
Wide siRNA Screens Reveals the Regulatory Landscape of App Processing.” PLoS ONE 
10 (2):1–21. https://doi.org/10.1371/journal.pone.0115369. 
Cauter, Tiffany Van, Jeremy Camon, Alice Alvernhe, Coralie Elduayen, Francesca Sargolini, 
and Etienne Save. 2013. “Distinct Roles of Medial and Lateral Entorhinal Cortex in 
Spatial Cognition.” Cerebral Cortex 23 (2):451–59. 
https://doi.org/10.1093/cercor/bhs033. 
Chapuis, J, F Hansmannel, M Gistelinck, a Mounier, C Van Cauwenberghe, K V Kolen, F 
Geller, et al. 2013. “Increased Expression of BIN1 Mediates Alzheimer Genetic Risk by 
 Bibliography 
160 
 
Modulating Tau Pathology.” Molecular Psychiatry 18 (February):1225–34. 
https://doi.org/10.1038/mp.2013.1. 
Chapuis, Julien, Amandine Flaig, Benjamin Grenier-Boley, Fanny Eysert, Virginie Pottiez, 
Gaspard Deloison, Alexandre Vandeputte, et al. 2017. “Genome-Wide, High-Content 
siRNA Screening Identifies the Alzheimer’s Genetic Risk Factor FERMT2 as a Major 
Modulator of APP Metabolism.” Acta Neuropathologica 133 (6). Springer Berlin 
Heidelberg:955–66. https://doi.org/10.1007/s00401-016-1652-z. 
Charoenkwan, Phasit, Eric Hwang, Robert W Cutler, Hua-Chin Lee, Li-Wei Ko, Hui-Ling 
Huang, and Shinn-Ying Ho. 2013. “HCS-Neurons: Identifying Phenotypic Changes in 
Multi-Neuron Images upon Drug Treatments of High-Content Screening.” BMC 
Bioinformatics 14 (Suppl 16):S12. https://doi.org/10.1186/1471-2105-14-S16-S12. 
Cline, Erika N., Maria Assunção Bicca, Kirsten L. Viola, and William L. Klein. 2018. “The Aβ 
Oligomer Hypothesis – Beginning of the Third Decade.” Journal of Alzheimer’s Disease, 
1–87. https://doi.org/10.3233/JAD-179941. 
Cochran, J. Nicholas, Travis Rush, Susan C. Buckingham, and Erik D. Roberson. 2015. “The 
Alzheimer’s Disease Risk Factor CD2AP Maintains Blood-Brain Barrier Integrity.” Human 
Molecular Genetics 24 (23):6667–74. https://doi.org/10.1093/hmg/ddv371. 
Coon, Keith D., Amanda J. Myers, David W. Craig, Jennifer A. Webster, John V. Pearson, 
Diane Hu Lince, Victoria L. Zismann, et al. 2007. “A High-Density Whole-Genome 
Association Study Reveals That APOE Is the Major Susceptibility Gene for Sporadic Late-
Onset Alzheimer’s Disease.” Journal of Clinical Psychiatry 68 (4). [Physicians 
Postgraduate Press]:613–18. https://doi.org/10.4088/JCP.v68n0419. 
Cooper, Daniel J., Giulia Zunino, John L. Bixby, and Vance P. Lemmon. 2017. “Phenotypic 
Screening with Primary Neurons to Identify Drug Targets for Regeneration and 
Degeneration.” Molecular and Cellular Neuroscience 80 (April):161–69. 
https://doi.org/10.1016/j.mcn.2016.07.001. 
Corder, Eh, Am Saunders, Wj Strittmatter, De Schmechel, Pc Gaskell, Gw Small, Ad Roses, Jl 
Haines, and Ma Pericak-Vance. 1993. “E Type 4 Allele Gene Dose of Apolipoprotein and 
the Risk of Alzheimer ’ S Disease in Late Onset Families.” Science 261 (5123):921–23. 
Crehan, Helen, John Hardy, and Jennifer Pocock. 2013. “Blockage of CR1 Prevents Activation 
of Rodent Microglia.” Neurobiology of Disease 54 (5). Elsevier Inc.:139–49. 
https://doi.org/10.1016/j.nbd.2013.02.003. 
Creixell, Pau, Syed Haider, Guanming Wu, Tatsuhiro Shibata, Miguel Vazquez, Ville 
Mustonen, Abel Gonzalez-perez, et al. 2015. “Pathway and Network Analysis of Cancer 
Genomes.” Nature Methods 12 (7):615–21. https://doi.org/10.1038/nmeth.3440. 
Cruchaga, Carlos, Celeste M. Karch, Sheng Chih Jin, Bruno a. Benitez, Yefei Cai, Rita 
Guerreiro, Oscar Harari, et al. 2014. “Rare Coding Variants in the Phospholipase D3 
 Bibliography 
161 
 
Gene Confer Risk for Alzheimer’s Disease.” Nature 505 (7484). Nature Publishing 
Group:550–54. https://doi.org/10.1038/nature12825. 
Dahlgren, Karie N., Arlene M. Manelli, W. Blaine Stine, Lorinda K. Baker, Grant A. Krafft, and 
Mary Jo LaDu. 2002. “Oligomeric and Fibrillar Species of Amyloid-Β Peptides 
Differentially Affect Neuronal Viability.” Journal of Biological Chemistry 277 
(35):32046–53. https://doi.org/10.1074/jbc.M201750200. 
Dammers, C., M. Schwarten, a. K. Buell, and D. Willbold. 2017. “Pyroglutamate-Modified 
Aβ(3-42) Affects Aggregation Kinetics of Aβ(1-42) by Accelerating Primary and 
Secondary Pathways.” Chemical Science 8 (7):4996–5004. 
https://doi.org/10.1039/c6sc04797a. 
Daub, Aaron, Punita Sharma, and Steven Finkbeiner. 2009. “High-Content Screening of 
Primary Neurons: Ready for Prime Time.” Curr Opin Neurobiol. 29 (6):997–1003. 
https://doi.org/10.1016/j.biotechadv.2011.08.021.Secreted. 
Daudin, Rachel, Damien Marechal, Qian Wang, Yoshihumi Abe, Nicolas Bourg, Maxime 
Sartori, Yann Loe-Mie, et al. 2018. “BIN1 Genetic Risk Factor for Alzheimer Is Sufficient 
to Induce Early Structural Tract Alterations in Entorhinal Cortex-Dentate Gyrus Pathway 
and Related Hippocampal Multi-Scale Impairments.” bioRxiv, January, 1–40. 
https://doi.org/10.1101/437228. 
Decker, Jochen Martin, Lars Krüger, Astrid Sydow, Shanting Zhao, Michael Frotscher, 
Eckhard Mandelkow, and Eva Maria Mandelkow. 2015. “Pro-Aggregant Tau Impairs 
Mossy Fiber Plasticity due to Structural Changes and Ca(++) Dysregulation.” Acta 
Neuropathologica Communications 3:23. https://doi.org/10.1186/s40478-015-0193-3. 
Deijk, Anne-Lieke F. van, Laus M. Broersen, J. Martin Verkuyl, August B. Smit, and Mark H. G. 
Verheijen. 2017. “High Content Analysis of Hippocampal Neuron-Astrocyte Co-Cultures 
Shows a Positive Effect of Fortasyn Connect on Neuronal Survival and Postsynaptic 
Maturation.” Frontiers in Neuroscience 11 (AUG):1–14. 
https://doi.org/10.3389/fnins.2017.00440. 
Deshpande, Atul, Erene Mina, Charles Glabe, and Jorge Busciglio. 2006. “Different 
Conformations of Amyloid Beta Induce Neurotoxicity by Distinct Mechanisms in Human 
Cortical Neurons.” Journal of Neuroscience 26 (22):6011–18. 
https://doi.org/10.1523/JNEUROSCI.1189-06.2006. 
Despres, Clément, Cillian Byrne, Haoling Qi, François-Xavier Cantrelle, Isabelle Huvent, 
Béatrice Chambraud, Etienne-Emile Baulieu, et al. 2017. “Identification of the Tau 
Phosphorylation Pattern That Drives Its Aggregation.” Proceedings of the National 
Academy of Sciences 114 (34):201708448. https://doi.org/10.1073/pnas.1708448114. 
Dourlen, P., F. J. Fernandez-Gomez, C. Dupont, B. Grenier-Boley, C. Bellenguez, H. Obriot, R. 
Caillierez, et al. 2017. “Functional Screening of Alzheimer Risk Loci Identifies PTK2B as 
an in Vivo Modulator and Early Marker of Tau Pathology.” Molecular Psychiatry 22 (6). 
Nature Publishing Group:874–83. https://doi.org/10.1038/mp.2016.59. 
 Bibliography 
162 
 
Dourlen, Pierre, Julien Chapuis, and Jean-Charles Lambert. 2018. “Using High-Throughput 
Animal or Cell-Based Models to Functionally Characterize GWAS Signals.” Current 
Genetic Medicine Reports. Current Genetic Medicine Reports, 107–15. 
https://doi.org/doi/10.1007/s40142-018-0141-1. 
Dräger, Nina M, Eliana Nachman, Moritz Winterhoff, Stefan Brühmann, Pranav Shah, 
Taxiarchis Katsinelos, Steeve Boulant, Aurelio A Teleman, Jan Faix, and Thomas R Jahn. 
2017. “Bin1 Directly Remodels Actin Dynamics through Its BAR Domain.” EMBO 
Reports, September, e201744137. https://doi.org/10.15252/embr.201744137. 
Dunys, Julie, Audrey Valverde, and Frédéric Checler. 2018. “Are N- and C-Terminally 
Truncated Aβ Species Key Pathological Triggers in Alzheimer’s Disease?” Journal of 
Biological Chemistry 293:jbc.R118.003999. https://doi.org/10.1074/jbc.R118.003999. 
Eckermann, Katrin, Maria Magdalena Mocanu, Inna Khlistunova, Jacek Biernat, Astrid 
Nissen, Anne Hofmann, Kai Schönig, et al. 2007. “The Β-Propensity of Tau Determines 
Aggregation and Synaptic Loss in Inducible Mouse Models of Tauopathy.” Journal of 
Biological Chemistry 282 (43):31755–65. https://doi.org/10.1074/jbc.M705282200. 
Elie, Auréliane, Elea Prezel, Christophe Guérin, Eric Denarier, Sacnicte Ramirez-Rios, 
Laurence Serre, Annie Andrieux, et al. 2015. “Tau Co-Organizes Dynamic Microtubule 
and Actin Networks.” Scientific Reports 5 (1):9964. https://doi.org/10.1038/srep09964. 
Evans, Nicholas A., Laura Facci, Davina E. Owen, Peter E. Soden, Stephen A. Burbidge, Rab K. 
Prinjha, Jill C. Richardson, and Stephen D. Skaper. 2008. “AB1-42 Reduces Synapse 
Number and Inhibits Neurite Outgrowth in Primary Cortical and Hippocampal Neurons: 
A Quantitative Analysis.” Journal of Neuroscience Methods 175 (1):96–103. 
https://doi.org/10.1016/j.jneumeth.2008.08.001. 
Farrer, Lindsay A., L. Adrienne Cupples, Jonathan L. Haines, Bradley Hyman, Walter A. Kukull, 
Richard Mayeux, Richard H. Myers, Margaret A. Pericak-Vance, Neil Risch, and Cornelia 
M. van Duijn. 1997. “Effects of Age, Sex, and Ethnicity on the Association Between 
Apolipoprotein E Genotype and Alzheimer Disease.” JAMA 278 (16):1349. 
https://doi.org/10.1001/jama.1997.03550160069041. 
Felice, Fernanda G. De, and Douglas P. Munoz. 2016. “Opportunities and Challenges in 
Developing Relevant Animal Models for Alzheimer’s Disease.” Ageing Research Reviews 
26. Elsevier B.V.:112–14. https://doi.org/10.1016/j.arr.2016.01.006. 
Fernandez, Marty A., Kelly M. Biette, Georgia Dolios, Divya Seth, Rong Wang, and Michael S. 
Wolfe. 2016. “Transmembrane Substrate Determinants for Γ-Secretase Processing of 
APP CTFβ.” Biochemistry 55 (40):5675–88. 
https://doi.org/10.1021/acs.biochem.6b00718. 
Ferreira, I. L., L. M. Bajouco, S. I. Mota, Y. P. Auberson, C. R. Oliveira, and A. C. Rego. 2012. 
“Amyloid Beta Peptide 1-42 Disturbs Intracellular Calcium Homeostasis through 
Activation of GluN2B-Containing N-Methyl-D-Aspartate Receptors in Cortical Cultures.” 
Cell Calcium 51 (2). Elsevier Ltd:95–106. https://doi.org/10.1016/j.ceca.2011.11.008. 
 Bibliography 
163 
 
Ferrer, Isidro. 2018. “Oligodendrogliopathy in Neurodegenerative Diseases with Abnormal 
Protein Aggregates: The Forgotten Partner.” Progress in Neurobiology 169 (March). 
Elsevier:24–54. https://doi.org/10.1016/j.pneurobio.2018.07.004. 
Frandemiche, M L, S De Seranno, T Rush, E Borel, a Elie, I Arnal, F Lante, and a Buisson. 
2014. “Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted 
by Exposure to Amyloid-Beta Oligomers.” J Neurosci 34 (17):6084–97. 
https://doi.org/10.1523/JNEUROSCI.4261-13.2014. 
Freitas, a. de, S. Banerjee, N. Xie, H. Cui, K. I. Davis, a. Friggeri, M. Fu, E. Abraham, and G. Liu. 
2012. “Identification of TLT2 as an Engulfment Receptor for Apoptotic Cells.” The 
Journal of Immunology 188 (12):6381–88. https://doi.org/10.4049/jimmunol.1200020. 
Fugier, Charlotte, Arnaud F Klein, Caroline Hammer, Stéphane Vassilopoulos, Ylva Ivarsson, 
Anne Toussaint, Valérie Tosch, et al. 2011. “Misregulated Alternative Splicing of BIN1 Is 
Associated with T Tubule Alterations and Muscle Weakness in Myotonic Dystrophy.” 
Nature Medicine 17 (6):720–25. https://doi.org/10.1038/nm.2374. 
Fulga, Tudor a., Ilan Elson-Schwab, Vikram Khurana, Michelle L. Steinhilb, Tara L. Spires, 
Bradley T. Hyman, and Mel B. Feany. 2007. “Abnormal Bundling and Accumulation of F-
Actin Mediates Tau-Induced Neuronal Degeneration in Vivo.” Nature Cell Biology 9 
(2):139–48. https://doi.org/10.1038/ncb1528. 
García-Campos, Miguel A., Jesús Espinal-Enríquez, and Enrique Hernández-Lemus. 2015. 
“Pathway Analysis: State of the Art.” Frontiers in Physiology 6 (DEC):1–16. 
https://doi.org/10.3389/fphys.2015.00383. 
Gatz, Margaret, Chandra A. Reynolds, Laura Fratiglioni, Boo Johansson, James A. Mortimer, 
Stig Berg, Amy Fiske, and Nancy L. Pedersen. 2006. “Role of Genes and Environments 
for Explaining Alzheimer Disease.” Archives of General Psychiatry 63 (2):168. 
https://doi.org/10.1001/archpsyc.63.2.168. 
Ge, K., J. DuHadaway, W. Du, M. Herlyn, U. Rodeck, and G. C. Prendergast. 1999. 
“Mechanism for Elimination of a Tumor Suppressor: Aberrant Splicing of a Brain-
Specific Exon Causes Loss of Function of Bin1 in Melanoma.” Proceedings of the 
National Academy of Sciences 96 (17):9689–94. 
https://doi.org/10.1073/pnas.96.17.9689. 
Genin, E, D Hannequin, D Wallon, K Sleegers, M Hiltunen, O Combarros, M J Bullido, et al. 
2011. “APOE and Alzheimer Disease: A Major Gene with Semi-Dominant Inheritance.” 
Molecular Psychiatry 16 (9). NIH Public Access:903–7. 
https://doi.org/10.1038/mp.2011.52. 
Gentier, Romina J., and Fred W. van Leeuwen. 2015. “Misframed Ubiquitin and Impaired 
Protein Quality Control: An Early Event in Alzheimer’s Disease.” Frontiers in Molecular 
Neuroscience 8 (September):1–12. https://doi.org/10.1177/875512250802400304. 
 Bibliography 
164 
 
Glennon, Elizabeth B C, Isobel J Whitehouse, J Scott Miners, Patrick G Kehoe, Seth Love, 
Katherine A B Kellett, and Nigel M Hooper. 2013. “BIN1 Is Decreased in Sporadic but 
Not Familial Alzheimer’s Disease or in Aging.” PloS One 8 (10). Public Library of 
Science:e78806. https://doi.org/10.1371/journal.pone.0078806. 
Götz, J., F. Chen, J. Van Dorpe, and R. M. Nitsch. 2001. “Formation of Neurofibrillary Tangles 
in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils.” Science 293 (5534):1491–95. 
https://doi.org/10.1126/science.1062097. 
Götz, Jürgen, and Naeman N Götz. 2009. “Animal Models for Alzheimer’s Disease and 
Frontotemporal Dementia: A Perspective.” ASN Neuro 1 (4):AN20090042. 
https://doi.org/10.1042/AN20090042. 
Götz, Jürgen, and Lars M Ittner. 2008. “Animal Models of Alzheimer’s Disease and 
Frontotemporal Dementia.” Nature Reviews. Neuroscience 9 (7):532–44. 
https://doi.org/10.1038/nrn2420. 
Griciuc, Ana, Alberto Serrano-Pozo, Antonio R. Parrado, Andrea N. Lesinski, Caroline N. 
Asselin, Kristina Mullin, Basavaraj Hooli, Se Hoon Choi, Bradley T. Hyman, and Rudolph 
E. Tanzi. 2013. “Alzheimer’s Disease Risk Gene cd33 Inhibits Microglial Uptake of 
Amyloid Beta.” Neuron 78 (4). Elsevier Inc.:631–43. 
https://doi.org/10.1016/j.neuron.2013.04.014. 
Grundke-Iqbal, I, K Iqbal, Y. C. Tung, M Quinlan, H. M. Wisniewski, and L. I. Binder. 1986. 
“Abnormal Phosphorylation of the Microtubule-Associated Protein Tau (tau) in 
Alzheimer Cytoskeletal Pathology.” Proceedings of the National Academy of Sciences 83 
(13):4913–17. https://doi.org/10.1073/pnas.83.13.4913. 
Guennec, Kilan Le, Gaël Nicolas, Olivier Quenez, Camille Charbonnier, David Wallon, Céline 
Bellenguez, Benjamin Grenier-Boley, et al. 2016. “ABCA7 Rare Variants and Alzheimer 
Disease Risk.” Neurology 86 (23):2134–37. 
https://doi.org/10.1212/WNL.0000000000002627. 
Guerreiro, Rita, Aleksandra Wojtas, Jose Bras, Minerva Carrasquillo, Ekaterina Rogaeva, Elisa 
Majounie, Carlos Cruchaga, et al. 2013. “TREM2 Variants in Alzheimer’s Disease.” New 
England Journal of Medicine 368 (2):117–27. https://doi.org/10.1056/NEJMoa1211851. 
Gulisano, Walter, Daniele Maugeri, Marian a. Baltrons, Mauro Fà, Arianna Amato, Agostino 
Palmeri, Luciano D’Adamio, et al. 2018. “Role of Amyloid-Β and Tau Proteins in 
Alzheimer’s Disease: Confuting the Amyloid Cascade.” Journal of Alzheimer’s Disease 64 
(s1):S611–31. https://doi.org/10.3233/JAD-179935. 
Gunn, Adam P., Bruce X. Wong, Timothy Johanssen, James C. Griffith, Colin L. Masters, 
Ashley I. Bush, Kevin J. Barnham, James A. Duce, and Robert A. Cherny. 2016. “Amyloid-
Β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and 
Calcium Influx in Neurons.” Journal of Biological Chemistry 291 (12):6134–45. 
https://doi.org/10.1074/jbc.M115.655183. 
 Bibliography 
165 
 
Guo, Tong, Wendy Noble, and Diane P. Hanger. 2017. “Roles of Tau Protein in Health and 
Disease.” Acta Neuropathologica 133 (5):665–704. https://doi.org/10.1007/s00401-
017-1707-9. 
Gustafsdottir, Sigrun M., Edith Schallmeiner, Simon Fredriksson, Mats Gullberg, Ola 
Söderberg, Malin Jarvius, Jonas Jarvius, Mathias Howell, and Ulf Landegren. 2005. 
“Proximity Ligation Assays for Sensitive and Specific Protein Analyses.” Analytical 
Biochemistry 345 (1):2–9. https://doi.org/10.1016/j.ab.2005.01.018. 
Hardy, J., and G. Higgins. 1992. “Alzheimer’s Disease: The Amyloid Cascade Hypothesis.” 
Science 256 (5054):184–85. https://doi.org/10.1126/science.1566067. 
Hardy, John, and Dennis J Selkoe. 2002. “The Amyloid Hypothesis of Alzheimer’s Disease: 
Progress and Problems on the Road to Therapeutics.” Science (New York, N.Y.) 297 
(5580):353–56. https://doi.org/10.1126/science.1072994. 
Harrington, Adam J., Aram Raissi, Kacey Rajkovich, Stefano Berto, Jaswinder Kumar, Gemma 
Molinaro, Jonathan Raduazzo, et al. 2016. “MEF2C Regulates Cortical Inhibitory and 
Excitatory Synapses and Behaviors Relevant to Neurodevelopmental Disorders.” eLife 5 
(OCTOBER2016):1–27. https://doi.org/10.7554/eLife.20059. 
Hattori, H., K. K. Subramanian, J. Sakai, Y. Jia, Y. Li, T. F. Porter, F. Loison, et al. 2010. “Small-
Molecule Screen Identifies Reactive Oxygen Species as Key Regulators of Neutrophil 
Chemotaxis.” Proceedings of the National Academy of Sciences 107 (8):3546–51. 
https://doi.org/10.1073/pnas.0914351107. 
Herrup, Karl. 2015. “The Case for Rejecting the Amyloid Cascade Hypothesis.” Nature 
Neuroscience 18 (6):794–99. https://doi.org/10.1038/nn.4017. 
Hick, Meike, Ulrike Herrmann, Sascha W. Weyer, Jan Philipp Mallm, Jakob Andreas Tschäpe, 
Marianne Borgers, Marc Mercken, et al. 2015. “Acute Function of Secreted Amyloid 
Precursor Protein Fragment APPsα in Synaptic Plasticity.” Acta Neuropathologica 129 
(1):21–37. https://doi.org/10.1007/s00401-014-1368-x. 
Himmler, a, D Drechsel, M W Kirschner, and D W Martin. 1989. “Tau Consists of a Set of 
Proteins with Repeated C-Terminal Microtubule-Binding Domains and Variable N-
Terminal Domains.” Molecular and Cellular Biology 9 (4):1381–88. 
https://doi.org/10.1128/MCB.9.4.1381.Updated. 
Holler, Christopher J., Paulina R. Davis, Tina L. Beckett, Thomas L. Platt, Robin L. Webb, 
Elizabeth Head, and M. Paul Murphy. 2014. “Bridging Integrator 1 (BIN1) Protein 
Expression Increases in the Alzheimer’s Disease Brain and Correlates with 
Neurofibrillary Tangle Pathology.” Journal of Alzheimer’s Disease : JAD 42 (4):1221–27. 
https://doi.org/10.3233/JAD-132450. 
Hong, S., V. F. Beja-Glasser, B. M. Nfonoyim, A. Frouin, S. Li, S. Ramakrishnan, K. M. Merry, 
et al. 2016. “Complement and Microglia Mediate Early Synapse Loss in Alzheimer 
Mouse Models.” Science 352 (6286):712–16. https://doi.org/10.1126/science.aad8373. 
 Bibliography 
166 
 
Hong, Tingting, Huanghe Yang, Shan Shan Zhang, Hee Cheol Cho, Mariya Kalashnikova, 
Baiming Sun, Hao Zhang, et al. 2014. “Cardiac BIN1 Folds T-Tubule Membrane, 
Controlling Ion Flux and Limiting Arrhythmia.” Nature Medicine 20 (6):624–32. 
https://doi.org/10.1038/nm.3543. 
Hsin, H., M. J. Kim, C.-F. Wang, and M. Sheng. 2010. “Proline-Rich Tyrosine Kinase 2 
Regulates Hippocampal Long-Term Depression.” Journal of Neuroscience 30 
(36):11983–93. https://doi.org/10.1523/JNEUROSCI.1029-10.2010. 
Hu, Yan Shi, Juncai Xin, Ying Hu, Lei Zhang, and Ju Wang. 2017. “Analyzing the Genes Related 
to Alzheimer’s Disease via a Network and Pathway-Based Approach.” Alzheimer’s 
Research and Therapy 9 (1). Alzheimer’s Research & Therapy:1–15. 
https://doi.org/10.1186/s13195-017-0252-z. 
Hurtado, David E., Laura Molina-Porcel, Michiyo Iba, Awo K. Aboagye, Steven M. Paul, John 
Q. Trojanowski, and Virginia M.Y. Lee. 2010. “Aβ Accelerates the Spatiotemporal 
Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse 
Model.” American Journal of Pathology 177 (4). American Society for Investigative 
Pathology:1977–88. https://doi.org/10.2353/ajpath.2010.100346. 
Hutton, M., C. L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. H. Houlden, S. Pickering-Brown, 
et al. 1998. “Association of Missense and 5’-Splice-Site Mutations in Tau with the 
Inherited Dementia FTDP-17.” Nature 393 (6686):702–4. 
https://doi.org/10.1038/31508. 
Iaccarino, Leonardo, Gautam Tammewar, Nagehan Ayakta, Suzanne L. Baker, Alexandre 
Bejanin, Adam L. Boxer, Maria Luisa Gorno-Tempini, et al. 2018. “Local and Distant 
Relationships between Amyloid, Tau and Neurodegeneration in Alzheimer’s Disease.” 
NeuroImage: Clinical 17 (February 2017). Elsevier:452–64. 
https://doi.org/10.1016/j.nicl.2017.09.016. 
Iqbal, Khalid, Fei Liu, and Cheng-Xin Gong. 2016. “Tau and Neurodegenerative Disease: The 
Story so Far.” Nature Reviews Neurology 12 (1):15–27. 
https://doi.org/10.1038/nrneurol.2015.225. 
Itoh, Toshiki, and Pietro De Camilli. 2006. “BAR, F-BAR (EFC) and ENTH/ANTH Domains in the 
Regulation of Membrane-Cytosol Interfaces and Membrane Curvature.” Biochimica et 
Biophysica Acta - Molecular and Cell Biology of Lipids 1761 (8):897–912. 
https://doi.org/10.1016/j.bbalip.2006.06.015. 
Ittner, Lars M., Yazi D. Ke, Fabien Delerue, Mian Bi, Amadeus Gladbach, Janet van Eersel, 
Heidrun Wölfing, et al. 2010. “Dendritic Function of Tau Mediates Amyloid-Β Toxicity in 
Alzheimer’s Disease Mouse Models.” Cell 142 (3):387–97. 
https://doi.org/10.1016/j.cell.2010.06.036. 
Jack, Clifford R., David S. Knopman, William J. Jagust, Ronald C. Petersen, Michael W. 
Weiner, Paul S. Aisen, Leslie M. Shaw, et al. 2013. “Tracking Pathophysiological 
Processes in Alzheimer’s Disease: An Updated Hypothetical Model of Dynamic 
 Bibliography 
167 
 
Biomarkers.” The Lancet Neurology 12 (2):207–16. https://doi.org/10.1016/S1474-
4422(12)70291-0. 
Jain, Shushant, and Peter Heutink. 2010. “From Single Genes to Gene Networks: High-
Throughput-High-Content Screening for Neurological Disease.” Neuron 68 (2). Elsevier 
Inc.:207–17. https://doi.org/10.1016/j.neuron.2010.10.010. 
Jarvius, Malin, Janna Paulsson, Irene Weibrecht, Karl-Johan Leuchowius, Ann-Catrin 
Andersson, Carolina Wählby, Mats Gullberg, et al. 2007. “In Situ Detection of 
Phosphorylated Platelet-Derived Growth Factor Receptor Β Using a Generalized 
Proximity Ligation Method.” Molecular & Cellular Proteomics 6 (9):1500–1509. 
https://doi.org/10.1074/mcp.M700166-MCP200. 
Jay, Taylor R., Anna M. Hirsch, Margaret L. Broihier, Crystal M. Miller, Lee E. Neilson, Richard 
M. Ransohoff, Bruce T. Lamb, and Gary E. Landreth. 2017. “Disease Progression-
Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer’s Disease.” The 
Journal of Neuroscience 37 (3):637–47. https://doi.org/10.1523/JNEUROSCI.2110-
16.2017. 
Jonsson, Thorlakur, Jasvinder K. Atwal, Stacy Steinberg, Jon Snaedal, Palmi V. Jonsson, 
Sigurbjorn Bjornsson, Hreinn Stefansson, et al. 2012. “A Mutation in APP Protects 
against Alzheimer‘s Disease and Age-Related Cognitive Decline.” Nature 488 (7409):96. 
https://doi.org/10.1038/nature11283. 
Jonsson, Thorlakur, Hreinn Stefansson, Stacy Steinberg, Ingileif Jonsdottir, Palmi V. Jonsson, 
Jon Snaedal, Sigurbjorn Bjornsson, et al. 2013. “Variant of TREM2 Associated with the 
Risk of Alzheimer’s Disease.” New England Journal of Medicine 368 (2):107–16. 
https://doi.org/10.1056/NEJMoa1211103. 
Jun, G., C. a. Ibrahim-Verbaas, M. Vronskaya, J. C. Lambert, J. Chung, a. C. Naj, B. W. Kunkle, 
et al. 2016. “A Novel Alzheimer Disease Locus Located near the Gene Encoding Tau 
Protein.” Molecular Psychiatry 21 (1):108–17. https://doi.org/10.1038/mp.2015.23. 
Kanatsu, Kunihiko, Yuichi Morohashi, Mai Suzuki, Hiromasa Kuroda, Toshio Watanabe, 
Taisuke Tomita, and Takeshi Iwatsubo. 2014. “Decreased CALM Expression Reduces 
Aβ42 to Total Aβ Ratio through Clathrin-Mediated Endocytosis of Γ-Secretase.” Nature 
Communications 5. https://doi.org/10.1038/ncomms4386. 
Kanatsu, Kunihiko, and Taisuke Tomita. 2017. “Molecular Mechanisms of the Genetic Risk 
Factors in Pathogenesis of Alzheimer Disease.” Frontiers in Bioscience 22 (1):4480. 
https://doi.org/10.2741/4480. 
Kant, Rik van der, and Lawrence S.B. Goldstein. 2015. “Cellular Functions of the Amyloid 
Precursor Protein from Development to Dementia.” Developmental Cell 32 (4). Elsevier 
Inc.:502–15. https://doi.org/10.1016/j.devcel.2015.01.022. 
Karch, Celeste M., Amanda T. Jeng, Petra Nowotny, Janet Cady, Carlos Cruchaga, and Alison 
M. Goate. 2012. “Expression of Novel Alzheimer’s Disease Risk Genes in Control and 
 Bibliography 
168 
 
Alzheimer's Disease Brains.” PLoS ONE 7 (11). 
https://doi.org/10.1371/journal.pone.0050976. 
Kim, Minji, Jaehong Suh, Donna Romano, Mimy H. Truong, Kristina Mullin, Basavaraj Hooli, 
David Norton, et al. 2009. “Potential Late-Onset Alzheimer’s Disease-Associated 
Mutations in the ADAM10 Gene Attenuate Α-Secretase Activity.” Human Molecular 
Genetics 18 (20):3987–96. https://doi.org/10.1093/hmg/ddp323. 
Kitago, Yu, Masamichi Nagae, Zenzaburo Nakata, Maho Yagi-Utsumi, Shizuka Takagi-
Niidome, Emiko Mihara, Terukazu Nogi, Koichi Kato, and Junichi Takagi. 2015. 
“Structural Basis for Amyloidogenic Peptide Recognition by sorLA.” Nature Structural 
and Molecular Biology 22 (3):199–206. https://doi.org/10.1038/nsmb.2954. 
Knouff, Christopher, Myron E. Hinsdale, Hafid Mezdour, Michael K. Altenburg, Masahiko 
Watanabe, Steven H. Quarfordt, Patrick M. Sullivan, and Nobuyo Maeda. 1999. “Apo E 
Structure Determines VLDL Clearance and Atherosclerosis Risk in Mice.” Journal of 
Clinical Investigation 103 (11):1579–86. https://doi.org/10.1172/JCI6172. 
Krämer-Albers, Eva Maria, and Robin White. 2011. “From Axon-Glial Signalling to 
Myelination: The Integrating Role of Oligodendroglial Fyn Kinase.” Cellular and 
Molecular Life Sciences 68 (12):2003–12. https://doi.org/10.1007/s00018-010-0616-z. 
Krasemann, Susanne, Charlotte Madore, Ron Cialic, Caroline Baufeld, Narghes Calcagno, 
Rachid El Fatimy, Lien Beckers, et al. 2017. “The TREM2-APOE Pathway Drives the 
Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.” 
Immunity 47 (3). Elsevier Inc.:566–81.e9. 
https://doi.org/10.1016/j.immuni.2017.08.008. 
Kuperstein, Inna, Kerensa Broersen, Iryna Benilova, Jef Rozenski, Wim Jonckheere, Maja 
Debulpaep, Annelies Vandersteen, et al. 2010. “Neurotoxicity of Alzheimer’s Disease 
Aβ Peptides Is Induced by Small Changes in the Aβ42 to Aβ40 Ratio.” The EMBO Journal 
29 (19):3408–20. https://doi.org/10.1038/emboj.2010.211. 
LaFerla, F. M., and K. N. Green. 2012. “Animal Models of Alzheimer Disease.” Cold Spring 
Harbor Perspectives in Medicine 2 (11):a006320–a006320. 
https://doi.org/10.1101/cshperspect.a006320. 
Lambert, Jean Charles, and Philippe Amouyel. 2011. “Genetics of Alzheimer’s Disease: New 
Evidences for an Old Hypothesis?” Current Opinion in Genetics and Development 21 (3). 
Elsevier Ltd:295–301. https://doi.org/10.1016/j.gde.2011.02.002. 
Lambert, Jean-Charles, Simon Heath, Gael Even, Dominique Campion, Kristel Sleegers, 
Mikko Hiltunen, Onofre Combarros, et al. 2009. “Genome-Wide Association Study 
Identifies Variants at CLU and CR1 Associated with Alzheimer’s Disease.” Nature 
Genetics 41 (10). Nature Publishing Group:1094–99. https://doi.org/10.1038/ng.439. 
Lambert, Jean-Charles, C A Ibrahim-Verbaas, D Harold, A C Naj, R Sims, C Bellenguez, A L 
DeStafano, et al. 2013. “Meta-Analysis of 74,046 Individuals Identifies 11 New 
 Bibliography 
169 
 
Susceptibility Loci for Alzheimer’s Disease.” Nature Genetics 45 (12):1452–58. 
https://doi.org/10.1038/ng.2802. 
Landrieu, Isabelle, Caroline Smet-Nocca, Laziza Amniai, Justin Vijay Louis, Jean Michel 
Wieruszeski, Jozef Goris, Veerle Janssens, and Guy Lippens. 2011. “Molecular 
Implication of PP2A and Pin1 in the Alzheimer’s Disease Specific Hyperphosphorylation 
of Tau.” PLoS ONE 6 (6). https://doi.org/10.1371/journal.pone.0021521. 
Lee, Eunkyung, Melissa Marcucci, Laurie Daniell, Marc Pypaert, Ora a. Weisz, Gian Carlo 
Ochoa, Khashayar Farsad, Markus R. Wenk, and Pietro De Camilli. 2002. “Amphiphysin 
2 (Bin1) and T-Tubule Biogenesis in Muscle.” Science 297 (5584):1193–96. 
https://doi.org/10.1126/science.1071362. 
Lee, Gloria, and Chad J. Leugers. 2012. “Tau and Tauopathies.” Progress in Molecular Biology 
and Translational Science 107 (January). NIH Public Access:263–93. 
https://doi.org/10.1016/B978-0-12-385883-2.00004-7. 
Leprince, Corinne, Francisco Romero, Didier Cussac, Beatrice Vayssiere, Roland Berger, 
Armand Tavitian, and Jacques H. Camonis. 1997. “A New Member of the Amphiphysin 
Family Connecting Endocytosis and Signal Transduction Pathways.” Journal of Biological 
Chemistry 272 (24). American Society for Biochemistry and Molecular Biology:15101–5. 
https://doi.org/10.1074/jbc.272.24.15101. 
Leuchowius, Karl Johan, Irene Weibrecht, and Ola Söderberg. 2011. “In Situ Proximity 
Ligation Assay for Microscopy and Flow Cytometry.” Current Protocols in Cytometry, 
no. SUPPL. 56:1–15. https://doi.org/10.1002/0471142956.cy0936s56. 
Leuchowius, Karl-Johan, Malin Jarvius, Malin Wickström, Linda Rickardson, Ulf Landegren, 
Rolf Larsson, Ola Söderberg, Mårten Fryknäs, and Jonas Jarvius. 2010. “High Content 
Screening for Inhibitors of Protein Interactions and Post-Translational Modifications in 
Primary Cells by Proximity Ligation.” Molecular & Cellular Proteomics : MCP 9 (1):178–
83. https://doi.org/10.1074/mcp.M900331-MCP200. 
Li, Tong, Cheryl Hawkes, Hamid Y. Qureshi, Satyabrata Kar, and Hemant K. Paudel. 2006. 
“Cyclin-Dependent Protein Kinase 5 Primes Microtubule-Associated Protein Tau Site-
Specifically for Glycogen Synthase Kinase 3β.” Biochemistry 45 (10):3134–45. 
https://doi.org/10.1021/bi051635j. 
Liang, Shuang, Fan Yan Wei, Yu Mei Wu, Kenji Tanabe, Tadashi Abe, Yoshiya Oda, Yumi 
Yoshida, et al. 2007. “Major Cdk5-Dependent Phosphorylation Sites of Amphiphysin 1 
Are Implicated in the Regulation of the Membrane Binding and Endocytosis.” Journal of 
Neurochemistry 102 (5):1466–76. https://doi.org/10.1111/j.1471-4159.2007.04507.x. 
Logue, Mark W., Matthew Schu, Badri N. Vardarajan, John Farrell, David a. Bennett, Joseph 
D. Buxbaum, Goldie S. Byrd, et al. 2014. “Two Rare AKAP9 Variants Are Associated with 
Alzheimer’s Disease in African Americans.” Alzheimer’s and Dementia 10 (6). 
Elsevier:609–18. https://doi.org/10.1016/j.jalz.2014.06.010. 
 Bibliography 
170 
 
Mairet-Coello, Georges, Julien Courchet, Simon Pieraut, Virginie Courchet, Anton Maximov, 
and Franck Polleux. 2013. “The CAMKK2-AMPK Kinase Pathway Mediates the 
Synaptotoxic Effects of Aβ Oligomers through Tau Phosphorylation.” Neuron 78 (1). 
Elsevier Inc.:94–108. https://doi.org/10.1016/j.neuron.2013.02.003. 
Malik, M., J. F. Simpson, I. Parikh, B. R. Wilfred, D. W. Fardo, P. T. Nelson, and S. Estus. 2013. 
“CD33 Alzheimer’s Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing.” 
Journal of Neuroscience 33 (33):13320–25. https://doi.org/10.1523/JNEUROSCI.1224-
13.2013. 
Malki, Idir, François-Xavier Xavier Cantrelle, Yoann Sottejeau, Guy Lippens, Jean-Charles 
Charles Lambert, and Isabelle Landrieu. 2017. “Regulation of the Interaction between 
the Neuronal BIN1 Isoform 1 and Tau Proteins - Role of the SH3 Domain.” The FEBS 
Journal 284 (19):3218–29. https://doi.org/10.1111/febs.14185. 
Marks, Bruno, and Harvey T. McMahon. 1998. “Calcium Triggers Calcineurin-Dependent 
Synaptic Vesicle Recycling in Mammalian Nerve Terminals.” Current Biology 8 (13):740–
49. https://doi.org/10.1016/S0960-9822(98)70297-0. 
Mattiazzi Usaj, Mojca, Erin B. Styles, Adrian J. Verster, Helena Friesen, Charles Boone, and 
Brenda J. Andrews. 2016. “High-Content Screening for Quantitative Cell Biology.” 
Trends in Cell Biology 26 (8). Elsevier Ltd:598–611. 
https://doi.org/10.1016/j.tcb.2016.03.008. 
McDonough, Patrick M., Natalie L. Prigozhina, Ranor C.B. Basa, and Jeffrey H. Price. 2017. 
“Assay of Calcium Transients and Synapses in Rat Hippocampal Neurons by Kinetic 
Image Cytometry and High-Content Analysis: An In Vitro Model System for 
Postchemotherapy Cognitive Impairment.” ASSAY and Drug Development Technologies 
15 (5):220–36. https://doi.org/10.1089/adt.2017.797. 
McKenzie, Andrew T., Sarah Moyon, Minghui Wang, Igor Katsyv, Won Min Song, Xianxiao 
Zhou, Eric B. Dammer, et al. 2017. “Multiscale Network Modeling of Oligodendrocytes 
Reveals Molecular Components of Myelin Dysregulation in Alzheimer’s Disease.” 
Molecular Neurodegeneration 12 (1). Molecular Neurodegeneration:1–20. 
https://doi.org/10.1186/s13024-017-0219-3. 
Meunier, Brigitte, Muriel Quaranta, Laurent Daviet, Anastassia Hatzoglou, and Corinne 
Leprince. 2009. “The Membrane-Tubulating Potential of Amphiphysin 2/BIN1 Is 
Dependent on the Microtubule-Binding Cytoplasmic Linker Protein 170 (CLIP-170).” 
European Journal of Cell Biology 88 (2):91–102. 
https://doi.org/10.1016/j.ejcb.2008.08.006. 
Miyagawa, Toji, Ihori Ebinuma, Yuichi Morohashi, Yukiko Hori, Mee Young Chang, Haruhiko 
Hattori, Tomoaki Maehara, et al. 2016. “BIN1 Regulates BACE1 Intracellular Trafficking 
and Amyloid-Β Production.” Human Molecular Genetics 25 (14):ddw146. 
https://doi.org/10.1093/hmg/ddw146. 
 Bibliography 
171 
 
Morris, Meaghan, Sumihiro Maeda, Keith Vossel, and Lennart Mucke. 2011. “The Many 
Faces of Tau.” Neuron 70 (3). Elsevier Inc.:410–26. 
https://doi.org/10.1016/j.neuron.2011.04.009. 
Muller, Alexander J, Judith F Baker, James B Duhadaway, Kai Ge, George Farmer, P Scott 
Donover, Raymond Meade, et al. 2003. “Targeted Disruption of the Murine Bin1 / 
Amphiphysin II Gene Does Not Disable Endocytosis but Results in Embryonic 
Cardiomyopathy with Aberrant Myofibril Formation Targeted Disruption of the Murine 
Bin1 / Amphiphysin II Gene Does Not Disable Endocytosis B.” Molecular and Cellular 
Biology 23 (12):4295–4306. https://doi.org/10.1128/MCB.23.12.4295. 
Nhan, Hoang S., Karen Chiang, and Edward H. Koo. 2015. “The Multifaceted Nature of 
Amyloid Precursor Protein and Its Proteolytic Fragments: Friends and Foes.” Acta 
Neuropathologica 129 (1):1–19. https://doi.org/10.1007/s00401-014-1347-2. 
Nicolas, G., C. Charbonnier, D. Wallon, O. Quenez, C. Bellenguez, B. Grenier-Boley, S. 
Rousseau, et al. 2016. “SORL1 Rare Variants: A Major Risk Factor for Familial Early-
Onset Alzheimer’s Disease.” Molecular Psychiatry 21 (6):831–36. 
https://doi.org/10.1038/mp.2015.121. 
Nisbet, Rebecca M., Juan-Carlos Polanco, Lars M. Ittner, and Jürgen Götz. 2015. “Tau 
Aggregation and Its Interplay with Amyloid-Β.” Acta Neuropathologica 129 (2). 
Springer:207–20. https://doi.org/10.1007/s00401-014-1371-2. 
Noble, Wendy, Diane P. Hanger, Christopher C.J. Miller, and Simon Lovestone. 2013. “The 
Importance of Tau Phosphorylation for Neurodegenerative Diseases.” Frontiers in 
Neurology 4 JUL (July):1–11. https://doi.org/10.3389/fneur.2013.00083. 
Norris, Christopher M. 2018. “Calcineurin: Directing the Damage in Alzheimer Disease: An 
Editorial for ‘Neuronal Calcineurin Transcriptional Targets Parallel Changes Observed in 
Alzheimer Disease Brain’ on Doi: 10.1111/jnc.14469.” Journal of Neurochemistry, 1–4. 
https://doi.org/10.1111/jnc.14475. 
O’Brien, Richard J., and Philip C. Wong. 2011. “Amyloid Precursor Protein Processing and 
Alzheimer’s Disease.” Annual Review of Neuroscience 34 (1):185–204. 
https://doi.org/10.1146/annurev-neuro-061010-113613. 
O’Day, Danton H., Kristeen Eshak, and Michael a. Myre. 2015. “Calmodulin Binding Proteins 
and Alzheimer’s Disease.” Journal of Alzheimer’s Disease 46 (3):553–69. 
https://doi.org/10.3233/JAD-142772. 
Oddo, Salvatore, Antonella Caccamo, Jason D. Shepherd, M. Paul Murphy, Todd E. Golde, 
Rakez Kayed, Raju Metherate, Mark P. Mattson, Yama Akbari, and Frank M. LaFerla. 
2003. “Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles: 
Intracellular Aβ and Synaptic Dysfunction.” Neuron 39 (3):409–21. 
https://doi.org/10.1016/S0896-6273(03)00434-3. 
 Bibliography 
172 
 
Pagano, Katiuscia, Denise Galante, Cristina D’Arrigo, Alessandro Corsaro, Mario Nizzari, 
Tullio Florio, Henriette Molinari, Simona Tomaselli, and Laura Ragona. 2018. “Effects of 
Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and 
Toxicity.” Molecular Neurobiology, 1–15. https://doi.org/10.1007/s12035-018-1202-x. 
Pant, Saumya, Mahak Sharma, Kruti Patel, Steve Caplan, Chavela M. Carr, and Barth D. 
Grant. 2009. “AMPH-1/Amphiphysin/Bin1 Functions with RME-1/Ehd1 in Endocytic 
Recycling.” Nature Cell Biology 11 (12). Nature Publishing Group:1399–1410. 
https://doi.org/10.1038/ncb1986. 
Pei, Jin Jing, Heiko Braak, Wen Lin An, Bengt Winblad, Richard F. Cowburn, Khalid Iqbal, and 
Inge Grundke-Iqbal. 2002. “Up-Regulation of Mitogen-Activated Protein Kinases ERK1/2 
and MEK1/2 Is Associated with the Progression of Neurofibrillary Degeneration in 
Alzheimer’s Disease.” Molecular Brain Research 109 (1-2):45–55. 
https://doi.org/10.1016/S0169-328X(02)00488-6. 
Perl, Daniel P. 2010. “Neuropathology of Alzheimer’s Disease.” Mount Sinai Journal of 
Medicine: A Journal of Translational and Personalized Medicine 77 (1):32–42. 
https://doi.org/10.1002/msj.20157. 
Peter, Brian J., Helen M. Kent, Ian G. Mills, Yvonne Vallis, P. Jonathan G. Butler, Philip R. 
Evans, and Harvey T. McMahon. 2004. “BAR Domains as Sensors of Membrane 
Curvature: The Amphiphysin BAR Structure.” Science 303 (5657):495–99. 
https://doi.org/10.1126/science.1092586. 
Piaceri, Irene, Benedetta Nacmias, Sandro Sorbi, and Benedetta Naemias. 2013. “Genetics of 
Familial and Sporadic Alzheimer’s Disease.” Frontiers in Bioscience (Elite Edition) 5 
(5):167–77. https://doi.org/10.2741/E605. 
Pimenova, Anna a., Towfique Raj, and Alison M. Goate. 2018. “Untangling Genetic Risk for 
Alzheimer’s Disease.” Biological Psychiatry 83 (4):300–310. 
https://doi.org/10.1016/j.biopsych.2017.05.014. 
Pineda-Lucena, Antonio, Cynthia S W Ho, Daniel Y L Mao, Yi Sheng, Rob C Laister, Ranjith 
Muhandiram, Ying Lu, et al. 2005. “A Structure-Based Model of the c-Myc/Bin1 Protein 
Interaction Shows Alternative Splicing of Bin1 and c-Myc Phosphorylation Are Key 
Binding Determinants.” Journal of Molecular Biology 351 (1):182–94. 
https://doi.org/10.1016/j.jmb.2005.05.046. 
Pol, L. a. Van De, a. Hensel, F. Barkhof, H. J. Gertz, P. Scheltens, and W. M. Van Der Flier. 
2006. “Hippocampal Atrophy in Alzheimer Disease: Age Matters.” Neurology 66 
(2):236–38. https://doi.org/10.1212/01.wnl.0000194240.47892.4d. 
Polydoro, M., C. M. Acker, K. Duff, P. E. Castillo, and P. Davies. 2009. “Age-Dependent 
Impairment of Cognitive and Synaptic Function in the Htau Mouse Model of Tau 
Pathology.” Journal of Neuroscience 29 (34):10741–49. 
https://doi.org/10.1523/JNEUROSCI.1065-09.2009. 
 Bibliography 
173 
 
Prendergast, George C., Alexander J. Muller, Arivudanambi Ramalingam, and Mee Young 
Chang. 2009. “BAR the Door: Cancer Suppression by Amphiphysin-like Genes.” 
Biochimica et Biophysica Acta - Reviews on Cancer 1795 (1). Elsevier B.V.:25–36. 
https://doi.org/10.1016/j.bbcan.2008.09.001. 
Prokic, Ivana, Belinda S. Cowling, and Jocelyn Laporte. 2014. “Amphiphysin 2 (BIN1) in 
Physiology and Diseases.” Journal of Molecular Medicine 2 (March):1–11. 
https://doi.org/10.1007/s00109-014-1138-1. 
Pyndiah, Slovénie, Satoshi Tanida, Kazi M Ahmed, Erica K Cassimere, C. Choe, and D. 
Sakamuro. 2011. “C-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: 
A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance.” Science Signaling 4 
(166):ra19–ra19. https://doi.org/10.1126/scisignal.2001556. 
Qi, Haoling, Sudhakaran Prabakaran, François-Xavier Cantrelle, Béatrice Chambraud, Jeremy 
Gunawardena, Guy Lippens, and Isabelle Landrieu. 2016. “Characterization of Neuronal 
Tau Protein as a Target of Extracellular-Signal-Regulated Kinase.” Journal of Biological 
Chemistry 291 (6):jbc.M115.700914. https://doi.org/10.1074/jbc.M115.700914. 
Raj, Towfique, Katie J. Ryan, Joseph M. Replogle, Lori B. Chibnik, Laura Rosenkrantz, Anna 
Tang, Katie Rothamel, et al. 2014. “CD33: Increased Inclusion of Exon 2 Implicates the 
Ig V-Set Domain in Alzheimer’s Disease Susceptibility.” Human Molecular Genetics 23 
(10):2729–36. https://doi.org/10.1093/hmg/ddt666. 
Rameau, Gerald a., Ling Yu Chiu, and Edward B. Ziff. 2003. “NMDA Receptor Regulation of 
nNOS Phosphorylation and Induction of Neuron Death.” Neurobiology of Aging 24 
(8):1123–33. https://doi.org/10.1016/j.neurobiolaging.2003.07.002. 
Ramjaun, A. R., K. D. Micheva, I. Bouchelet, and P. S. McPherson. 1997. “Identification and 
Characterization of a Nerve Terminal-Enriched Amphiphysin Isoform.” Journal of 
Biological Chemistry 272 (26). American Society for Biochemistry and Molecular 
Biology:16700–706. https://doi.org/10.1074/jbc.272.26.16700. 
Ramjaun, Antoine R., and Peter S. McPherson. 2002. “Multiple Amphiphysin II Splice 
Variants Display Differential Clathrin Binding: Identification of Two Distinct Clathrin-
Binding Sites.” Journal of Neurochemistry 70 (6):2369–76. 
https://doi.org/10.1046/j.1471-4159.1998.70062369.x. 
Rapoport, M., H. N. Dawson, L. I. Binder, M. P. Vitek, and A. Ferreira. 2002. “Tau Is Essential 
to Β-Amyloid-Induced Neurotoxicity.” Proceedings of the National Academy of Sciences 
99 (9):6364–69. https://doi.org/10.1073/pnas.092136199. 
Reinhard, Constanze, Sébastien S Hébert, and Bart De Strooper. 2005. “The Amyloid-Β 
Precursor Protein: Integrating Structure with Biological Function.” The EMBO Journal 24 
(23):3996–4006. https://doi.org/10.1038/sj.emboj.7600860. 
 Bibliography 
174 
 
Reitz, Christiane, and Richard Mayeux. 2014. “Alzheimer Disease: Epidemiology, Diagnostic 
Criteria, Risk Factors and Biomarkers.” Biochemical Pharmacology 88 (4). Elsevier 
Inc.:640–51. https://doi.org/10.1016/j.bcp.2013.12.024. 
Resende, R., E. Ferreiro, C. Pereira, and C. Resende de Oliveira. 2008. “Neurotoxic Effect of 
Oligomeric and Fibrillar Species of Amyloid-Beta Peptide 1-42: Involvement of 
Endoplasmic Reticulum Calcium Release in Oligomer-Induced Cell Death.” Neuroscience 
155 (3):725–37. https://doi.org/10.1016/j.neuroscience.2008.06.036. 
Reynolds, C. Hugh, Claire J. Garwood, Selina Wray, Caroline Price, Stuart Kellie, Timothy 
Perera, Marketa Zvelebil, et al. 2008. “Phosphorylation Regulates Tau Interactions with 
Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase Cγ1, Grb2, 
and Src Family Kinases.” Journal of Biological Chemistry 283 (26):18177–86. 
https://doi.org/10.1074/jbc.M709715200. 
Rosenthal, Samantha L, and M Ilyas Kamboh. 2014. “Late-Onset Alzheimer’s Disease Genes 
and the Potentially Implicated Pathways.” Current Genetic Medicine Reports 2:85–101. 
https://doi.org/10.1007/s40142-014-0034-x. 
Rossi, Pierre De, Virginie Buggia-Prevot, Robert Andrew, Sofia Krause, Elizabeth Woo, Peter 
Nelson, Peter Pytel, and Gopal Thinakaran. 2017. “BIN1 Localization Is Distinct from Tau 
Tangles in Alzheimer’s Disease.” Matters, January, 1–8. 
https://doi.org/10.19185/matters.201611000018. 
Rossi, Pierre De, Virginie Buggia-Prévot, Benjamin L. L. Clayton, Jared B. Vasquez, Carson van 
Sanford, Robert J. Andrew, Ruben Lesnick, et al. 2016. “Predominant Expression of 
Alzheimer’s Disease-Associated BIN1 in Mature Oligodendrocytes and Localization to 
White Matter Tracts.” Molecular Neurodegeneration 11 (1). Molecular 
Neurodegeneration:59. https://doi.org/10.1186/s13024-016-0124-1. 
Ryan, Kristen R., Oksana Sirenko, Fred Parham, Jui Hua Hsieh, Evan F. Cromwell, Raymond R. 
Tice, and Mamta Behl. 2016. “Neurite Outgrowth in Human Induced Pluripotent Stem 
Cell-Derived Neurons as a High-Throughput Screen for Developmental Neurotoxicity or 
Neurotoxicity.” NeuroToxicology 53. Elsevier B.V.:271–81. 
https://doi.org/10.1016/j.neuro.2016.02.003. 
Saftig, Paul, and Stefan F. Lichtenthaler. 2015. “The Alpha Secretase ADAM10: A 
Metalloprotease with Multiple Functions in the Brain.” Progress in Neurobiology 135. 
Elsevier Ltd:1–20. https://doi.org/10.1016/j.pneurobio.2015.10.003. 
Sakamuro, Daitoku, Katherine J. Elliott, Robert Wechsler-Reya, and George C. Prendergast. 
1996. “BIN1 Is a Novel MYC-Interacting Protein with Features of a Tumour Suppressor.” 
Nature Genetics 14 (1):69–77. https://doi.org/10.1038/ng0996-69. 
Satoh, Kanayo, Sumiko Abe-Dohmae, Shinji Yokoyama, Peter St. George-Hyslop, and Paul E. 
Fraser. 2015. “ATP-Binding Cassette Transporter A7 (ABCA7) Loss of Function Alters 
Alzheimer Amyloid Processing.” Journal of Biological Chemistry 290 (40):24152–65. 
https://doi.org/10.1074/jbc.M115.655076. 
 Bibliography 
175 
 
Schellenberg, Gerard D., and Thomas J. Montine. 2012. “The Genetics and Neuropathology 
of Alzheimer’s Disease.” Acta Neuropathologica 124 (3):305–23. 
https://doi.org/10.1007/s00401-012-0996-2. 
Selkoe, Dennis J, and John Hardy. 2016. “The Amyloid Hypothesis of Alzheimer’s Disease at 
25 Years.” EMBO Molecular Medicine 8 (6):595–608. 
https://doi.org/10.15252/emmm.201606210. 
Sengupta, Amitabha, Michal Novak, Inge Grundke-Iqbal, and Khalid Iqbal. 2006. “Regulation 
of Phosphorylation of Tau by Cyclin-Dependent Kinase 5 and Glycogen Synthase Kinase-
3 at Substrate Level.” FEBS Letters 580 (25):5925–33. 
https://doi.org/10.1016/j.febslet.2006.09.060. 
Seshadri, S, A L Fitzpatrick, A Ikram, A L DeStafano, V Gudnason, M Boada, J C Bis, et al. 
2010. “Genome-Wide Analysis of Genetic Loci Associated With Alzheimer Disease.” The 
Journal of the American Medical Association 303 (18):1832–40. 
https://doi.org/10.1001/jama.2010.574. 
Sherman, Sean P, and Anne G Bang. 2018. “High-Throughput Screen for Compounds That 
Modulate Neurite Growth of Human Induced Pluripotent Stem Cell-Derived Neurons.” 
Disease Models & Mechanisms 11 (2):dmm031906. 
https://doi.org/10.1242/dmm.031906. 
Shukla, Varsha, Susan Skuntz, and Harish C. Pant. 2012. “Deregulated Cdk5 Activity Is 
Involved in Inducing Alzheimer’s Disease.” Archives of Medical Research 43 (8). Elsevier 
Inc:655–62. https://doi.org/10.1016/j.arcmed.2012.10.015. 
Shulman, Joshua M., Selina Imboywa, Nikolaos Giagtzoglou, Martin P. Powers, Yanhui Hu, 
Danelle Devenport, Portia Chipendo, et al. 2014. “Functional Screening in Drosophila 
Identifies Alzheimer’s Disease Susceptibility Genes and Implicates Tau-Mediated 
Mechanisms.” Human Molecular Genetics 23 (4):870–77. 
https://doi.org/10.1093/hmg/ddt478. 
Sims, Rebecca, Sven J. Van Der Lee, Adam C. Naj, Céline Bellenguez, Nandini Badarinarayan, 
Johanna Jakobsdottir, Brian W. Kunkle, et al. 2017. “Rare Coding Variants in PLCG2, 
ABI3, and TREM2 Implicate Microglial-Mediated Innate Immunity in Alzheimer’s 
Disease.” Nature Genetics 49 (9):1373–84. https://doi.org/10.1038/ng.3916. 
Singh, Shantanu, Anne E. Carpenter, and Auguste Genovesio. 2014. “Increasing the Content 
of High-Content Screening.” Journal of Biomolecular Screening 19 (5):640–50. 
https://doi.org/10.1177/1087057114528537. 
Slepnev, Vladimir I., Gian Carlo Ochoa, Margaret H. Butler, Detlev Grabs, and Pietro De 
Camilli. 1998. “Role of Phosphorylation in Regulation of the Assembly of Endocytic Coat 
Complexes.” Science 281 (5378):821–24. 
https://doi.org/10.1126/science.281.5378.821. 
 Bibliography 
176 
 
Söderberg, Ola, Mats Gullberg, Malin Jarvius, Karin Ridderstråle, Karl-Johan Leuchowius, 
Jonas Jarvius, Kenneth Wester, et al. 2006. “Direct Observation of Individual 
Endogenous Protein Complexes in Situ by Proximity Ligation.” Nature Methods 3 
(12):995–1000. https://doi.org/10.1038/nmeth947. 
Sotiropoulos, Ioannis, André T. Lopes, Vitor Pinto, Sofia Lopes, Sara Carlos, Sara Duarte-
Silva, Andreia Neves-Carvalho, et al. 2014. “Selective Impact of Tau Loss on Nociceptive 
Primary Afferents and Pain Sensation.” Experimental Neurology 261:486–93. 
https://doi.org/10.1016/j.expneurol.2014.07.008. 
Sottejeau, Yoann, Alexis Bretteville, François-Xavier Cantrelle, Nicolas Malmanche, Florie 
Demiaute, Tiago Mendes, Charlotte Delay, et al. 2015. “Tau Phosphorylation Regulates 
the Interaction between BIN1’s SH3 Domain and Tau’s Proline-Rich Domain.” Acta 
Neuropathologica Communications 3 (1). Acta Neuropathologica Communications:58. 
https://doi.org/10.1186/s40478-015-0237-8. 
Spires-Jones, Tara, and Shira Knafo. 2012. “Spines, Plasticity, and Cognition in Alzheimer’s 
Model Mice.” Neural Plasticity 2012. https://doi.org/10.1155/2012/319836. 
Spires-Jones, Tara L., and BradleyT Hyman. 2014. “The Intersection of Amyloid Beta and Tau 
at Synapses in Alzheimer’s Disease.” Neuron 82 (4). Elsevier Inc.:756–71. 
https://doi.org/10.1016/j.neuron.2014.05.004. 
Stadler, Charlotte, Elton Rexhepaj, Vasanth R Singan, Robert F Murphy, Rainer Pepperkok, 
Mathias Uhlén, Jeremy C Simpson, and Emma Lundberg. 2013. “Immunofluorescence 
and Fluorescent-Protein Tagging Show High Correlation for Protein Localization in 
Mammalian Cells.” Nature Methods 10 (4). Nature Publishing Group:315–23. 
https://doi.org/10.1038/nmeth.2377. 
Steinberg, Stacy, Hreinn Stefansson, Thorlakur Jonsson, Hrefna Johannsdottir, Andres 
Ingason, Hannes Helgason, Patrick Sulem, et al. 2015. “Loss-of-Function Variants in 
ABCA7 Confer Risk of Alzheimer’s Disease.” Nature Genetics 47 (5). Nature Publishing 
Group:445–47. https://doi.org/10.1038/ng.3246. 
Strittmatter, W. J., a. M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. S. 
Salvesen, and a. D. Roses. 1993. “Apolipoprotein E: High-Avidity Binding to Beta-
Amyloid and Increased Frequency of Type 4 Allele in Late-Onset Familial Alzheimer 
Disease.” Proceedings of the National Academy of Sciences 90 (5):1977–81. 
https://doi.org/10.1073/pnas.90.5.1977. 
Strittmatter, Warren J, Karl H Weisgraber, David Y Huang, Li-Ming Dong, Guy S Salvesen1, 
Margaret Pericak-Vance, Donald Schmechel, Ann M Saunders, Dmitry Goldgaberii, and 
Allen D Roses. 1993. “Binding of Human Apolipoprotein E to Synthetic Amyloid ,B 
Peptide: Isoform-Specific Effects and Implications for Late-Onset Alzheimer Disease.” 
Medical Sciences 90 (September):8098–8102. 
https://doi.org/10.1073/pnas.90.17.8098. 
 Bibliography 
177 
 
Strooper, B. De. 2010. “Proteases and Proteolysis in Alzheimer Disease: A Multifactorial 
View on the Disease Process.” Physiological Reviews 90 (2):465–94. 
https://doi.org/10.1152/physrev.00023.2009. 
Sun, Y, S Wu, G Bu, M K Onifade, S N Patel, M J LaDu, A M Fagan, and D M Holtzman. 1998. 
“Glial Fibrillary Acidic Protein-Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-
Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and 
apoE4 Lipoproteins.” The Journal of Neuroscience : The Official Journal of the Society 
for Neuroscience 18 (9):3261–72. https://doi.org/10.1523/JNEUROSCI.18-09-
03261.1998. 
Tackenberg, C., S. Grinschgl, a. Trutzel, a. C. Santuccione, M. C. Frey, U. Konietzko, J. Grimm, 
R. Brandt, and R. M. Nitsch. 2013. “NMDA Receptor Subunit Composition Determines 
Beta-Amyloid-Induced Neurodegeneration and Synaptic Loss.” Cell Death and Disease 4 
(4). Nature Publishing Group:e608–10. https://doi.org/10.1038/cddis.2013.129. 
Tan, Meng-Shan Shan, Jin-Tai Tai Yu, and Lan Tan. 2013. “Bridging Integrator 1 (BIN1): Form, 
Function, and Alzheimer’s Disease.” Trends in Molecular Medicine 19 (10). Elsevier 
Ltd:594–603. https://doi.org/10.1016/j.molmed.2013.06.004. 
Tanzi, Rudolph E. 2012. “The Genetics of Alzheimer Disease.” Cold Spring Harbor 
Perspectives in Medicine 2 (10):a006296–a006296. 
https://doi.org/10.1101/cshperspect.a006296. 
Teipel, Stefan J., Wilhelm H. Flatz, Helmut Heinsen, Arun L.W. Bokde, Stefan O. Schoenberg, 
Stephanie Stöckel, Olaf Dietrich, Maximilian F. Reiser, Hans Jürgen Möller, and Harald 
Hampel. 2005. “Measurement of Basal Forebrain Atrophy in Alzheimer’s Disease Using 
MRI.” Brain 128 (11):2626–44. https://doi.org/10.1093/brain/awh589. 
Tian, Yuan, Jerry C Chang, Emily Y Fan, Marc Flajolet, and Paul Greengard. 2013. “Adaptor 
Complex AP2/PICALM, through Interaction with LC3, Targets Alzheimer’s APP-CTF for 
Terminal Degradation via Autophagy.” Proceedings of the National Academy of 
Sciences of the United States of America 110 (42):17071–76. 
https://doi.org/10.1073/pnas.1315110110. 
Tomizawa, Kazuhito, Satoshi Sunada, Yun Fei Lu, Yoshiya Oda, Masahiro Kinuta, Toshio 
Ohshima, Taro Saito, et al. 2003. “Cophosphorylation of Amphiphysin I and Dynamin I 
by Cdk5 Regulates Clathrin-Mediated Endocytosis of Synaptic Vesicles.” Journal of Cell 
Biology 163 (4):813–24. https://doi.org/10.1083/jcb.200308110. 
Toussaint, Anne, Belinda Simone Cowling, Karim Hnia, Michel Mohr, Anders Oldfors, Yannick 
Schwab, Uluc Yis, et al. 2011. “Defects in Amphiphysin 2 (BIN1) and Triads in Several 
Forms of Centronuclear Myopathies.” Acta Neuropathologica 121 (2):253–66. 
https://doi.org/10.1007/s00401-010-0754-2. 
Tricoire, Ludovic, and Tania Vitalis. 2012. “Neuronal Nitric Oxide Synthase Expressing 
Neurons: A Journey from Birth to Neuronal Circuits.” Frontiers in Neural Circuits 6 
(December):1–16. https://doi.org/10.3389/fncir.2012.00082. 
 Bibliography 
178 
 
Ubelmann, Florent, Tatiana Burrinha, Laura Salavessa, Ricardo Gomes, Cláudio Ferreira, 
Nuno Moreno, and Cláudia Guimas Almeida. 2017. “Bin1 and CD2AP Polarise the 
Endocytic Generation of Beta‐amyloid.” EMBO Reports 18 (1):102–22. 
https://doi.org/10.15252/embr.201642738. 
Varma, Hemant, Donald C Lo, and Brent R Stockwell. 2011. High-Throughput and High-
Content Screening for Huntington’s Disease Therapeutics. Neurobiology of Huntington’s 
Disease: Applications to Drug Discovery. https://doi.org/NBK55989. 
Villemagne, Victor L., Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A. Ellis, 
Olivier Salvado, Cassandra Szoeke, et al. 2013. “Amyloid Β Deposition, 
Neurodegeneration, and Cognitive Decline in Sporadic Alzheimer’s Disease: A 
Prospective Cohort Study.” The Lancet Neurology 12 (4). Elsevier Ltd:357–67. 
https://doi.org/10.1016/S1474-4422(13)70044-9. 
Wang, Hui-Fu, Yu Wan, Xiao-Ke Hao, Lei Cao, Xi-Chen Zhu, Teng Jiang, Meng-Shan Tan, et al. 
2016. “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer’s Disease Risk by 
Altering Neuronal Degeneration.” Edited by Daniela Galimberti. Journal of Alzheimer’s 
Disease 52 (1):179–90. https://doi.org/10.3233/JAD-150972. 
Wang, Jian Zhi, Yi Yuan Xia, Inge Grundke-Iqbal, and Khalid Iqbal. 2012. “Abnormal 
Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of 
Neurofibrillary Degeneration.” Advances in Alzheimer’s Disease 3:123–39. 
https://doi.org/10.3233/978-1-61499-154-0-123. 
Wang, Xin, Xuan Zhou, Gongying Li, Yun Zhang, Yili Wu, and Weihong Song. 2017. 
“Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease.” 
Frontiers in Molecular Neuroscience 10 (September):1–15. 
https://doi.org/10.3389/fnmol.2017.00294. 
Wang, Yipeng, and Eckhard Mandelkow. 2016. “Tau in Physiology and Pathology.” Nature 
Reviews Neuroscience. https://doi.org/10.1038/nrn.2015.1. 
Watts, Vabren L., Fernando M. Sepulveda, Oscar H. Cingolani, Alice S. Ho, Xiaolin Niu, Rosa 
Kim, Karen L. Miller, et al. 2013. “Anti-Hypertrophic and Anti-Oxidant Effect of beta3-
Adrenergic Stimulation in Myocytes Requires Differential Neuronal NOS 
Phosphorylation.” Journal of Molecular and Cellular Cardiology 62. The Authors:8–17. 
https://doi.org/10.1016/j.yjmcc.2013.04.025. 
Wechsler-Reya, Robert, Katherine Elliott, Meenhard Herlyn, and George C. Prendergast. 
1997. “The Putative Tumor Suppressor BIN1 Is a Short-Lived Nuclear Phosphoprotein, 
the Localization of Which Is Altered in Malignant Cells.” Cancer Research 57 (15):3258–
63. 
Wechsler-Reya, Robert, Daitoku Sakamuro, Jing Zhang, James Duhadaway, and George C. 
Prendergast. 1997. “Structural Analysis of the Human BIN1 Gene.” The Journal of 
Biological Chemistry 272 (50):31453–58. https://doi.org/10.1074/jbc.272.50.31453. 
 Bibliography 
179 
 
Weibrecht, Irene, Karl-Johan Leuchowius, Carl-Magnus Clausson, Tim Conze, Malin Jarvius, 
W Mathias Howell, Masood Kamali-Moghaddam, and Ola Söderberg. 2010. “Proximity 
Ligation Assays: A Recent Addition to the Proteomics Toolbox.” Expert Review of 
Proteomics 7 (3):401–9. https://doi.org/10.1586/epr.10.10. 
Wenk, Gary L. 2003. “Neuropathologic Changes in Alzheimer’s Disease.” Journal of Clinical 
Psychiatry. [Physicians Postgraduate Press]. 
Wetzel-Smith, Monica K., Julie Hunkapiller, Tushar R. Bhangale, Karpagam Srinivasan, Janice 
a. Maloney, Jasvinder K. Atwal, Susan M. Sa, et al. 2014. “A Rare Mutation in UNC5C 
Predisposes to Late-Onset Alzheimer’s Disease and Increases Neuronal Cell Death.” 
Nature Medicine 20 (12). Nature Publishing Group:1452–57. 
https://doi.org/10.1038/nm.3736. 
Wigge, P, K Köhler, Y Vallis, C A Doyle, D Owen, S P Hunt, and H T McMahon. 1997. 
“Amphiphysin Heterodimers: Potential Role in Clathrin-Mediated Endocytosis.” 
Molecular Biology of the Cell 8 (10):2003–15. https://doi.org/10.1016/0040-
6031(88)85258-4. 
Wigge, Patrick, and Harvey T. McMahon. 1998. “The Amphiphysin Family of Proteins and 
Their Role in Endocytosis at the Synapse.” Trends in Neurosciences 21 (8):339–44. 
https://doi.org/10.1016/S0166-2236(98)01264-8. 
Winblad, B, A Cedazo-Minguez, C Graff, G Johansson, L Jönsson, M Kivipelto, T P Sakmar, et 
al. 2016. “The Lancet Neurology Commission Defeating Alzheimer’s Disease and Other 
Dementias: A Priority for European Science and Society.” The Lancet Neurology 
Commision 15 (15):455–532. https://doi.org/10.1016/S1474-4422(16)00062-4. 
Xia, Xiaofeng, and Stephen T. Wong. 2012. “Concise Review: A High-Content Screening 
Approach to Stem Cell Research and Drug Discovery.” STEM CELLS 30 (9):1800–1807. 
https://doi.org/10.1002/stem.1168. 
Yeh, Felix L., Yuanyuan Wang, Irene Tom, Lino C. Gonzalez, and Morgan Sheng. 2016. 
“TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby 
Facilitates Uptake of Amyloid-Beta by Microglia.” Neuron 91 (2). Elsevier Inc.:328–40. 
https://doi.org/10.1016/j.neuron.2016.06.015. 
Youmans, Katherine L., Leon M. Tai, Evelyn Nwabuisi-Heath, Lisa Jungbauer, Takahisa 
Kanekiyo, Ming Gan, Jungsu Kim, et al. 2012. “APOE4-Specific Changes in Aβ 
Accumulation in a New Transgenic Mouse Model of Alzheimer Disease.” Journal of 
Biological Chemistry 287 (50):41774–86. https://doi.org/10.1074/jbc.M112.407957. 
Yuan, Xiang Zhen, Sen Sun, Chen Chen Tan, Jin Tai Yu, and Lan Tan. 2017. “The Role of 
ADAM10 in Alzheimer’s Disease.” Journal of Alzheimer’s Disease 58 (2):303–22. 
https://doi.org/10.3233/JAD-170061. 
Zempel, Hans, Julia Luedtke, Yatender Kumar, Jacek Biernat, Hana Dawson, Eckhard 
Mandelkow, and Eva Maria Mandelkow. 2013. “Amyloid-Β Oligomers Induce Synaptic 
 Bibliography 
180 
 
Damage via Tau-Dependent Microtubule Severing by TTLL6 and Spastin.” EMBO Journal 
32 (22). Nature Publishing Group:2920–37. https://doi.org/10.1038/emboj.2013.207. 
Zhang, Xiaojie, and Weihong Song. 2013. “The Role of APP and BACE1 Trafficking in APP 
Processing and Amyloid-Β Generation.” Alzheimer’s Research and Therapy 5 (5):1–8. 
https://doi.org/10.1186/alzrt211. 
Zheng, Honghua, Chia Chen Liu, Yuka Atagi, Xiao Fen Chen, Lin Jia, Longyu Yang, Wencan He, 
et al. 2016. “Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 
and Triggering Receptor Expressed on Myeloid Cells-like Transcript 2 in Microglia 
Activation.” Neurobiology of Aging 42. Elsevier Inc:132–41. 
https://doi.org/10.1016/j.neurobiolaging.2016.03.004. 
Zheng, Hui, and Edward H. Koo. 2011. “Biology and Pathophysiology of the Amyloid 
Precursor Protein.” Molecular Neurodegeneration 6 (1):1–16. 
https://doi.org/10.1186/1750-1326-6-27. 
Zhou, Kang, and Tingting Hong. 2017. “Cardiac BIN1 (cBIN1) Is a Regulator of Cardiac 
Contractile Function and an Emerging Biomarker of Heart Muscle Health.” Science 
China Life Sciences 60 (3):257–63. https://doi.org/10.1007/s11427-016-0249-x. 
Zhou, Li, and Dong Ya Zhu. 2009. “Neuronal Nitric Oxide Synthase: Structure, Subcellular 
Localization, Regulation, and Clinical Implications.” Nitric Oxide - Biology and Chemistry 
20 (4). Elsevier Inc.:223–30. https://doi.org/10.1016/j.niox.2009.03.001. 
Zhou, Yuan, Ikuo Hayashi, Jacky Wong, Katherine Tugusheva, John J. Renger, and Celina 
Zerbinatti. 2014. “Intracellular Clusterin Interacts with Brain Isoforms of the Bridging 
Integrator 1 and with the Microtubule-Associated Protein Tau in Alzheimer’s Disease.” 
PLoS ONE 9 (7):e103187. https://doi.org/10.1371/journal.pone.0103187. 
 
 
